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Abstract

REVERSAL OF NEURODEGENERATION BY ENGINEERED
MONOCYTES IN ALZHEIMER’S DISEASE
Chao-Hsien Chen, M.D.
Advisory Professor: Michael A. Curran, Ph.D.
The health challenges posed by Alzheimer’s disease (AD) continue to grow as societies
age worldwide. Accumulation of Tau-associated pathology correlates with clinical
cognitive deterioration in AD. Resident myeloid cells within the central nervous system
(CNS) have a limited capacity to uptake and degrade Tau; however, the resulting
secretion of proinflammatory cytokines only acts to accelerate neurodegeneration.
Therapeutic antibodies can reduce the neurotoxic oligomeric form of Tau (o-Tau), but in
doing so they also aggravate inflammation. Attenuating mutation of the antibody Fc
region can silence inflammation but also eliminates its capacity to mediate o-Tau
clearance by CNS myeloid cells. Thus, there is an unmet need for a novel therapeutic
that catalyzes o-Tau degradation without triggering neurotoxic inflammation. In tumor
immunity, scavenger receptors such as CD163, CD204 and FcgRIIb act to limit the
proinflammatory responses of the myeloid stroma. We sought to repurpose this system
to facilitate o-Tau internalization in AD while limiting inflammation. Unlike microglia in
late stage AD, monocytes retain the ability to clear Tau assemblies, but also secrete
inflammatory cytokines. We propose the novel concept of chimeric scavenger receptors
(CSR) that facilitate clearance of o-Tau while limiting proinflammatory responses in
monocytes. We successfully engineered a peripheral macrophage/monocyte cell line to
stably express our CSR consisting of a scavenger receptor scaffold and an anti-o-Tau
single-chain variable fragment. Our engineered CSR-monocytes not only mediate
enhanced removal of extracellular o-Tau, but also uncouple phagocytosis from
vi

neurotoxic proinflammatory cytokine production. The majority of the monocyteassociated o-Tau is internalized where it co-localizes with lysosomes, likely as a prelude
to proteolytic degradation. CSR monocytes demonstrate an elevated lysosome
consumption activity relative to parental monocytes, indicative of a similarly higher
degradative capacity. In primary culture, CSR-monocytes can protect primary neurons
from o-Tau-induced cytopathology. To validate the therapeutic efficacy of these CSR
monocytes in relevant in vivo preclinical models, we established a minimally invasive
procedure enabling repeated intracerebroventricular adoptive transfer of these cellular
therapeutics. In our early in vivo study, we observed a trend of improved motor functions
in P301S Tau overexpressing transgenic mice receiving the engineered monocytes. This
is the first proof of concept that myeloid cell-based immunotherapies engineered to safely
target and reduce Tau pathology through CSR expression can be harnessed to treat
neurodegenerative diseases such as AD.
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Chapter 1: Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that impairs
the memory and cognitive functions of patients and eventually incapacitates them. AD
has a broad societal impact because it primarily affects the elderly population, and
societies worldwide are aging rapidly. Despite its tremendous impact, there is no cure
yet. Understanding the pathogenesis of AD will help us discover and design better
therapeutics to help these patients.
Researchers have gained considerable insight into the complexity of AD from
decades of investigation, but AD is still incurable. In 1907, Dr. Alois Alzheimer examined
the brain of a patient presenting with progressive cognitive impairment and found
neurofibrillary tangles (NFT) and plaques1. NFT and plaques are the aggregation of the
prion-like proteins hyperphosphorylated Tau (pTau) and b-Amyloid (Ab). In addition to
proteinopathy, scientific advancements in immunology, human genomics, epidemiology,
and other areas, in addition to neuroscience, has begun to demonstrate that
pathogenesis to AD is multifactorial. Other etiologies such as inflammation, genetic
mutations, and cardiovascular diseases have been reported as risks for developing AD2.
The complexity of these interlinked etiologies has made treating AD extremely
challenging. Despite progress and an immense effort invested around the globe, we still
lack a disease-modifying therapeutic to combat AD.
To find better treatments for AD patients, we need a comprehensive understanding
of AD. The following chapter will provide a clinical overview of AD and its predominant
etiologies, including proteinopathy and inflammation. This chapter will also briefly update
on the current advancement and challenges of therapeutics against AD, with an
emphasis on immunotherapy.
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1.1 Clinical overview of Alzheimer’s disease
AD is an incurable progressive neurodegenerative disease that impairs patients’
memory as well as daily functions, leading to the patient becoming dependent on others
and, eventually, death. Patients with AD are frequently first noted by their family
members for the hallmark symptom of memory impairment. As the disease progresses,
patients lose their high-level executive functions necessary for jobs and their abilities
essential for independent living, such as shopping, transportation, cooking, and
managing personal medications. Later, patients also present behavioral and
psychological symptoms that add considerable stress, especially to close family
members, which often results in significant caregiver burdens or even burnout3. In the
late disease stages, patients become increasingly dependent. Eventually, they can no
longer perform the necessary activities for daily living, including maintaining personal
hygiene, walking, and even food intake4. The patients usually die from complications due
to nutrition and infection. The median survival time ranges from 3 to 8 years after
diagnosis5,6.
AD has a broad societal impact because patients eventually become dependent on
long-term care provided by either their family members or from institutions. Family
members often give up jobs to care for the patient, or set aside a significant proportion
of income in exchange for care. The global cost for dementia has been estimated to be
818 billion US dollars per year and is projected to rise over two trillion US dollars by
20307,8.
The societal impact will be even greater since the elderly population is on a sharp
rise, and AD affects this population the most. It is estimated that 5.8 million people aged
65 and older suffer from AD in the United States in 20209,10. As societies age rapidly
worldwide, the number of patients diagnosed with dementia, including AD, is projected
18

to be as high as 131 million globally while the number of patients diagnosed with AD is
estimated to reach 13.8 million in the United States by 20508,9.
Although AD poses an imminent threat to our aging societies, there is no cure and
the current treatment provides only mild cognitive improvement. Standard treatment of
AD includes the neurotransmitter modulator class of drugs that was approved by the US
Food and Drug Administration (FDA) more than 20 years ago and is still the cornerstone
of AD treatment today. This class of drugs includes acetylcholine esterase (AChE)
inhibitors, such as donepezil, rivastigmine, and galantamine, and an N-methyl-Daspartate (NMDA) receptor antagonist, memantine, which are approved for various
disease stages11.
Acetylcholine is an essential neurotransmitter in the brain. It is associated with
memory encoding, consolidation, and recall12,13. Loss of acetylcholine-producing
neurons in the nucleus basalis of Meynert, has been found to correlate with memory
dysfunction14,15. The mechanism of AChE inhibitors is to prevent the breakdown of
acetylcholine in the synapses, thereby increasing its concentration in the brain despite
the degeneration of the cholinergic neurons. Clinically, AChE inhibitors are indicated for
patients with mild to severe dementia16.
The other approved medication, memantine, is a non-competitive NMDA receptor
antagonist with a low to moderate affinity to the receptor-mediated cation channel. Overactivation of NMDA receptors could lead to excitotoxicity of neurons, and modulation of
the excessive stimulation helps to prevent neuronal dysfunction17,18. In the clinic,
memantine is suggested as an add-on therapy to the AChE inhibitors in treating
moderate-to-severe AD19. Both AChE inhibitors and memantine marginally improve
cognitive function after 3 months of treatment20,21; however, they do not modify or prevent
disease progression22. Yet these are the only options we have in the clinic for our patients.
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Informing this discouraging fact to AD patients in our daily practice not only reminds us
about our current predicament but also urges us to re-examine the pathogenesis of the
disease, and to develop a novel therapeutic.

1.2 Pathogenesis of Alzheimer’s disease
AD is a complex disease that is contributed to by multiple factors including
inflammation, amyloid plaques, and NFT. Proteinopathy, including amyloid plaques and
NFT, has been the predominant focus of research; however, increasing evidence
indicates that AD is a disease of chronic inflammation. It is widely believed that
dysfunctional innate immunity plays a central role in neuroinflammation in AD23, despite
a growing literature that also suggests the critical role of adaptive immunity24,25. Other
potential factors found by epidemiology studies that are associated with higher risks of
developing AD include hypertension, atherosclerosis, diabetes mellitus, and frailty26,27.
Studies of early-onset familial AD patients pinpoint specific genetic contributions to
the disease, while research on the predominant late-onset AD indicates the involvement
of multiple genes and other factors. Investigations of early-onset familial AD have
identified causative genes, including amyloid precursor protein (APP), presenilin 1
(PSEN1), and presenilin 2 (PSEN2). Identifying genetic risk factors in the more common
late-onset AD has been challenging, however, because the disease involves multiple
genes and potential interactions with environmental factors. Advancement of human
genomics has helped to establish that high-risk genetic variants, including the e4 alleles
of apolipoprotein E (ApoE) and TREM2 (triggering receptor expressed on myeloid cells
2), are strongly associated with late-onset AD28,29. These genes are mainly involved in
lipid metabolism and immune functions, which further demonstrates the role of
20

inflammation in AD. How these genetic variants interact with proteinopathy, leading to
the disease state, is the subject of intense research.
To better understand the pathogenesis of late-onset AD, this section will discuss
not only the well-established etiologies, proteinopathy and innate immunity, but also the
interaction between these two etiologies.

1.2.1 Proteinopathy
In the last few decades, researchers have widely believed that AD is a
proteinopathy, in which its pathology is caused by abnormal protein accumulation.
Accumulation of abnormal proteins including amyloid plaques and NFT are the key
features in AD brain pathology. Amyloid plaques are extracellular aggregates of Ab
peptides, and NFT are intracellular assemblies of pTau. These abnormal proteins are
shown to play essential roles in the pathogenesis of AD in both clinical and animal studies.
This section will review current views on the proteinopathies of AD with an emphasis on
Tau as increasing data demonstrate its close association with clinical presentation in AD.

1.2.1.1 Amyloid cascade hypothesis
Amyloid plaques are the result of aggregation of Ab, which is processed from APP.
Ab is 39 to 42 amino acids, and the two significant species are Ab40 and Ab42. The
physiologic role of Ab has not been entirely elucidated. Although Ab has been reported
to regulate synaptic functions30,31, the loss of Ab in mice does not result in significant
detrimental phenotypic changes32. Ab is only one of the products of APP processing.
Different APP processing pathways lead to either amyloidogenic Ab or nonamyloidogenic peptides. While b-secretase and g-secretase catalyze amyloidogenic Ab
21

formation from APP in the clathrin-mediated endosomal compartments, APP can also be
cleaved by a-secretase and g-secretase on the cell surface to generate nonamyloidogenic peptides. Although the balance between these two pathways, and hence
the resultant peptides, prevents excessive amyloidogenic Ab production, the regulation
governing which processing pathways APP will undergo remains unclear32,33.
Previous literature has indicated that amyloid plaques contribute to AD
pathogenesis, and they are hypothesized to initiate multiple pathologies found in AD.
The role of amyloid plaques in AD pathogenesis has been demonstrated by both
pathologic and genetic studies. Brain pathology shows a higher amyloid plaque load in
the later disease stage of AD. Furthermore, studies also showed that Ab can catalyze
NFT formation, and amyloid plaques appears to occur before distinct NFT34,35. Genetic
studies identified genetic mutations in APP and g-secretase components (presenilin-1
and -2) that can cause familial autosomal dominant AD, in which the phenotypes were
reproduced in animal models by overexpressing APP or introducing the mutations.
These data established the role of Ab in AD pathogenesis and supported the amyloid
cascade hypothesis, which hypothesized that the accumulation of Ab leads to the
neuronal death, vascular damage, and NFT formation in AD pathology36.
Although the data widely support the amyloid cascade hypothesis, none of the Abtargeting treatments have reached the market yet. Based on a disease-initiating role of
Ab, researchers have developed therapeutics with mechanisms including inhibition of
essential proteins responsible for Ab formation, administration of Ab-degrading enzymes
such as neprilysin, and immunotherapies to promote Ab removal37,38. After years of basic
research and clinical trials, very few drugs demonstrate significant clinical improvement
and acceptable safety profiles39.
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Monoclonal antibody therapy has shown the most promise thus far. Several
monoclonal antibodies have failed, but one has shown promise. Aducanumab is a fully
human immunoglobulin G1 (IgG1) monoclonal antibody that recognizes amino acids 3–
7 of the sequence of the Ab peptide. Aducanumab has a more than 10,000-fold increase
in affinity for soluble Ab oligomer and insoluble fibrils over Ab monomer. It is one of the
most promising therapeutics against Ab because it shows a dose-dependent and timedependent reduction of Ab in the brain as well as an attenuation of reduced cognitive
functions in a Phase Ib clinical trial40. The Phase III trial was terminated early because
no significant reduction of cognitive decline was detected in patients. However, in a
recent re-analysis of the Phase III trial data, the company has reported a significant
reduction in cognitive decline in patients receiving high-dose aducanumab41.
Researchers have extensively investigated the role of Ab in AD in the past few
decades. Their data support the amyloid cascade hypothesis, which argues that
aggregation of Ab initiates the pathologies in AD including neuronal damage, vascular
impairment, and NFT formation. To counter Ab accumulation in the brain, several Abtargeting therapeutics were developed. While most of the drugs failed, one monoclonal
antibody, aducanumab, showed promising results in its Phase III clinical trials. The
limited success in targeting Ab has prompted researchers to re-examine the
pathogenesis of AD.

1.2.1.2 Tau pathology
Tau is a microtubule-associated protein enriched in neurons, encoded by the MAPT
gene on human chromosome 1742. Physiologically, Tau stabilizes intracellular
microtubules critical in intracellular trafficking in neurons43. Together with other
23

destabilizing proteins involved in microtubule assembly, Tau regulates the dynamics of
microtubule construction44. The functional domains of Tau protein include an N-terminal
projection domain, a proline-rich domain, a microtubule-binding domain, and a Cterminal domain44. Six isoforms of Tau are expressed in the brain with slight differences
in sizes ranging from 352 to 441 amino acids via alternative splicing of mRNA after its
transcription from MAPT45. The isoforms differ by having one, two, or no N-terminal
domains (N1, N1+N2, or N0), and having three or four microtubule-binding domains
(absence or presence of R2) that result in the six isoforms46.
An increasing body of research indicates that the abnormal accumulation of Tau
induces neurotoxicity and is associated with the clinical disease progression of AD.
Therefore, understanding the mechanisms leading to its accumulation will help to halt
disease progression. Modifications of Tau, such as hyperphosphorylation, facilitate the
abnormal aggregation of Tau that results in the pathologic hallmark in AD, NFT. A
diminished elimination due in part to impaired maturation of autolysosomes containing
Tau aggregates and a dysfunctional proteasome system also contributes to the
accumulation of Tau47,48. Tau pathology not only induces neuronal damage directly, but
also aids Ab-mediated neurotoxicity, in which reduction of Tau expression in Aβoverexpressing AD mouse models has been shown to attenuate cognitive impairment49,50.
Tau pathology also follows a more invariant progression pattern in the brain, and is
closely associated with disease progression in patients51,52, in that higher levels of Tau
pathologies in the brain correlate to a more severe cognitive impairment53 and a more
rapid disease progression54. Because the abnormal accumulation of Tau is clinically
relevant and critical to neuronal damage, a better grasp of the mechanisms governing
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the accumulation and elimination of abnormal Tau will help to reverse neurodegeneration
in AD.

1.2.1.2.1 Post-transcriptional modification of Tau
The equilibrium of the isoforms of Tau is not only critical in maintaining microtubule
structure and intracellular trafficking in neurons but is also influential in the aggregation
of Tau. Alternative mRNA splicing after transcription of MAPT leads to various isoforms
with slightly different properties. The isoform that contains four microtubule-binding
domains (4R, with exon 10 inclusion) has a higher affinity for microtubules, while the 3R
isoform provides a faster dynamic for axonal transport in neurons. The distinction
between these isoforms might explain the relative abundance of the 3R isoform in the
fetal brain when synapse formation is active55-57. More importantly, the 4R isoform is
more prone to aggregate, which can be inhibited by the 3R isoform58. In this way, the
isoforms in a healthy mature adult brain are usually kept in a balance, where the 3R
isoform and 4R isoforms remain at a one-to-one ratio45. When mutations affect
alternative splicing of MAPT transcript resulting in an unfavorable 4R isoform
overexpression, the imbalance will disrupt intracellular trafficking in neurons, and
increase free isoforms of Tau that could facilitate abnormal aggregations and subsequent
pathology59.
Mutations in MAPT result in alternative splicing that promotes the production of proaggregation isoforms. The role of mutations in MAPT in neurodegeneration and
dementia has been best demonstrated in a subtype of autosomal dominant
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), where
significant Tau accumulation and neurodegeneration are caused by preferential
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production of 4R via alternative mRNA splicing due to mutations in MAPT. These
mutations in MAPT, including missense point mutations, G272V, P301L, and R406W60,
not only cause overexpression of the 4R isoform by the inclusion of exon 10, but the
mutations themselves, such as P301L, also contribute to fibrilization because they shift
the protein toward a pro-aggregation β-structure61.
Other isoforms generated by alternative mRNA splicing also play a role in the
aggregation of Tau. Therefore, elucidating the mechanism governing alternative splicing
may help to prevent Tau accumulation. In addition to microtubule-binding domains that
play an essential role in Tau aggregation, the N-terminal domain of Tau also regulates
Tau binding to microtubules as well as Tau aggregation62,63. These data showed that
alternative mRNA splicing of MAPT transcripts significantly impacts the aggregation of
Tau, and that understanding the mechanisms may provide a therapeutic opportunity.
Previous research has expanded our understanding of the molecular details of Tau
expression; however, how the mis-splicing of MAPT transcript contributes to sporadic
neurodegeneration cases, and how to further regulate this splicing process to avoid
undesired isoforms, is still under active investigation46.

1.2.1.2.2 Post-translational modification of Tau
The physiologic function and aggregation capability of Tau are markedly influenced
by post-translational modifications, of which hyperphosphorylation is most crucial. In
addition to alternative splicing at the mRNA level, Tau function is greatly affected at the
protein level by post-translational modifications, including hyperphosphorylation,
acetylation, O-GlcNAcylation (addition of b-N-acetyl-glucosamine), N-glycosylation, and
truncation64. Hyperphosphorylation is the most extensively studied post-translational
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modification of Tau. Phosphorylation of Tau negatively affects its physiological function,
binding to microtubules65. A weaker binding and consequent dissociation from
microtubules as a result of phosphorylation or alternative splicing further facilitates Tau
phosphorylation66. Furthermore, hyperphosphorylation has been shown to be a
necessary modification for the prion-like activity of abnormal Tau, which serves as a
template to convert normal Tau into aggregates. Removal of the phosphorylation on Tau
can abolish its self-assembly activity67,68. Other post-translational modifications, like
acetylation and O-GlcNAcylation, are also involved in the prion-like activity of Tau
through regulation of phosphorylation, which further demonstrates the central role of
hyperphosphorylation in governing the prion-like activity of Tau69-71.
Phosphorylation of Tau is catalyzed by two major categories of kinases
synergistically, and phosphatases responsible for dephosphorylation are often found
impaired in AD. The kinases responsible can be largely grouped into two categories:
proline-directed protein kinases (PDPK) and non-PDPK. The phosphorylation mainly
takes place at serine or threonine residues, as well as some tyrosine residues, of Tau.
PDPKs that phosphorylate a serine or threonine followed by proline include glycogen
synthase kinase-3b (GSK-3b), cyclin-dependent-like kinase-5 (CDK5), and dualspecificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A)72-75. Non-PDPKs,
such as calcium/calmodulin-activated protein kinase II (CaMKII), microtubule affinityregulated kinase 110 (MARK p110), protein kinase A (PKA), and casein kinase 1 (CK1),
can phosphorylate serine or threonine residues not followed by a proline76-79. PDPK and
non-PDPK synergistically phosphorylate Tau, in a process in which residues of Tau
previously-phosphorylated by non-PDPKs facilitate further efficient phosphorylation of
other residues by other PDPKs80. Conversely, the phosphate groups of Tau are removed
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by phosphatases such as protein phosphatase 2A (PP2A). PP2A not only regulates
around 70% of Tau dephosphorylation but also modulates the activity of protein kinases.
The balance between the activities of kinases and phosphatases determines the
resultant burden of pTau81. In AD, the activity of PP2A is often found impaired, which
might explain the accumulation of pTau82-84.
Many factors, such as inflammation and acidosis, affect the equilibrium between the
phosphorylation and dephosphorylation of Tau. Inflammation of the central nervous
system (CNS) contributes to increased neuronal kinase activity: proinflammatory
cytokine IL-1b overexpression has been demonstrated to result in increased GSK-3b
activity along with increased pTau in neurons85. Additionally, acidosis has been reported
to impair PP2A activity, resulting in Tau hyperphosphorylation. Focal brain acidosis from
pathological conditions like ischemic stroke, traumatic brain injuries, and diabetes
mellitus may partially explain their association with AD risks81,86. Research pinpointing
the mechanisms leading to the phosphorylation imbalance is ongoing.

1.2.1.2.3 Oligomeric Tau is the most neurotoxic Tau assembly species
Aggregation of Tau is a continuous spectrum, and an oligomer with three or more
monomeric Tau proteins is required for propagation. pTau, similar to Ab, is a prion-like
protein that is capable of self-assembly and transforms normal protein into pathologic
secondary structures to catalyze its aggregation. Formation from a monomeric Tau to
filament or NFT is a continuous and dynamic process that undergoes a critical
intermediate oligomeric stage, which sets a necessary threshold for its seeding capability.
Three or more Tau peptides in an oligomer are required for intracellular seeding to cause
pathologic aggregation87.
28

Not every oligomeric Tau (o-Tau) is the same, as isolation from different Tauinduced diseases (tauopathies) found different strains of o-Tau. Most of the o-Tau have
a b-sheet secondary structure that is a crucial characteristic in prion-like proteins88,89.
Researchers have found that o-Tau prepared from different patients with the same
diagnosis, or from patients of different tauopathies, have distinct properties. The o-Tau
isolated from different patients can induce distinct pathological patterns in vivo, and show
unique proteolysis patterns and aggregation morphologies in vitro. These discrete
biochemical properties further classify the o-Tau into different strains, which may help
explain the heterogeneous progression among different patients and diseases. More
importantly, finding the strains unique to a specific tauopathy may help design precise
therapeutics that can effectively target the responsible strains90-92.
Similar to various strains of o-Tau, Tau filaments with different structures have been
identified in distinct Tau-induced diseases. Using atomic force microscopy and
transmission electron microscopy, researchers identified that o-Tau is granular in shape.
This granular o-Tau can further assemble into a linear protofilament like a string of beads,
then fuse into filaments93. More recently, the detailed structures of filaments, including
the straight filament and paired helical filament, were unraveled using cryo-electron
microscopy. The cores of both filaments are composed of two identical proto-filaments,
but the difference between the straight filament and paired helical filament lies in the
inter-protofilament packing94. The fact that specific tauopathies have only particular types
of filament might indicate the differential pathogenicity of the Tau filaments95.
In contrast to fibril and monomeric Tau, o-Tau is the most neurotoxic species and
spreads among neurons. Because the deposition of NFT correlates well with the
neuronal loss in the brain, NFT have long been considered the toxic species causing
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neuronal death among the spectrum of Tau assemblies51. This concept was challenged
when researchers identified that o-Tau is in effect the neurotoxic Tau species, as they
found the most neuronal apoptosis in wild-type mice that were injected with o-Tau, but
not fibril or monomer, into the brain. Mechanistically, o-Tau disrupts both synaptic and
mitochondrial functions and also activates apoptosis pathways96,97. Another group also
demonstrated the neurotoxicity of o-Tau by using a regulatable transgenic mouse model,
rTg4510, in which transgenic Tau expression could be inhibited by tetracycline treatment.
When they treated rTg4510 mice with tetracycline, they found that both soluble o-Tau
and cognitive impairment were reduced, although the NFT pathology progressed98,99. In
addition, studies found that extracellular o-Tau can be taken up by neurons and serve as
a seed for further aggregation, which further bolsters the neurotoxic role of o-Tau54,87.
Furthermore, monoclonal antibodies against o-Tau have been shown to prevent o-Tau
propagation-induced neuronal toxicity in vitro effectively, and limit Tau pathology in
vivo100.
In summary, Tau pathology is a continuous spectrum of Tau assemblies from
oligomers to fibrils. o-Tau harbors the essential structure to enable prion-like
transmission, and has distinct strains resulting in differential disease progression.
Importantly, o-Tau is the species responsible for direct neurotoxicity and, conversely,
inhibition of o-Tau prevents neuronal damage.

1.2.1.2.4 Tau is closely associated with clinical progression in Alzheimer’s disease
Tau burden in the brain correlates with the cognitive function decline in AD patients.
Because aducanumab is the only Ab-targeting therapy which continues in clinical trials
while many others have aborted40, researchers have begun to shift their focus and
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reconsider the pathogenic targets in AD. Although more Ab was found in the brain
pathology of AD patients at late disease stages, studies have not found an association
between amyloid plaque burden and cognitive function53,101. In contrast, Tau NFT burden
in the brain is closely associated with cognitive function in AD patients, in which lower
Tau burden correlates with a higher cognitive function102.
Tau is associated with the clinical presentations of AD. The propagation of the NFT
also follows a more invariant pattern compared to amyloid plaques. In the early disease
stage, NFT are mostly found in the hippocampus, which is critical in memory functions.
NFT then spread to the neighboring entorhinal cortex, cingulate gyrus, and the limbic
system, which is vital to both memory and emotional responses. In the later disease
stages, NFT disseminate to the cerebral cortex that is essential in executive function4,52.
Overall, the pattern of NFT propagation in the brain pathology at different disease stages
reflects the clinical presentations.
Tau is also strongly associated with the clinical progression of AD. Not only did a
postmortem analysis find a significantly higher concentration of soluble Tau in the
temporal lobes of AD patients compared to normal subjects103, one retrospective study
analyzing Tau levels in the cerebrospinal fluid of AD patients also showed a close
association between high total Tau level (≥ 900 ng/L or 0.02 nM) and rapid clinical
deterioration104. Additionally, a recent study confirmed that the seeding activity of o-Tau
in the brain is closely associated with the clinical progression of AD54. These data
suggest that the dose of Tau as well as its seeding capability may determine the disease
progression of AD, which suggests Tau as a clinically-relevant target in AD.
Tau pathology alone is sufficient to induce clinical symptoms of AD. In FTDP-17
patients with the R406W missense mutation, there is no b-amyloid pathology but the
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patients also present memory loss similar to AD patients and personality changes105.
Experimentally, reducing Tau expression in Ab-overexpressing AD mouse models was
shown to attenuate cognitive impairment49,50. Although the debate over Ab or Tau being
the dominating pathogen in AD is far from settled106, both clinical and preclinical studies
suggest that Tau pathology, independent of amyloid plaques, can initiate and dominate
the pathogenesis of AD, contributing to clinical manifestations.
In summary, Tau is a clinically-relevant target in AD because Tau pathology reflects
the disease presentation, and correlates with cognitive decline and disease progression.
Moreover, the capability of Tau to drive the symptoms of AD independently suggests that
Tau is an ideal therapeutic target.

1.2.1.2.5 Tau pathology summary
Tau normally stabilizes microtubules that are essential in the axonal transport of
neurons. An imbalance between kinases and phosphatases caused by inflammation or
acidosis increases the level of pTau, which results in the destabilization of microtubules
as well as neuronal dysfunction. Hyperphosphorylation of Tau promotes its aggregation
into a spectrum of Tau assembly species, of which o-Tau is the most neurotoxic species,
and is capable of propagating between neurons. Tau pathology, in comparison to that of
Ab, closely correlates with the clinical progression of AD patients; thus, targeting Tau
pathology, especially o-Tau, is a logical treatment strategy in AD.

1.2.1.3 Proteinopathy summary
Proteinopathy, or abnormal protein aggregation, is a critical pathology in AD. Both
pTau and Ab proteins possess prion-like activity resulting in aggregation that is the
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cornerstone of the pathogenesis of AD. They can incapacitate normal functional proteins
by converting them into toxic assemblies, and even worse, propagate among neurons in
the CNS akin to a chain reaction. Past extensive research on the amyloid cascade
hypothesis has established the essential role of Ab in AD pathogenesis, although rational
therapeutic designs aimed at Ab elimination have yet generated substantial efficacy.
Increasing evidence demonstrates that Tau deposition has more clinical relevance and
lays the foundation for designing therapeutics targeting the neurotoxic o-Tau species.

1.2.2 Chronic inflammation in Alzheimer’s disease
AD is not merely a proteinopathy but a multifactorial disease in which inflammation
also plays an essential role. The early studies of the brains from AD patients had
identified abnormal microglial pathology in addition to the evident proteinopathy. Other
inflammatory changes, including cellular activation and cytokine and chemokine
secretion, have also been found to precede protein aggregates in the brain of AD
patients1,107,108. These data, together with the rapidly expanding literature, are bolstering
the causal role of chronic inflammation in AD23,109.
Inflammation in the CNS of AD is dominated by myeloid cells, including microglia
and peripheral monocytes, while the contribution from adaptive immunity is still under
investigation. Microglia are a unique, innate immune cell population residing in the CNS.
Although microglia are similar in phenotype to their peripheral counterpart, macrophages,
microglia are distinct from macrophages in ontogeny and are sequestered early into the
CNS before peripheral hematopoiesis in fetal liver and bone marrow110. Microglia are
pivotal in the inflamed CNS in AD, because activated microglia are not only the primary
source and master regulator of cytokines and chemokines, but are also capable of
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clearing protein aggregates and cellular debris64-67. Moreover, the peripheral myeloid
counterpart of microglia, monocytes, have also been shown to traffic into the inflamed
CNS through an impaired blood–brain barrier (BBB) and contribute to inflammation111,112.
Burgeoning studies have demonstrated the influence of the adaptive immune system in
AD; however, there is relatively little presence of adaptive immune cells in the AD brain,
and their overall significance is under active research24,25.
This section will provide a focused review of the role of the myeloid compartments
as well as their secreted cytokines, and how they interact with proteinopathy and
influence the complex pathogenesis of AD.

1.2.2.1 Microglia play a central role in the inflammation of Alzheimer’s disease
Microglia form a versatile innate immune population that contributes to inflammation
in AD. Microglia are capable of phagocytosis and degradation of damaged neuronal
debris as well as degradation of abnormal Ab and Tau aggregation113-115. In response,
microglia are activated and orchestrate the production of inflammatory cytokines and
chemokines, which in part help them clear the waste23,116-119.
Exacerbated inflammation and impaired clearance of abnormal protein aggregates
by microglia are critical in the pathogenesis of the late-onset form of AD primarily
affecting the elderly population9. Aging or senescent microglia are found to be “primed”,
which makes them more sensitive to environmental stimuli and leads to exaggerated
responses, including cytokine secretion120-122. Although the mechanism of this “priming”
process is still unclear, this enhanced microglial inflammation has been shown to
contribute to the chronic inflammation in the CNS109. Furthermore, these senescent
microglia have also been shown to have a reduced capability for phagocytosis and
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degradation of protein aggregates121, and they even exacerbate Tauopathy in vivo123.
Both the enhanced inflammation and the reduced clearance capacity by senescent
microglia contribute to the pathogenesis of the late-onset form of AD that is most
prevalent in the aging population.
Microglial inflammation damages neurons and is central to AD pathogenesis.
Clinical samples have demonstrated the presence of reactive microglia in AD pathology1,
and microglial inflammation occurs early in AD, where reactive microglia induce neuronal
damage, such as synapse loss, before apparent NFT deposition is observed108. A recent
preclinical longitudinal study using Tau-overexpressing transgenic mice also showed that
the elevated microglial activation marker, the 18 kDa translocator protein (TSPO),
correlates with poor cognitive function, especially at a later disease stage124. These data
demonstrate

that

microglia

act

as

central

perpetrators

that

contribute

to

neurodegeneration and disease progression in AD.
Microglial inflammation not only induces neuronal death but can also exacerbate
Tau pathology in the CNS. Reactive microglia were reported to both aggravate Tau
pathology in Tau-overexpressing transgenic mice and induce Tau pathology in nontransgenic mice after adoptive transfer125. Conversely, depletion of the microglia has
been shown to slow the propagation of Tau pathology and the progression of the disease
in vivo126. These observational and experimental studies established the essential role
of microglia in exacerbating Tau pathology in AD.
Dysregulated microglia cause inflammation and contribute to AD pathologies.
CX3CR1 is a specific chemokine receptor expressed on microglia that is critical in
regulating microglial activation but often found down-regulated in AD patients127,128.
Although reduced CX3CR1 signaling may enhance Ab phagocytosis in Ab-
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overexpressing mouse models129, reduced CX3CR1 signaling also results in higher
neurotoxic proinflammatory cytokine secretion and an aggravated Tau pathology that
contributes to a worse cognitive outcome127,128. In support of these findings, the deletion
of CX3CR1 in the Tau transgenic mouse model increases Tau hyperphosphorylation130
and contributes to the spread of Tau pathology125.
Microglia are also regulated by TREM2, and its mutation can lead to microglial
dysfunction. Genetic studies have found that patients who carry a key mutation in TREM2
have a similar risk of developing AD as do patients who bear ApoE e4 alleles29. Myeloid
cells, including microglia, robustly express TREM2120,131, which can regulate the removal
of damaged neurons by microglia132, mediate autophagy, and maintain metabolic fitness
in microglia133. Furthermore, studies showed that TREM2 also signals through the ApoE
pathway in microglia, and jointly drive microglial transcriptome away from homeostatic
status toward a reactive state found in neurodegenerative condition134.
In summary, microglia are an innate immune subset critical in the eliciting of
inflammation to remove pathogens, including abnormal protein aggregates, in the CNS.
Aging microglia have impaired clearance of protein aggregates but an exacerbated
inflammatory response. Dysregulated microglial inflammation not only induces neuronal
death but also aggravates Tau pathology, which underscores the pivotal role of microglia
in AD pathogenesis.

1.2.2.2 Microglia inflame Alzheimer’s disease with proinflammatory cytokines
Microglia secrete proinflammatory cytokines that are deleterious to neurons.
Microglia are capable of clearing toxic protein aggregates in the early stages of AD but
become dysfunctional, in that they are ineffective in removing the aggregates, at the later
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stages and also secrete more proinflammatory cytokines100,114,115,135,136. Although some
studies have found that proinflammatory cytokines might help clear protein aggregates
at the early stage of AD, more studies indicate that these cytokines have an overall
detrimental impact on neurons, especially at the later disease stage, and contribute to
AD pathogenesis109.
Proinflammatory cytokines tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6),
and interleukin-1b (IL-1b) are critical in AD. Studies found elevated levels of TNF-a, IL-6
and IL-1b in the AD brain137-139, while these proinflammatory cytokines also co-localize
with protein aggregates in an AD mouse model140. Elevated levels of these cytokines
and their association with other key pathologies demonstrate their importance in the
pathogenesis of AD. How these proinflammatory cytokines abet the inflammatory rally in
the CNS of AD will be discussed below.

1.2.2.2.1 Tumor necrosis factor-a
TNF-a is a master regulator of microglial inflammation and is elevated in the CNS
of AD. TNF-a acts in an autocrine manner that promotes and perpetuates microglial
activation141,142, which stimulates microglia to effectively produce other proinflammatory
cytokines such as IL-1b and IL-6141. Furthermore, TNF-a expression by reactive
microglia is elevated both in AD patients139 and in murine AD models140,143. Outside of
the brain, studies have not shown a consistent trend for TNF-a levels in cerebrospinal
fluid or serum144,145.
Increased TNF-a levels induce neurodegeneration and impair clearance of protein
aggregates by microglia. Overexpression of TNF-a exacerbates neuronal death in an AD
transgenic mouse model142. In addition to its direct adverse effects on neuronal cells146,
37

TNF-a is also capable of inducing neuronal loss by microglia-mediated phagocytosis in
vitro147. Furthermore, microglia exposed to TNF-a are found to have a reduced capability
for clearing protein aggregates, including Ab, which might explain the dysfunctional
microglia observed in the later stages of AD135. These data demonstrated that chronically
elevated levels of TNF-a in AD are detrimental to the neurons via various pathways.
Overall, TNF-a plays a pivotal role in the inflammation of AD. Elevated TNF-a levels
in AD are shown to damage neurons and impair the clearance capability of microglia.

1.2.2.2.2 Interleukin-6
The level of IL-6 is elevated in the CNS of AD. Studies found that IL-6 co-localizes
with amyloid plaques in the brain pathology of AD patients138,139 as well as in animal
models140,143. Although serum IL-6 level is increased in AD patients in some individual
studies, a recent meta-analysis of the available studies revealed no statistical
significance145.
IL-6 promotes neuronal damage as well as abnormal protein accumulation. In
murine models, IL-6 has been found to damage neurons by impairing long-term
potentiation of neurons148,149. It has also been shown that IL-6 together with Ab
synergistically damages neurons in vitro150. Although one study found that IL-6 can
suppress Ab plaque deposition in a murine model at the early stage of AD151, other
studies indicated that elevated IL-6 levels promote abnormal protein aggregation and
that IL-6 is capable of promoting pTau formation in vitro152,153. These data support the
hypothesis that the elevated levels of IL-6 in the CNS is an essential contributing factor
in AD pathogenesis.
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1.2.2.2.3 Interleukin-1b
IL-1b promotes direct neuronal toxicity and inflammation in the CNS. IL-1b
enhances cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS)
expression by neurons that mediate neurotoxicity154,155. Furthermore, IL-1b also
regulates calcium influx, which is implicated in neuronal death in vitro156. In addition to
its deleterious effect on neurons, IL-1b can also promote adhesion molecule expression
on endothelial cells, resulting in increased peripheral leukocyte infiltration and activation
in the CNS157.
IL-1b exacerbates proteinopathy in the brain and is essential in AD pathogenesis.
Locally, IL-1b-expressing microglia are positively associated with deposition of NFT, and
IL-1b levels are also elevated in the pathologic brain compared to non-demented
individuals107. Systemically, the plasma level of IL-1b is also elevated in AD patients
compared to non-demented controls, which suggests its substantial role in AD145,158.
Furthermore, studies also demonstrated that IL-1b mediates Tau phosphorylation, and
overexpression of IL-1b aggravates Tau pathologies85,159. Conversely, blockade of IL-1b
signaling rescues both pathology and cognitive impairment in vivo160. These data
demonstrate that IL-1b not only damages neurons via several mechanisms but also
exacerbates the inflammation by activating and recruiting leukocytes into the CNS155-157.
In summary, reactive microglia and their secreted proinflammatory cytokines are
essential in the pathogenesis of AD. Elevated levels of these cytokines often co-exist in
both clinical and preclinical samples. They synergistically promote the inflammation in
the CNS and jointly contribute to the pathogenesis of AD.
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1.2.2.3 Proteinopathy incites and fuels microglial inflammation
AD is a multifactorial disease, and the etiologies often lace together in contributing
to the disease. Distinct etiologies such as proteinopathy and inflammation damage
neurons synergistically. These apparently-discrete etiologies also interact with each
other in a way similar to a feed-forward loop in that they tend to exacerbate each other
and jointly aggravate the disease progression.
Proteinopathy stimulates the CNS myeloid cells that result in the inflammation in
AD. In sporadic AD, although it is not entirely understood how protein aggregates disrupt
the production–clearance balance and initiate accumulation of the waste, studies have
revealed how these abnormal protein assemblies impact the immune system even
before their prominent presence in pathology, and the intertwined consequences that
follow.
Abnormal protein aggregates like Ab fibrils activate myeloid cells via the
inflammasome cascade. Myeloid cells like macrophages in the periphery or microglia in
the CNS detect and eliminate pathogens by phagocytosis and subsequent clearance
through intracellular degradation machinery. When the myeloid cells internalize Ab fibrils,
phagosomes are fused with the lysosomal compartment for degradation. Ab fibrils have
been found to disrupt lysosome and lead to cathepsin B release into the cytoplasm,
causing activation of the NLRP3 (nucleotide-binding oligomerization domain, leucine-rich
repeat containing protein 3) inflammasome. Activation of the NLRP3 inflammasome
cascade leads to the recruitment of ASC (apoptosis-associated speck-like protein
containing a caspase-recruitment domain (CARD)) and the activation of Caspase-1.
Active Caspase-1 subsequently cleaves pro-IL-1b to release functional IL-1b161,162. IL1b signaling in neurons can promote Tau phosphorylation and neuronal damage85,159.
40

Inflammasomes activated by the Ab aggregates aggravate both Tau and Ab
proteinopathy in return. A recent study showed that the NLRP3 inflammasome and the
subsequently induced IL-1b are necessary for Ab-induced Tau pathology, in which
knockout of inflammasome components NLRP3 or ASC led to reduced Tau pathology in
a Tau-overexpressing transgenic mouse model163. In addition to the exacerbation of Tau
pathology, ASC specks generated during the NLRP3 inflammasome cascade can be
released into extracellular compartments and act as seeds for Ab aggregates164. These
data demonstrated that proteinopathy and reactive microglia constitute a feed-forward
loop that worsens the pathology of AD.
Like Ab assemblies, o-Tau activates microglia, which also contribute to the
neurotoxic feed-forward cycle. Similar to the Ab assemblies that are capable of activating
microglia, Tau assemblies also can activate microglia. Among the Tau assemblies, which
are composed of a spectrum of various numbers of monomers, o-Tau is not only the
most neurotoxic species in vivo96 but is also capable of inducing inflammation. Studies
have demonstrated that o-Tau can activate microglia, resulting in the secretion of several
proinflammatory cytokines, including TNF-a, IL-6 as well as IL-1b100,136. Although the
mechanism of Tau activation of microglia has not been entirely elucidated, one study
suggested that Tau assemblies activate microglia via two pathways. First, Tau
assemblies promote pro-IL-1b production via a toll-like receptor (TLR)/Myeloid
differentiation primary response 88 (MyD88)-dependent pathway in microglia. Second,
Tau assemblies enable NLRP3 inflammasome activation in microglia, which leads to the
processing of pro-IL-1b and functional IL-1b secretion165.
Overall, Tau and Ab proteinopathies in AD are capable of activating microglia.
These reactive microglia not only serve as a source of neurotoxic proinflammatory
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cytokines but also aggravate the proteinopathy in the CNS. Together, they perpetuate
each other and sustain a vicious cycle accelerating neuronal loss and disease
progression of AD.

1.2.2.4 Peripheral monocytes contribute to the inflammation in the central nervous
system
The CNS was once considered an “immune privileged” space, an area free from
peripheral immune surveillance. Current evidence has demonstrated that the CNS is
instead constantly monitored by the peripheral immune system. The BBB is a
multicellular structure physically separating brain parenchyma from peripheral blood that
limits and regulates the access of the peripheral immune system to the CNS166. However,
this concept was challenged by researchers in the early 1990s. In the homeostatic
condition, without inflammation, it was found that a lymph drainage system surrounds
the CNS, and drains into the deep cervical lymph nodes that constitute an immune
trafficking route connecting the CNS to the periphery167,168. This concept was reiterated
recently using more sophisticated imaging modalities, demonstrating the presence of the
lymphatic system in the CNS that allows the constant surveillance by the peripheral
immune cells, including T cells and myeloid cells169.
Peripheral immune cells migrate into the CNS via an impaired BBB in AD. The
presence of peripheral immune cells like monocytes in postmortem brain samples112 and
fibrinogen leakage from the brain vasculature of AD patients suggest a compromised
BBB in AD that allows infiltration of peripheral monocytes into the brain parenchyma170.
The question of whether an influx of peripheral monocytes to the CNS contributes to
inflammation was not wholly settled earlier because the markers that were used to
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identify peripheral monocytes could not separate them from microglia completely, which
made it difficult to identify the origins of the CNS myeloid cells109. This debate was
clarified in animal studies, in which peripheral pre-labeled monocytes migrate to the brain
in AD mouse models. Compared to the healthy brains, researchers demonstrated that
more pre-labeled monocytes traffic to the CNS after intravenous adoptive transfer into
AD mouse models171,172. These clinical and preclinical findings both demonstrated that
the inflamed AD brain is not an isolated island, and peripheral monocytes also contribute
to its inflammation.
An upregulation of cytokines, chemokines, and adhesion molecules in addition to
Tau pathology help to recruit peripheral monocytes into the inflamed CNS in AD. In a
migration system using primary human astrocyte and endothelial cells for manufacturing
BBB separation in vitro, researchers found that human peripheral monocytes activated
by Ab on one side of the artificial BBB promoted the migration of monocytes from the
other side. They also found a dose-dependent association of chemokines (monocyte
chemoattractant protein-1 (MCP-1), macrophage inflammatory porotein-1a (MIP-1a),
MIP-1b and IL-8) as well as cytokines (TNF-a, IL-6 and IL-1b) with migration activity111.
Furthermore, cytokines, including TNF-a and IL-1b, were shown to disrupt the vascular
endothelial cell lining and upregulate the adhesion molecules on endothelial cells that
lead to a more efficient infiltration of peripheral immune cells173,174. Recently, Tau
pathology was also found to enhance the expression of adhesion molecules on vascular
endothelial cells that facilitate the infiltration of peripheral immune cells175. These
mechanisms collectively aid the influx of peripheral immune cells into the inflamed CNS
of AD.
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Both peripheral monocytes and microglia contribute to inflammation in the CNS
after uptake of abnormal protein aggregates. Microglia in the later stages of AD are often
dysfunctional in phagocytosis and clearance of the protein aggregates135, while
peripheral monocytes are more capable of clearing protein aggregates such as Tau
assemblies136. Although peripheral monocytes have a higher capacity to clear protein
aggregates, we found that peripheral monocytes similar to microglia also produce
proinflammatory cytokines endangering neurons. A further illustration will be provided in
the Results section in Chapter 5 (Fig. 2). These data showed that myeloid cells aid
inflammation in the CNS, and that there exists a common mechanism in myeloid cells
linking the uptake of abnormal protein aggregates and the secretion of proinflammatory
cytokines.
In summary, the CNS is not isolated from the peripheral immune system by the BBB,
which tightly regulates immune trafficking between the CNS and the periphery. Upon
inflammation reactive to insults like Ab and Tau pathology in the CNS, this barrier can be
disrupted and enables an increased influx of peripheral immune cells. Peripheral
monocytes are recruited to cross the BBB and further contribute to the inflammation
through the upregulation of cytokines, chemokines, and adhesion molecules originating
from the reactive responses in the CNS.

1.2.2.5 Chronic inflammation summary
Microglia are the principal immune population triggering immune responses against
protein aggregates in AD by secreting proinflammatory cytokines, including TNF-a, IL-6
and IL-1b, and chemokines, which further recruit peripheral monocytes into the CNS.
Peripheral monocytes harbor the potential of a more efficient uptake and degradation of
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Tau assemblies but still secrete proinflammatory cytokines that exacerbate the
inflammation. The proinflammatory cytokines secreted by both myeloid cell types further
promote the accumulation of both Ab and Tau. As the disease progresses, the inefficient
clearance of protein aggregates and the linked secretion of proinflammatory cytokines
by the myeloid cells lead to a constant feed-forward loop pathology in AD brains.

1.3 Immunotherapy for Alzheimer’s disease
Although a cure or disease-modifying agent for AD is currently unavailable, novel
drug development based on the re-examination of the etiologies of AD is bringing hope.
The drugs of choice prescribed in the clinics are AChE inhibitors and NMDA receptor
antagonists4. In a meta-analysis, both of them could slightly improve cognitive test scores
(e.g., Mini-Mental State Exam) of AD patients after 3 months of treatment20,21. But
because these drugs are not disease-modifying agents, the pathology of AD still
progresses even under treatment. As the etiologies of AD have been re-examined in
greater detail as the technology has advanced, novel therapeutics have also been
developed to target those identified etiologies in the hope of reversing the pathogenesis.
Although several drugs have been developed against the clinically-relevant Tau
pathology,

only

immunotherapy

has

shown

promise

thus

far.

Increased

hyperphosphorylation of Tau in AD promotes production of neurotoxic Tau species and
is associated with clinical progression. To restore the pTau and Tau balance, drugs like
tideglusib and lithium chloride have been used to inhibit kinase GSK-3b, and sodium
selenate has been used to activate PP2A phosphatase activity176-179. To prevent the
pTau from aggregation and subsequent spreading, methylene blue was found to keep
pTau monomer in a conformation that inhibits its aggregation180. In addition to these
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small molecule drugs, another class of drugs developed to remove pTau has been
immunotherapy. These approaches have included the infusion of monoclonal antibodies
to specifically block pTau in the patients and inoculating patients with vaccines to elicit
self-generated antibodies to remove pTau. Among the therapeutics that have been
developed, immunotherapy, especially passive immunization with monoclonal antibodies,
was the most promising and is still active in clinical trials.
The following discussion will focus on the development of immunotherapy for AD,
from the suppression of general inflammation to the immunotherapy specific for protein
pathologies including Ab, and Tau.

1.3.1 General suppression of immune responses
Inflammation is pivotal in the pathogenesis of AD and general suppression of the
inflammation with non-steroid anti-inflammatory drugs (NSAIDs) is a rational approach.
The literature has demonstrated that inflammation of the CNS exacerbates proteinopathy
and these two etiologies jointly promote neurodegeneration in AD. It has been
hypothesized that suppression of the inflammation in the CNS could curb the worsening
pathology in AD. NSAIDs such as naproxen are over-the-counter medications that are
safely used in patients, and could be an ideal candidate to examine this hypothesis.
Clinical trials have reported that general suppression of inflammation with NSAIDs
failed to prevent the progression of AD; hence, fine-tuning of a specific inflammatory
response in AD is needed. The Alzheimer’s Disease Anti-inflammatory Prevention Trial
(ADAPT) was a randomized clinical trial using either naproxen or celecoxib (a selective
COX-2 inhibitor) in older adults with AD family history. Both of the drugs failed to prevent
the cognitive decline compared to the placebo group181. Another clinical trial in Canada,
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Investigation of Naproxen Treatment Effects in Pre-symptomatic Alzheimer’s Disease
(INTREPAD), also echoed this result. Naproxen again did not show protection for
patients from progression to AD but caused adverse side effects182. These data suggest
that a therapy fine-tuning the immune responses in a more specific way is warranted
rather than bluntly suppressing the overall inflammation.

1.3.2 Lessons learned from the anti-Ab immunotherapy
Only one passive immunotherapy using a monoclonal antibody targeting Ab has
shown promise thus far, after decades of development of Ab-targeting treatments, which
has prompted researchers to reconsider the primary etiology for AD. The development
of Ab-targeting therapy started earlier than Tau-targeting treatment. Small molecule
therapies inhibiting enzymes like b-secretase or g-secretase to reduce Ab production,
and immunotherapy such as active vaccination or passive antibody to eliminate existing
Ab assemblies, were developed37,183. One monoclonal antibody therapy against Ab has
demonstrated its potential and is still active in the clinical trials. Aducanumab is an IgG1
monoclonal antibody that recognizes both soluble Ab oligomers and insoluble fibrils over
monomer. A Phase III study of aducanumab, EMERGE (NCT02484547), found a
significant reduction of cognitive decline and amyloid plaque in patients who received
high doses of aducanumab compared to patients who received placebo40,41. Based on
these results, the developers of aducanumab, Biogen and Eisai, submitted a Biologics
License Application for aducanumab to the FDA.
Compared to passive immunotherapy, which infuses exogenous monoclonal
antibody, the vaccine is active immunotherapy that elicits self-generated antibodies
against pathogens. Previous clinical trials evaluating several Ab vaccine candidates did
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not reveal significant cognitive improvement in AD patients despite the level of Abspecific antibodies being elevated. Similar disappointing results were also observed in
clinical trials evaluating monoclonal antibody therapies. These collective suboptimal
results were partly attributed to the possibility that Ab pathology may be an
epiphenomenon rather than a significant disease-driving factor37. These data suggest
that there exists an equally or more critical etiology other than Ab in AD pathogenesis
and progression.
The adverse immune response elicited by immunotherapy hampers the progress of
the treatment. In addition to the therapeutic target issue, immune responses elicited by
immunotherapy could also bring adverse effects that limit its clinical application. In one
clinical trial that is evaluating active immunotherapy agent AN-1792 using full-length Ab142,

6% of patients presented with meningoencephalitis, which is inflammation of

meninges and brain parenchyma. Researchers found the incidence was not associated
with the induced anti-Ab antibody level, and suggested that activation of T cell and
microglia by vaccination could be the mechanism behind the inflammation184. An active
immunotherapy trial sponsored by Novartis also found that 38% of enrolled patients had
microhemorrhage in the brain185. These adverse effects were not only limited to active
immunotherapy; brain vasogenic edema and microhemorrhage were also reported in
patients receiving monoclonal antibody therapy. In one clinical trial evaluating
bapineuzumab, an IgG1 that targets the N-terminal of Ab, approximately 5–17% of
patients presented with vasogenic edema in imaging, which led to an increase in patient
withdrawal from the study186.
Late recruitment of AD patients for intervention could be solved using advanced
diagnostic tools for early detection. The reduced protein aggregate-related neurotoxicity
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provided by therapy may not be able to rescue the global cognitive function resulting
from the significant neuronal death, as most patients recruited to the trials had an evident
cognitive decline. The administration of treatment in patients with a milder disease or
before evident clinical impairment such as mild cognitive impairment could be beneficial
and is currently under evaluation37,64. Increasingly, novel non-invasive imaging and
biomarker technologies are being developed and optimized for the early detection of the
abnormal accumulation of protein aggregates or inflammation in patients’ brains187-189.
Although the correlation between these diagnostic results and AD progression are still
under examination, some of these tools, such as amyloid positron emission tomography
(PET), are currently helping clinicians select suitable prodromal AD patients for clinical
trials and treatment190.
In summary, earlier research on Ab-targeting treatment provides insightful lessons
for AD therapeutic development. First, the limited success of Ab-targeting treatment has
urged researchers to develop therapeutics against another primary etiology of AD.
Secondly, adverse immune reactions induced by immunotherapy hampers the
development of the treatment, which could be due to activated microglia and T cells.
Lastly, the recruitment of patients with milder symptoms or prodromal patients identified
by novel diagnostic modalities for treatments could better benefit patients.

1.3.3 Immunotherapy against Tau pathology
The observation that immunotherapy capable of reducing Ab burden in the brain
does not benefit patients suggests that other etiologies such as Tau might play a more
critical role in AD. Accumulating evidence demonstrates the neurotoxicity of Tau
pathology, its essential role in pathogenesis, and its close association with clinical
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progression in AD patients. These data suggest Tau pathology as a potential therapeutic
target, and more clinical trials and preclinical studies are also directing the
immunotherapeutic development toward targeting the Tau pathology49-52,96,100,105.
Anti-pTau antibody can block extracellular pTau propagation among neurons,
although blocking intracellular spreading is under debate. Unlike extracellular amyloid
plaques, Tau pathology composed of pTau species is mainly an intracellular pathology,
which is released to the extracellular compartments upon neuronal death. Because pTau
species exist in both intracellular and extracellular compartments, it will be ideal to
develop an antibody therapeutic that can block the cell-to-cell propagation as well as the
intracellular seeding activity. Whether antibodies generated either by active vaccination
or passive infusion will be capable of entering neurons to target the intracellular pTau is
still under debate as different groups have demonstrated opposing results; however,
these antibodies were all shown capable of blocking the propagation of pathological pTau
species entering neurons191,192.
Adverse effects intrinsic to immunotherapy have to be solved to unleash the full
potential of immunotherapy. Although immunotherapy has shown the most promise in
treating AD patients, some treated patients withdrew prematurely from the studies due
to adverse immune reactions, including cerebral hemorrhages and inflammation, which
were

found

with

both

active

and

passive

immunotherapies184-186.

Passive

immunotherapy using a monoclonal antibody appears to have a lower safety concern
compared to active immunotherapy using vaccines, which may explain why there are
more clinical trials for monoclonal antibodies64. Revealing the mechanism of these
adverse immune reactions will advance immunotherapy development.
Immunotherapy-induced

adverse

immune

reactions

may

stem

from

the

engagement of the Fc domains of the antibodies by activating Fc receptors on immune
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cells. Experience gained from Ab-targeted immunotherapy indicates that activation of
microglia by immunotherapy could result from the engagement between Fc receptors
and the Fc region of antibodies. Different Fc domains have distinct affinities to the Fc
receptors on immune cells: for instance, human IgG1 has a higher affinity for activatory
Fcg receptor IIA (FcgRIIA) than inhibitory FcgRIIB while IgG4 has a universally low affinity
for FcgR193. One preclinical study mutated the antibody Fc region and showed a
diminished microglial activation, highlighting the importance of selecting an optimal
antibody backbone100. Further information on FcgR will be discussed in Chapter 2.
The understanding that different antibody Fc domains have distinct binding and
activation profiles of Fc receptors has had a significant impact on immunotherapy design.
Monoclonal antibody therapeutics developed previously have had an IgG1 isotype that
is known to stimulate activating Fc receptors on myeloid cells, including microglia, for
inflammation. The adverse effects observed in patients receiving IgG1 immunotherapy
and a better understanding of the Fc receptor biology have led to a shift in the design of
antibodies. The monoclonal antibodies that are currently active in clinical trials, including
gosuranemab (BMS-986168, Bristol-Myers Squibb), ABBV-8E12 (AbbVie), and
semorinemab (RO 7105705, Genentech and ACImmune) are all IgG4191. Their targets
and current status in clinical trials will be briefly discussed below.
Gosuranemab targets the residues 9–18 at the N-terminal of a secreted
extracellular Tau peptide. Extracellular Tau is elevated in familial AD patients, and it was
shown to facilitate Ab aggregation in vitro. Gosuranemab was found to decrease the
levels of both Tau and Ab in vivo194. It has completed a Phase I clinical trial and is
currently in Phase II64. ABBV-8E12 targets the residues 25–30 at the N-terminus of the
Tau peptide. It was demonstrated to prevent the uptake of Tau aggregates by neurons
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and the subsequent seeding activity195. Preclinical testing using the P301S Tauoverexpressing transgenic mouse model showed a reduced level of pTau and improved
cognitive function196. ABBV-8E12 is now being evaluated for its safety and efficacy in
early AD patients in a Phase II clinical trial64. The data for semorinemab are limited as
its epitope has not been disclosed. The target was speculated to be at pSer409 or the
N-terminus of Tau peptide, and it has completed a Phase I clinical trial64,191.
In summary, researchers gained much experience during the early development of
immunotherapy for Ab. The focus has now shifted to Tau-targeting therapy, with
improved antibody Fc region design to avoid adverse immune reactions. The
development of Tau immunotherapy is on a rapid rise, and it will be exciting to learn more
about these antibodies once the results of the clinical trials become available.

1.3.4 Summary of immunotherapy for Alzheimer’s disease
Past efforts in general suppression of inflammation and Ab-targeting therapeutic
research have provided invaluable insights into future therapeutic design and
development, despite their minimal success. The lessons learned from these pioneering
studies, including treatment timing, target, and adverse effects of immunotherapy, aid in
the design of better future immunotherapy. Passive immunotherapy using monoclonal
antibodies is the most promising approach thus far. Antibodies against Tau pathology
are under active investigation, and their isotype backbones have been carefully selected
using IgG4 to avoid inflammatory Fc functions. Clinical trials are ongoing to evaluate the
efficacy of these treatments.
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Chapter 2: Modulation of Myeloid Cells—a Lesson from Tumor
Immunology

AD is a multifactorial disease in which both Tau pathology and inflammation are
critical in the pathogenesis. Inflammation in AD is dominated by the activated CNS
myeloid cells and not only accelerates neurodegeneration but also exacerbates Tau
pathology. A better understanding of the modulation of myeloid cells will enable us to
alleviate the CNS myeloid cell-induced inflammation and mitigate the pathology in AD.
Our knowledge of the suppressive myeloid cell populations has been advanced
significantly by recent cancer immunology research. Breakthroughs in cancer
immunology have led to a clearer view of regulatory mechanisms of immune cells,
including myeloid cells. Inhibitory molecules and checkpoint molecules expressed on
immune cells such as myeloid cells and T cells were discovered to inhibit tumor rejection
in patients. These discoveries led to the development of a new class of therapeutic
modalities that are improving the survival of cancer patients197.
Although successful immunotherapy has become a new paradigm in cancer
treatment, only selected immunotherapies have provided marginal benefits to AD
patients, and none of them have succeeded in entering the market191. Previous studies
used NSAIDs to suppress the inflamed brain in AD but in vain. Passive immunotherapy
approaches, such as monoclonal antibodies, appear to be promising but is still under
investigation.
Leveraging the knowledge from cancer immunology could benefit the development
of immune-modulating therapeutics in AD. While how to activate suppressive myeloid
cells for tumor rejection is the focus of cancer immunology, how to inhibit dysfunctional
activated myeloid cells for neuron preservation is the key in AD. Learning how to release
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the brake on inflammation will also help us to decelerate it. A better understanding of
immune regulatory systems in cancer will significantly help researchers to repurpose the
knowledge to halt the progression of AD.

2.1 Myeloid cells play an essential role in immune suppression in the tumor
microenvironment
In contrast to the proinflammatory environment in AD, the tumor microenvironment
is a suppressive condition contributed to by myeloid cells that keep the inflammatory
responses, such as tumoricidal effects from effector T cells, at bay. Suppressed or
suppressive myeloid cells, which include dendritic cells (DCs), myeloid-derived
suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), are associated
with poor outcomes in cancer patients and contribute to the treatment resistance in
cancer immunotherapy198. Understanding the resistance derived from these suppressive
myeloid subsets will help overcome these treatment barriers in cancer patients.
DCs are professional antigen-presenting cells (APCs) that specialize in processing
and presenting antigens, but their stimulatory functions are often compromised in the
tumor microenvironment. In response to stimuli, DCs upregulate the expression of costimulatory molecules and cytokines to activate T cells. DCs also upregulate the
expression of chemokine receptors that facilitate their traffic to lymphoid tissue to further
promote T cell activation. In cancer environments that are usually hypoxic, low pH, and
with abundant adenosine, the stimulatory functions of DCs are often impaired199-201.
MDSCs inhibit the anti-tumoral effects of T cells via various mechanisms, including
secretion of anti-inflammatory cytokines and the production of reactive oxygen species
(ROS). MDSCs are immature myeloid cells that are expanded during a chronic
unresolved inflammatory response such as cancer. MDSC can be further categorized
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into polymorphonuclear MDSCs (PMN-MDSCs) and monocytic MDSC (M-MDSCs)
based on their morphology and phenotype. M-MDSCs, which are phenotypically similar
to monocytes, suppress T cells in antigen-specific and non-specific ways. M-MDSCs
secrete the anti-inflammatory cytokines IL-10 and transforming growth factor-b (TGF-b),
iNOS, and arginase, which combine to inhibit T cell activation. PMN-MDSCs, the other
form of MDSC, are phenotypically similar to neutrophils and secrete ROS as their major
pathway to suppress T cells198. Reactive nitrogen species resulting from ROS reacting
with nitric oxide can directly modify the T cell receptor and prevent it from effectively
engaging the antigen in the context of MHC (major histocompatibility complex), blocking
the subsequent activation202. Moreover, these MDSCs also upregulate co-inhibitory
molecules such as programmed death-ligand 1 (PD-L1) to further suppress T cell
activation203.
Activated macrophages can be generally categorized into two phenotypes, M1 and
M2, which have distinct immune functions. Macrophages are also professional APCs that
are responsible for phagocytosis of pathogens and cellular debris, presentation of
antigens, and secretion of cytokines and chemokines after sensing danger. Based on
their surface marker and cytokine production profiles, macrophages can be generally
categorized into classically (M1) and alternatively (M2) activated phenotypes or
polarizations204. M1 macrophages have a proinflammatory phenotype and are capable
of pathogen elimination. They secrete cytokines, including IL-1b, IL-6, IL-12, and TNF-a.
They also upregulate the expression of surface markers such as MHC class II and CD86,
which is a critical co-stimulatory molecule for T cell activation. M2 macrophages play
essential roles in tissue repair and cell proliferation. They secrete anti-inflammatory
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cytokines such as IL-10 and upregulate markers such as the inhibitory scavenger
receptors CD163, CD204, and CD206205-207.
TAMs that contribute to the suppression in the tumor microenvironment are similar
to M2 macrophages and express inhibitory scavenger receptors. The phenotype of TAMs
resembles the M2 macrophage phenotype206 that suppresses T cells and prevents
effective tumor rejection208. The density of TAMs, identified by scavenger receptor
CD163 alone or with CD204, in the tumor microenvironment, is associated with a higher
histological grade of cancer and poor clinical outcome. Moreover, the CD163 expression
level of the tumor samples is also closely linked with poor survival209,210. These data
demonstrated that the scavenger receptors not only have been used to define TAMs and
M2 macrophages but also have prognostic value in cancer patients.
In summary, the unfavorable tumor microenvironment that impedes T cell-driven
tumor rejection is shaped by various suppressive myeloid cells. These suppressive
myeloid cells can express inhibitory molecules including scavenger receptors that are
associated with poor prognosis in cancer patients.

2.2 Scavenger receptors on myeloid cells in the tumor microenvironment
The definition and classification of scavenger receptors have been split in the past
but were unified recently. Scavenger receptors are not native to cancer research. Their
activity was first described in cardiovascular and lipid research211, and the name was first
coined for an alternative receptor that can bind to a modified low-density lipoprotein
(LDL)212. Later, other structurally similar or functionally similar receptors have been
discovered and included in this family, which made the definition and nomenclature of
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scavenger receptors inconsistent and confusing. Recently, a consensus has been
reached for the definition and the systemic classification of these scavenger receptors.
Scavenger receptors are defined as “cell surface receptors that typically bind
multiple ligands and promote the removal of non-self or altered-self targets213.” They
usually function in adhesion, phagocytosis, endocytosis, and signaling to remove
substances that are detrimental or degenerated. The mammalian scavenger receptors
are currently classified into 12 classes213.
Scavenger receptors are widely studied in cancer immunology. CD163 and CD204
are commonly used to define suppressive TAMs or M2 macrophages that are associated
with poor prognosis of cancer patients209,210. FcgRIIb possesses the properties of a
scavenger receptor and also inhibits anti-tumoral effects214. The following sections will
discuss the regulation and signaling pathways of these scavenger receptors in driving an
inhibitory polarization of myeloid cells.

2.2.1 CD163
CD163 is classified as a Class I scavenger receptor that has three isoforms.
Structurally, CD163 has nine scavenger receptor cysteine-rich (SRCR) domains in its
extracellular domain and a short cytoplasmic tail. Three isoforms are generated from
alternative splicing. The cytoplasmic tail of all three isoforms has a conserved region that
contains an internalization motif as well as phosphorylation sites for protein kinase C and
creatine kinase215. The shortest form is the most abundant and is mostly found on the
cellular membrane. The longer isoforms largely localize in the endoplasmic reticulum and
Golgi networks and have been suggested to harbor other potential phosphorylation sites
at the intracellular tail216,217.
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CD163 is involved in maintaining the balance of the immune system, and its
expression can be regulated via various immune mediators. It was reported that
inflammatory regulators like glucocorticoid, IL-10, and IL-6 induce CD163 expression.
Glucocorticoid receptor binding sites were also found at the CD163 promoter region218.
Conversely, proinflammatory mediators such as TNF-a and interferon-g (IFN-g) have
been shown to suppress the expression of CD163 in monocytes219. CD163 expression
is also regulated by inflammatory stimuli like lipopolysaccharide (LPS). LPS-induced
TLR4 activation leads to a rapid cleavage of surface CD163 on monocytes by a
metalloproteinase, which results in a reduced detection of CD163 on the cells in the early
phase of LPS stimulation220,221. Upregulation and re-expression of CD163 on the surface
are observed later, which is due to regulatory secretion of IL-6 and IL-10 in response to
LPS-induced TLR4 activation222. These data demonstrate that CD163 is associated with
immune homeostasis.
CD163 is generally believed to be expressed exclusively by monocytes and
macrophages,

especially

in

the

reticuloendothelial

system223,224.

Consistently,

macrophages differentiated from monocytes in vitro using macrophage colonystimulating factors (M-CSF) also exhibit enhanced CD163 expression219. Other than
being expressed on myeloid cells, a recent report suggests that CD163 expression can
also be found on neurons in an intracerebral hemorrhage model in piglets225.
One of the major functions of CD163 is to remove the extracellular hemoglobin
released from erythrocytes during either the breakdown of senescent erythrocytes in the
spleen or hemolysis in the circulation226. The released hemoglobin is rapidly captured by
haptoglobin, forming a stable hemoglobin-haptoglobin (Hb-Hp) complex to prevent
oxidative injury resulted from free heme227. The complex is bound to the third SRCR
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domain (SRCR3) of CD163 and internalized via the endocytosis pathway in monocytes
or macrophages228. The internalized heme is further degraded by the induced heme
oxidase-1 (HO-1) that produces ferrous ion (Fe2+), carbon monoxide, and biliverdin229. In
addition to Hb-Hp, CD163 can also bind to other ligands such as erythroblasts and
bacteria at the SRCR2 domain and TNF-like weak inducer of apoptosis (TWEAK) at the
SRCR1-4, 6, and 7-9 domains230,231. Some viruses have also been reported to utilize
CD163 as a receptor gaining access into the cells for infection232,233.
CD163 also has immunomodulatory functions, in addition to facilitating ligand
internalization and degradation in monocyte and macrophages. Engagement of Hb-Hp
complex to CD163 can lead to the production of anti-inflammatory cytokine IL-10, while
inhibition of CD163 by an anti-CD163 blocking antibody (clone RM3/1) abolished IL-10
production. Although Hb-Hp itself may be implicated in contributing to anti-inflammation,
administration of an agonist anti-CD163 antibody (clone Ki-m8) in the absence of Hb-Hp
complex also promoted IL-10 secretion in myeloid cells234.

Another study using

nanoparticle transfection in the human peripheral monocyte cell line THP-1 to
overexpress CD163 demonstrated that overexpression of CD163 leads to increased IL10 and IL-1 receptor antagonist (IL-1ra) production in an LPS-induced sub-acute
inflammatory condition. Furthermore, these anti-inflammatory cytokine expressions
could be inhibited by the anti-CD163 antibody (clone RM3/1)235. Since LPS is not a
known CD163 ligand, and no Hb-Hp complex was present in the experimental system,
these data suggest that CD163 can regulate inflammatory responses. Although the
ligand driving CD163 signaling was not determined in the study, TWEAK was postulated
to be the ligand because its secretion post LPS has been reported235. Collectively, these
studies indicate that activation of CD163 skews myeloid cells toward the antiinflammatory phenotype to maintain immune homeostasis.
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CD163 is essential for the role of M2 myeloid cells in hyperresponsive airway
disease, while its role in AD is less clear. In asthma, M2 myeloid cells also play a crucial
role in balancing the homeostasis. One study has reported that abundant CD163expressing (M2) macrophages are found in asthmatic lungs in patients. Conversely,
ovalbumin-induced airway hyperresponsiveness and the number of eosinophils were
greatly reduced in CD163-deficient mice236. Although hemolysis and the generation of
Hb-Hp complexes were not determined in the study, prominent hemolysis in an airway
hypersensitivity condition has not been reported. This study supports a critical role for
CD163 in M2 polarization, contributing to asthmatic airway remodeling. In AD, CD163
expression on microglia is increased in patients’ brain parenchyma compared to non-AD
cases237,238. Because CD163 expression is not correlated with the number of Ab or NFT,
CD163 expression was postulated to be a general reaction to both neuronal debris and
abnormal extracellular proteins, but not specific to Ab or NFT170. Given the limitations of
correlational studies, more evidence on the role of CD163 in AD is needed.
Different ligands or antibodies can lead to distinct signaling pathways following
CD163 engagement. Interestingly, a proinflammatory response has also been reported
after CD163 activation. One study that activated CD163 by cross-linking with antibody
(clone EDHU1) resulted in IL-6, IL-1b and GM-CSF production via calcium mobilization
initiated by tyrosine kinase phosphorylations in CD163239. This finding indicates that the
conformation change of CD163 mediated by ligands or antibodies could direct the
signaling pathways. The exact mechanism of CD163 activation of IL-10 secretion is still
under investigation. Different ligands may induce distinct signaling of CD163, which
makes delineating CD163 signal transduction more challenging.
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In summary, CD163 can bind to various ligands and has anti-inflammatory functions
in general. Despite phosphorylation sites in the intracellular domain being identified, the
signaling pathway from CD163 internalization to IL-10 secretion or anti-inflammatory
responses has not been entirely elucidated. Correlational studies in tumor immunology
have demonstrated its anti-inflammatory function in myeloid cells, although the role of
CD163 in AD remains unclear. CD163 is more than a marker reflecting an antiinflammatory state, as in vivo as well as ex vivo studies simulating pathologic state in
other diseases like asthma demonstrated that activation of CD163 modulates M2
response in myeloid cells.

2.2.2 CD204
CD204 is a class A scavenger receptor that is predominantly expressed on myeloid
cells such as macrophages and microglia240. It is a single-pass transmembrane protein
with its C-terminal on the extracellular side. CD204 is characterized by a homotrimeric
structure on the cell surface, and each monomer comprises an SRCR, collagen, and
coiled-coil domain. The SRCR has been shown to bind to dead cells through spectrin241,
while the collagen domain is the primary binding domain for ligands, including acetylLDL, LPS, fucoidan, and many others240. LPS can promote CD204 expression on
myeloid cells via its mitogen-activated protein kinase (MAPK)/extracellular signalregulated kinase (ERK) pathway activation242. Other inflammatory mediators like TNF-a
and IL-6 have also been reported to upregulate CD204 expression on endothelial cells.
However, how the induced CD204 further modifies the effect of these cytokines on
myeloid cells is unclear243.
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CD204 expression is essential in the removal of amyloid plaques in AD. Microglia
expressing CD204 were observed near amyloid plaques in the brain pathology of AD
patients244. CD204 is important in microglial adhesion to amyloid plaques, as both fibrillar
and soluble Ab were found to be ligands for CD204245,246. Accumulation of amyloid
plaque was considered to be the result of a decrease in the Ab clearance capacity of
microglia, which have a reduced level of Ab-degrading enzymes in the later disease
stages. This diminished capacity of microglia might be due in part to the increased
proinflammatory cytokines that were stimulated by CD36 activation135,247.
CD204 also has a critical role in immune modulation in AD. In a common mouse
model used in AD research, the PS1-APP mouse model, decreasing CD204 expression
is inversely correlated with increasing proinflammatory cytokine IL-1b and TNF-a
expression as disease progresses135. On the contrary, crossing the CD204 KO (scara-/-)
mouse with the PS1-APP mouse resulted in increased Ab accumulation and mortality248.
Collectively, the evidence demonstrates the critical role of CD204 in the clearance of Ab
and modulation of proinflammatory responses in AD, although subsequent CD204
signaling in microglia downstream of Ab engagement has not been elucidated.
The functional output by CD204 activation is as versatile as its ligand collection,
which might be due to signaling with co-factors. For instance, polyinosinic acid (poly(I))
and fucoidan both compete with fibrillar Ab for the binding of CD204245. In a study of
astrocytes, nitric oxide and IL-1b secretions were significantly induced by the
engagement of poly(I) to CD204. However, only low levels of secretion were triggered
by the engagement of fucoidan to CD204. Furthermore, intracellular signaling analysis
also showed increased phosphorylation of c-Jun N-terminal Kinase (JNK) and ERK in
the poly(I)-treated group but not in the fucoidan-treated group. This finding demonstrated
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that CD204 signaling could be significantly affected by the bound ligands and that CD204
might transduce signals with the help of other co-factors249.
CD204 regulates inflammatory responses by modulating their signaling. CD204
does not have a tyrosine residue in its cytoplasmic domain. Instead of activating typical
signaling through phosphorylation of tyrosine, CD204 was found to induce signaling
through serine phosphorylation240,250. Furthermore, studies also found that CD204
associates with other receptors in regulating their signaling. For instance, modification of
TLR4 signaling by CD204 has been well demonstrated. Typically, activation of TLR4 by
LPS induces subsequent phosphorylation of IL-1 receptor-associated kinase 1 (IRAK1)
that recruits TNF receptor-associated factor (TRAF6) for its dimerization and polyubiquitination. The poly-ubiquitinated TRAF6 further forms a complex with TGF-bactivated kinase 1 (TAK1) and TAK1-binding protein 2 (TAB2) that activate nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB) which results in transcription of
proinflammatory cytokines. CD204 has been shown to compete with phosphorylated
IRAK1 in binding TRAF6, and thus interrupts the ubiquitination of TRAF6, the subsequent
NF-kB activation, and cytokine production251.
In line with its modulatory function on TLR4, CD204 has also been shown to inhibit
the downstream interferon regulatory factor 3 (IRF-3) pathway and IFN-b secretion252.
This inhibitory function has implications in cancer in which decreased IFN-b has been
shown to be critical in restraining lymphoma growth253. Moreover, inhibition of CD204 by
a small molecule inhibitor or loss of CD204 by genetic knockout was shown to impede
ovarian and pancreatic cancer invasion and metastases254. Another example of CD204
co-signaling is its interaction with Mer tyrosine kinase (MerTK) in M2 macrophages.
MerTK expression is mostly restricted to M2 macrophages, and its expression is
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inversely associated with prognosis in cancer patients. Activation of MerTK leads to IL10 secretion that further maintains the M2 polarization of the TAMs. CD204 was found
to be essential for the signaling of MerTK, as loss of CD204 led to reduced MerTK
phosphorylation and function255,256. These data demonstrate that CD204 is more than
simply a marker denoting M2 macrophages and that it regulates inflammatory responses
by associating with other receptors and modulating their signal transduction.
CD204 can induce distinct inflammatory responses following interaction with
different ligands. Interestingly, CD204 has also been shown to associate with TLR3 and
TLR9, leading to proinflammatory cytokine secretion257, which again demonstrated that
CD204 has a versatile capability in modulating immune responses via its association with
other receptors, in addition to its vast collection of ligands in different diseases. However,
in pathologic conditions like cancer and AD, in vivo and in vitro studies have established
the immune inhibitory role of CD204 in their pathogeneses.
In summary, CD204 binds a variety of ligands, and does not have a typical
intracellular signaling domain. CD204 was shown to associate with other receptors to
facilitate or modulate their signaling transduction. In the tumor microenvironment and AD
brains, the inhibitory role of CD204 has been established both in vitro and in vivo. This
modulatory capability could result from inhibiting activation of TRAF6-NFkB and IRF3. In
contrast to the situation where the suppressive role of CD204 in the tumor
microenvironment leads to a decrease in the desired anti-tumor effect, loss of CD204
promotes inflammation and exacerbates neurodegeneration in AD. Harnessing the
immune-modulatory property of CD204 in AD to mitigate the inflammatory damage
remains to be explored.
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2.2.3 FcgRIIb
Fcg receptors (FcgRs) have the properties of scavenger receptors. While FcgR was
not classified as a scavenger receptor in a recent nomenclature consensus workshop213,
increasing numbers of studies have shown that FcgRs can bind to multiple ligands such
as modified LDL and Ab in addition to their typical ligand, IgG258,259. According to the
definition, that scavenger receptors are surface receptors capable of binding various selfor non-self-ligands for removal, FcgRs are indeed scavenger receptors.
FcgRs are critical in both innate and adaptive immunity, while its dysfunction
contributes to a range of diseases. FcgRs are predominantly expressed on immune cells
that are critical in defense mechanisms. For example, natural killer (NK) cells and
neutrophils use FcgRs for antibody-dependent cell-mediated cytotoxicity (ADCC), while
myeloid cells use FcgRs to facilitate the removal of opsonized cells or substances. Given
their essential function in mounting an effective host defense, most of the members in
the FcgR family are activating receptors, the exception being FcgRIIb193,260. Both
activatory and inhibitory FcgRs are critical in bridging innate immune responses to
adaptive immune responses. Immune complexes internalized via activating FcgRs on
DCs preferentially help T cell activation for adaptive cellular responses, and
internalization via FcgRIIb on DCs favors activation of B cells for humoral responses261.
Additionally, inadequate or excessive FcgRIIb function can result in autoimmune
diseases or tumor progression in cancer, respectively214,262,263. Therefore, FcgRIIb acts
as a checkpoint molecule that has important implications in maintaining immune
homeostasis.
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Expression of FcgRIIb, the only inhibitory FcgR, is regulated by cytokines. FcgRIIb
is predominantly expressed on B cells, basophils, macrophages, and monocytes264,265.
Other than the expression on immune cells, the expression of FcgRIIb was also found on
sinusoidal endothelial cells in the liver, smooth muscles in the airway, and neurons in
brain259,266,267. FcgRIIb is characterized by a C2-set immunoglobulin-related domain in its
extracellular region, a single-pass transmembrane domain, and an intracellular
domain265,268. The expression of FcgRIIb is upregulated by cytokines such as IL-4, IL-10,
and IL-6, and down-regulated by TNF-a and IFN-g269,270.
Isoforms of FcgRIIb have different internalization efficiency but the same inhibitory
signaling domain. Two isoforms, FcgRIIb1 and FcgRIIb2, are generated by alternative
splicing. FcgRIIb1 is mostly found on B cells, while FcgRIIb2 is found on myeloid cells.
Compared to the rapid internalization property of FcgRIIb2, FcgRIIb1 has a more
extended cytoplasmic domain that slows the endocytosis of the receptor271. Nevertheless,
both of the isoforms contain the endocytosis di-leucine signal and an immunoreceptor
inhibitory motif (ITIM) domain that is critical in regulating immune activation272,273.
ITIM stimulation down-regulates activating signaling pathways initiated by other
receptors. When an immunoreceptor activatory motif (ITAM)-containing receptor is
activated, a tyrosine residue in ITAM is phosphorylated by Src family kinases such as
Lyn, which results in the recruitment of Syk family kinases that leads to the generation of
downstream signaling molecules like phosphatidylinositol (3,4,5)-triphosphate (PIP3)274.
The ITIM can also be phosphorylated by Lyn and another Src family kinase, Blk. However,
ITIM phosphorylation will preferentially recruit inositol phosphatases Src homology 2
(SH2) domain-containing inositol polyphosphate 5-phosphatase (SHIP) 1 and 2 that
degrade the activating signaling molecule PIP3275,276. SHIP is also critical in the
66

recruitment of p62 Dok and subsequently Ras GTPase activating protein (RasGAP) to
activate Ras GTPase, which will result in ERK inhibition277,278. While the discoveries of
the signaling pathways were mostly made in B cells, the inhibitory pathways initiated by
FcgRIIb are also reportedly applicable in myeloid cells193,279. Overall, the balance
between activating and inhibitory signaling within a cell determines its inflammatory state.
Similar

to

the

role

of

other

inhibitory

scavenger

receptors

in

tumor

microenvironments, enhanced FcgRIIb expression in the tumor microenvironment is
correlated with poor anti-tumor responses and the resistance of the tumor to antibodybased therapy. Genetic removal of FcgRIIb in mouse models resulted in an enhanced
anti-tumor effect of antibody therapies, while the removal of activating FcgR led to tumor
progression214. In line with the genetically modified models, blocking FcgRIIb with an antiFcgRIIb monoclonal antibody or modifying the Fc region of the therapeutic antibody for a
better affinity to activatory FcgR have been shown to promote antibody-based cancer
treatments280,281.
Harnessing the potential of the regulatory function of the ITIM in an inflammatory
condition such as AD has not been well established. The idea of manipulating ITIM
signaling in the inflammatory state in AD is tempting. However, extra caution should be
taken, because it was reported that FcgRIIb expressed on neurons mediates
neurotoxicity of Ab259. Ab1-42 binding to FcgRIIb on neurons activates Lyn kinase that
induces phosphorylation of the receptor, hyperphosphorylation of Tau, and cellular death,
which are prevented by Lyn inhibition282. These studies demonstrated that activation of
the FcgRIIb pathway has the potential to exacerbate Ab toxicity and Tau
hyperphosphorylation in neurons, although inflammatory responses by myeloid cells
after inhibition by FcgRIIb were not determined. Based on these data, it would be ideal
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to specifically either promote FcgRIIb on immune cells or to inhibit FcgRIIb only on
neuronal cells to avoid potential side effects.
In summary, FcgRs have the scavenger receptor capability of binding to multiple
ligands for removal, although they are not officially classified as scavenger receptors.
Among the FcgRs, FcgRIIb is unique due to its inhibitory function. FcgRIIb comprises an
intracellular ITIM domain which counters ITAM signaling and ERK activation and is
critical in maintaining immune homeostasis. The role of FcgRIIb on myeloid cells has
been widely studied in cancer immunology as it dampens the inflammatory responses
required for tumor rejection. While it is undesirable in most cancer settings, specific
FcgRIIb activation in myeloid cells may help to curb the inflammatory responses in AD
and remains to be explored.

2.3 Summary
Knowledge gained from tumor immunology has illuminated how myeloid cells in the
tumor shape a tolerant microenvironment allowing tumor growth, in which upregulation
and activation of scavenger receptors CD163, CD204, and FcgRIIb on myeloid cells help
to regulate inflammatory responses. A better understanding of their signal transduction
pathways will enable us to harness and apply anti-inflammatory properties to other
inflammatory diseases, such as AD.
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Chapter 3: Novel Therapeutic—Engineered Monocytes that Efficiently
Clear o-Tau and Redirect the Inherent Linked Proinflammatory
Cytokine Secretion

3.1 Introduction
AD is a multifactorial disease in which o-Tau and neuroinflammation are both found
to be highly clinically relevant in accelerating neurodegeneration23,52,102,109. Moreover,
they are not independent pathogenic entities but intertwined in promoting
neurodegeneration in AD. Tau pathology stimulates inflammatory responses of myeloid
cells, and myeloid cells further catalyze the aggravation of proteinopathy (Fig. 1).
Disturbed generation and clearance of pTau in neurons results in a net elevation of
intracellular pTau level, which can be caused by various factors such as mutation of the
MAPT gene, unfavorable alternative splicing, imbalance of kinase and phosphatase
activity due to conditions like inflammation and acidosis, and other post-translational
modifications of Tau60,69,70,81,85,86. As pTau builds up and oligomerizes in the neurons,
loss of the physiologic function of Tau proteins and the presence of the newly formed
neurotoxic o-Tau together induce synaptic toxicity, impair mitochondrial function, and
promote apoptotic pathway activation96,97. In addition to exosome dissemination,
exocytosis, and synaptic transmission of neurotoxic Tau species from neuron to neuron,
these Tau species are also released into the extracellular compartment after neuronal
death126.
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Figure 1: Neurotoxic oligomeric Tau and chronic inflammation jointly perpetuate
a positive feedback cycle that damages neurons.
Hyperphosphorylated Tau (pTau) oligomerizes into a higher order of assembly, including
a neurotoxic Tau oligomer (o-Tau). These Tau species are released extracellularly and
can be taken up by other neurons to serve as a seed for further Tau aggregation. Myeloid
cells, like resident microglia and recruited monocytes, can also take up o-Tau but at the
cost of proinflammatory cytokine secretion. The myeloid cells even lose clearing capacity
at a later stage of the disease, despite secreting more proinflammatory cytokines.
Moreover, the proinflammatory cytokines are neurotoxic and further stress neurons,
promoting phosphorylation of Tau, which feeds forward in a vicious cycle.
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The presence of o-Tau and its interaction with myeloid cells creates a positive
feedback loop for abnormal Tau accumulation. Species of o-Tau composed of three or
more Tau monomers can be taken up by other neurons and induce conformational
change in normal Tau inside the neurons54,87. Extracellular o-Tau can also be taken up
by the scavenger cells in the CNS, such as microglia, that try to degrade them using
lysosomal pathways but with limited effect113,136. At the same time, microglia secrete
proinflammatory cytokines100,136 that can have an autocrine effect141,142, attract peripheral
immune cells like monocytes into the CNS111,112, promote further hyperphosphorylation
of Tau in neurons, and lead to neuronal death108,125. Monocytes are peripheral myeloid
cells recruited into the brain that can also contribute to the proinflammatory cytokine
production, although they possess a better ability to phagocytose and degrade o-Tau136.
In summary, the myeloid cells in the CNS appear to have “good intentions” to clear
neurotoxic Tau species to protect neurons, but they end up causing more damage to
neurons and resulting in even more pTau accumulation in the CNS.
Targeting Tau pathology using an antibody as a strategy to interrupt the feedforward loop could instead lead to a stronger inflammation that causes more neuronal
death. The most promising therapeutic method to date is immunotherapy to block
proteinopathy propagation, including a monoclonal antibody that targets pTau species
including o-Tau. However, observed adverse effects like cerebral inflammation and
microhemorrhage, and limited cognitive improvement in the clinical trials to date, have
raised concerns with this approach. Causes underlying the adverse effect were attributed
to the activation of myeloid cells exacerbated by the antibody or vaccine. One group has
proposed that the key may lie in the Fc domain of the monoclonal antibody used. They
have demonstrated that an unmodified monoclonal antibody can prevent o-Tau from
entering neurons and associated neuronal damages in the absence of microglia. When
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they mimicked the pathological brain by co-culturing microglia with neurons,
administration of the unmodified antibody activated Fc receptors on the myeloid cells,
inducing abundant proinflammatory cytokines and further damaging the neurons. In
contrast, administration of the antibody with a mutated Fc domain that cannot bind FcgR
not only prevented o-Tau from entering neurons but also significantly reduced
proinflammatory cytokine secretion from microglia and preserved the co-cultured
neuron100.
Mutating the Fc domain of antibody provides a solution to the undesired FcgR
activation on myeloid cells and the subsequent inflammatory bursts; however, it impairs
the clearance of the pathologic Tau burden in the CNS. FcgR-mediated endocytosis and
the subsequent degradation by myeloid cells is a major pathway to clear o-Tau:antibody
complexes283. Antibodies are also capable of internalization into neurons via FcgRII/III
and may target intracellular o-Tau for degradation284,285. Therefore, loss of binding to
FcgRs reduces the intracellular o-Tau targeting efficacy of antibodies.
In summary, impaired engagement with FcgRs due to antibody Fc modification
raises concerns of reduced o-Tau:antibody complex clearance in the CNS. Moreover, it
is unknown whether o-Tau:antibody complexes retain oligomerization capability and
prion-like activity. The stability of the complexes makes it unclear if o-Tau would
eventually dissociate from the antibody. These data indicate that the modification of the
Fc region of the antibody may not be able to facilitate simultaneous clearance of o-Tau
and limitation of inflammation, leaving an opportunity for o-Tau to feed the pathogenesis
cycle again. However, a therapeutic capable of promoting o-Tau clearance while
dampening proinflammatory activation is not currently available.
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3.2 The rationale of engineered monocytes stably expressing a chimeric
scavenger receptor
Peripheral monocytes have a higher capacity for neurotoxic o-Tau clearance, but
their inherent inflammatory response limits their use as a treatment. The most neurotoxic
Tau species, o-Tau, can be found in the CNS even at the early stage of disease96,286.
Moreover, o-Tau is not only toxic to the neurons directly but also mediates Ab toxicity.
Peripheral monocytes were demonstrated to have a higher potential for clearing o-Tau
compared to microglia136. Introducing peripheral monocytes into the brain to aid
dysfunctional microglia in providing a more efficient o-Tau clearance seems to be an
attractive approach. However, the observation that o-Tau induces proinflammatory
cytokine production in peripheral monocytes in vitro supports the idea that the linked
proinflammatory cytokine secretion after the uptake of o-Tau is also hard-wired in
peripheral monocytes as well as microglia100. Therefore, recruited peripheral monocytes
are also capable of aggravating the ongoing inflammation in the brain.
To decouple the undesired inherent proinflammatory cytokine production from the
favorable

o-Tau

clearance

capacity

of

peripheral

monocytes

would

require

reprogramming the cellular machinery to redirect the engaged o-Tau from activating
inflammatory responses. From tumor immunology, we learned that anti-inflammatory
signaling of scavenger receptors on myeloid cells contributes to a dampened immune
response against tumors in the tumor microenvironment. Unwelcome as it may seem in
tumor microenvironments, anti-inflammatory scavenger receptors could be leveraged to
divert peripheral monocytes to calm the inflammation. However, the idea of harnessing
the anti-inflammatory properties of scavenger receptors to alter the myeloid response to
o-Tau in AD has yet to be explored.
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The concept of the chimeric antigen receptor (CAR) involves redirecting the
recognition of extracellular antigen and strengthening the intracellular signaling. In tumor
immunotherapy, the engineering and application of CAR-T cells to treat cancer patients
have been widely studied. CAR-T cells are equipped with an activating signaling domain
and an artificial receptor composed of an antigen-recognition domain that is usually a
single-chain variable fragment (scFv) from a monoclonal antibody. This approach
enables the CAR-T cell to specifically target tumor cells via the scFv and transduce the
designed functional signals intracellularly to enhance its cytotoxicity, proliferation, or
cytokine secretion to better eliminate tumor cells. Such an approach has had great
success in cancer patients, especially in leukemic patients, for a specific range of
targets287. The CAR concept is not only limited to T cell receptor signaling and T cells. It
has recently been applied to engineer other receptors, such as TLRs, and has also been
used in peripheral myeloid cells like monocytes and macrophages288. Very recently,
another group demonstrated success in treating ovarian cancer in a humanized mouse
model with engineered CAR-monocytes289.
The application of cellular therapy is not only limited to cancer. In the
neurodegeneration field, the idea of adoptive cell therapy has also been tested, although
the cells were not engineered to express CAR. Researchers intravenously infused
peripheral monocytes overexpressing an Ab degrading enzyme neprilysin into an AD
mouse model in vivo. Although the availability of the engineered monocytes to migrate
into the brain was limited due to entrapment in the peripheral organs, Ab deposits in the
brain were reduced171. These data gave support to the concept of CAR technology and
engineering peripheral monocytes, and their potential application in AD. However, the
idea of a chimeric scavenger receptor (CSR) has not been examined, let alone in AD.
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3.3 Specific aims
Tackling a multifactorial and complex disease like AD requires a multipotent
therapeutic. Previous efforts by others have allowed us arrive at a vantage point where
we can consider the two clinically-relevant factors, o-Tau and neuroinflammation, that
jointly catalyze neurodegeneration in AD. More importantly, the history of the rise and fall
of therapeutics in pursuit of curing AD has provided invaluable lessons that help reorient
our focus on a better target when designing a next-generation therapeutic. A therapeutic
capable of simultaneously resolving more than one etiology, or circumventing
deterioration of other etiologies, is urgently needed yet does not exist. Thus, there is an
unmet need for a novel therapeutic that catalyzes o-Tau degradation without triggering
neurotoxic proinflammatory cytokine release from the CNS myeloid cells.
Here, we introduce the entirely novel concept in AD treatment of integrating the
superior o-Tau clearing capability of peripheral monocytes with the anti-inflammatory
potential of scavenger receptors. We propose to leverage CAR technology to engineer
monocytes expressing CSR that are capable of efficient internalization of o-Tau without
inflammatory activation upon o-Tau clearance.

We hypothesize that monocytes

engineered to bind and internalize o-Tau via antibody-redirected CSR will halt the
progression of AD by protecting neurons from o-Tau-mediated neurotoxicity, while
dampening proinflammatory cytokine release. This hypothesis will be addressed by the
following aims:
Aim 1. Construct a functional CSR composed of an M2 scavenger receptor and
anti-o-Tau scFv, and demonstrate stable surface expression by monocytes.
Aim 2. Assess the capacity of CSR monocytes to internalize and degrade o-Tau
with limited inflammatory cytokine release and investigate the mechanisms
of o-Tau internalization and degradation.
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Aim 3. Determine the capacity of CSR monocytes to halt the progression of
neurodegeneration both in vitro and in a preclinical model of AD.

3.4 The innovation of engineered monocytes stably expressing chimeric
scavenger receptors
This proposed idea is conceptually innovative because it simultaneously targets
critical etiologies of AD, inflammation, and Tau pathology. As illustrated earlier, previous
efforts focusing on a single etiology such as targeting Aβ proteins with monoclonal
antibodies or vaccines, or curbing inflammation by NSAIDs, failed to show clinical
benefit37,181,182. Trials of monoclonal antibodies against the more clinically-relevant Tau
pathology have yet to report positive findings in the clinic290. Moreover, the antibody
approach has been shown to induce undesired inflammatory responses. Modification of
the Fc domain of the monoclonal antibody to prevent inflammation in turn impairs the
clearance of pTau100.
Our innovative CSR approach is an interdisciplinary integration of the knowledge
from both tumor immunology and AD. We adopt an scFv based on an anti-pTau antibody
with validated potential to limit o-Tau induced neurodegeneration in an AD mouse model
in our CSR design. This design not only serves to enhance the clearance of neurotoxic
o-Tau but also redirects monocyte responses by signaling through anti-inflammatory
scavenger receptors. The invention of CSRs incorporating an scFv, in this case with
specificity for o-Tau, is technologically innovative and has never been previously
reported. Our concept aims to not only attenuate Tau pathology but also to overcome
the accompanying inflammation, an overarching challenge in the AD field.
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Adoptively transferring engineered cell therapy via an intracerebroventricular (ICV)
route is an innovative concept in AD. Injections through ICV devices are safe and widely
used in the clinic and well tolerated by patients. Their current use has been mostly limited
to delivering chemicals such as chemotherapy or antibiotics291. To prevent the undesired
entrapment of the engineered cells during in vivo delivery observed in other studies171, I
propose to adoptively transfer the engineered cells into cerebral ventricles via an ICV
device for efficient delivery. As proof of this concept, I have successfully performed
repeated infusions via an ICV device in mice without significant complications in vivo.
Transferring cell therapy via an ICV device to avoid off-site loss as well as side effects,
and to improve delivery efficiency would be a pioneering advance in AD.

77

Chapter 4: Methods
4.1 Experimental animals
Male and female C57BL/6J mice, as well as male P301S mice and female noncarrier mice on a C57BL/6 x C3H/HeJ background, were obtained from The Jackson
Laboratory (Bar Harbor, ME). The carrier status of the P301S mice was confirmed by
genotyping. The mice were housed according to the Association for Assessment and
Accreditation of Laboratory Animal Care and NIH standards. All experiments were
conducted per the protocols approved by the University of Texas MD Anderson Cancer
Center Institutional Animal Care and Use Committee.

4.2 Cell lines and media
The mouse peripheral monocyte/macrophage cell line PMJ2-PC was obtained from
the American Type Culture Collection (ATCC) and maintained in 10% fetal bovine serum
(FBS) in RPMI media (GE Health) supplemented with L-glutamine (Gibco) and penicillin–
streptomycin (Gibco). The cells were detached from the flask using 0.05% Trypsin
(Gibco). Dr. Jim Ray, at the Neurodegeneration Consortium, generously provided the
BV2 microglial cell line. The BV2 cell line was maintained in 5% FBS in DMEM
supplemented with L-glutamine and penicillin–streptomycin. The cells were dissociated
from the flask with 2 mM of EDTA (Promega) in phosphate-buffered saline (PBS).
Primary hippocampal neurons were plated using Neurobasal plating media (10%
FBS in Neurobasal media (Thermo Fisher) supplemented with B27 (Gibco), L-glutamine
(Corning), and penicillin–streptomycin). The neurons were maintained in Neurobasal
feeding media (Neurobasal media supplemented with B27, L-glutamine, and penicillin–
streptomycin)292.
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4.3 Oligomerization and isolation of Tau
Drs. Ines Moreno-Gonzalez and Claudio Soto of the Department of Neurology at
the University of Texas McGovern Medical School generously provided Tau and the
equipment necessary to extract, oligomerize and isolate o-Tau. The process could not
have been done without the help of Mr. Nicolas Mendez in the laboratory of Drs. MorenoGonzalez and Soto.
Human full-length Tau (2N4R) was produced by Escherichia coli from Tau40
expression plasmids. Protein content was extracted using ammonium sulfate (SigmaAldrich), and the Tau was isolated by size exclusion chromatography (SEC) using an
AKTA Pure (Cytiva) with a HiTrap SP HP cation exchange chromatography column
(Cytiva). The product collected was further dialyzed into a buffer containing 10 mM of
HEPES and 100 mM NaCl, pH 7.4. The monomeric Tau was collected in the supernatant
after centrifugation. The concentration was determined using the Pierce BCA
(Bicinchoninic Acid) Protein Assay (Thermo Fisher) before the monomeric Tau stock was
stored at -80 °C.
To oligomerize Tau, 25 µM of high molecular weight Heparin (Sigma-Aldrich) was
added to 50 µM of 2N4R monomeric Tau. The mixture was incubated at 500 rpm, 37 °C
for 16 hours using a thermomixer (Eppendorf). The mixture was passed through 0.2 µm
filter (Millipore) to remove large insoluble aggregates before it was injected into the SEC
Superdex 200 10/300 GL chromatography column. The proteins were eluted with PBS,
and the fractions containing o-Tau were collected. The collected fractions were further
passed through a 0.2 µm filter to remove potential microbial contamination. The o-Tau
fractions were then snap-frozen in liquid nitrogen and stored at -80 °C.
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The concentration was determined using BCA, and the molar concentration was
calculated based on the molecular weight of a Tau monomer87. The endotoxin level in
the o-Tau fractions was also determined by using the Pierce Chromogenic Endotoxin
Quant Kit (Thermo Fisher).

4.4 Design and synthesis of chimeric scavenger receptor constructs
The coding sequence sequences of murine FcgRIIb, CD204, and CD163 were
acquired from the Consensus of Coding Sequence (CCDS) database and UniProt
database293. The natural ligand-binding domains of these scavenger receptors were
removed (CD204 and CD163) or modified (FcgRIIb), and replaced with an scFv that can
limit o-Tau propagation.
To provide proof-of-concept for our CSR, we used an anti-pTau monoclonal
antibody that has been shown to effectively limit o-Tau propagation in vitro to build our
scFv100,294. An anti-pTau affinity-matured variant of the antibody with a Kd 5.2 nM was
selected, and the amino acid sequences of the variable regions of the heavy and light
chains were used in our CSR design. To generate the scFv, the heavy chain variable
region and the light chain variable region were connected with a linker. The scFv was
further linked to the modified scavenger receptors with a hinge. To obtain the coding
sequence of the CSR, the amino acid sequence of the scFv was converted to codons
and integrated with the coding sequence of the modified scavenger receptors.
The coding sequence of the CSR was further optimized for a more stable
transcription and higher translation by using an online codon optimizer (Integrated DNA
Technologies). The sequences were further edited to accommodate restriction enzyme
sites at the ends of various functional domains using Serial Cloner 2.6. The finalized
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constructs of CSR were synthesized into pUC57 plasmids by a commercial service
provider (GenScript).

4.5 Cloning of the chimeric scavenger receptor constructs into retroviral vectors
To clone the designed constructs into the retroviral vector pMG-Neo containing the
ampicillin selection gene, synthesized plasmids containing the designed FcgRIIb-CSR,
CD204-CSR, or CD163-CSR in pUC57 plasmids were enzymatically digested using
PspOMI and XhoI (NEB). The pMG-Neo vector was digested with NotI and SalI (NEB).
The digested products were separated in a 0.8% agarose gel by electrophoresis. The
bands containing the constructs or the vector were individually isolated with a new
scalpel for each band.

DNA was extracted from the gel using the GeneJET Gel

Extraction Kit (Thermo Fisher), and the amount and quality of the extracted DNA were
determined using a Nanodrop Spectrophotometer (Thermo Fisher). Ligation reactions
with T4 Ligase (NEB) were set up with a construct to vector molar ratio of 1:3, 1:6, and
1:10. After 2 hours of incubation at room temperature, competent E. coli cells with a low
recombination rate (NEB) were transformed with the ligation products. The transformed
cells were plated on ampicillin selection agar plates and incubated at 30 °C overnight. At
least five ampicillin-resistant clones were picked per plate and expanded for diagnosis.
For the cloning of FcgRIIb-CSR and FcgRIIb2-CSR into the pMG-YFP retroviral vector,
the protocol was the same as described above except that the digestion enzymes used
were NotI and XhoI (NEB).
The successful cloning was confirmed by restriction enzyme digestion, and its
accuracy was further validated by Sanger sequencing. The bacterial clones with correct
sequences were further expanded on a larger scale. The plasmids were extracted using
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the Macherey-Nagel Maxiprep Kit (Fisher Scientific), and its accuracy was again verified
by both restriction enzyme digestion and Sanger sequencing.

4.6 Verifying the chimeric scavenger receptor cloning products
Plasmid DNA from the expanded bacteria was extracted using the ZR Plasmid
Miniprep Kit (Genesee Scientific) or Maxiprep kit. The plasmids were digested with
different combinations of restriction enzymes, such as NotI with StuI or SphI with MfeI
(NEB). The digested products were loaded onto a 0.8% agarose gel. After
electrophoresis, the gel was imaged by using the ChemiDoc gel imaging system (BioRad).
To further verify the accuracy of the genetic material transfer during cloning and
expansion in the competent E. coli cells, the extracted plasmids were also examined by
Sanger sequencing performed by the Sequencing and Microarray Facility at the
Department of Genetics at UT MD Anderson Cancer Center. All the plasmids needed to
have accurate sequence alignments in both forward and reverse sequencing before they
were used in the transduction.

4.7 Modular modification of chimeric scavenger receptor constructs
The restriction enzyme sites at the ends of different functional domains in the CSR
were designed to enable removal of a specific domain sequence or swapping for another
functional domain. In the initially-designed CD163-CSR, the cassette domain was
removed using restriction enzyme MscI (NEB) digestion of the pUC57-CD163-CSR
plasmid. The remaining part of the plasmid was extracted from the gel and ligated using
T4 Ligase using the cloning method described above. The successful bacterial clones
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were selected and their sequence accuracy was determined with enzyme digestion as
well as sequencing.
The intracellular domain containing the FcgRIIb1-specific sequence was removed
from the pUC57-FcgRIIb-CSR plasmid by enzymatic digestion with MfeI and XhoI. The
DNA was extracted and ligated with the FcgRIIb2-specific sequence using T4 Ligase.
The ligated product was used to transform competent E. coli cells, and the newly
generated pUC57-FcgRIIb2-CSR plasmid was confirmed by restriction enzyme digestion
as well as Sanger sequencing. Both of the modified plasmids were further used for
cloning into retroviral vectors, as described above.

4.8 Transduction of peripheral monocytes
The retroviral vectors pMG-Neo containing FcgRIIb-CSR, CD204-CSR, or CD163CSR were packaged along with the envelope plasmid (pCI-VSV-G) and packaging
plasmid (pKF3RSV*GP) using TransIT-293 transfection reagent (Mirus Bio). Phoenix GP
cells were transfected to produce viral particles. The viral particles were collected 48
hours

post-transfection

and

were

used

to

transduce

the

peripheral

monocyte/macrophage cell line PMJ2-PC in a 6-well plate. Polybrene (Sigma-Aldrich)
was used to facilitate the uptake of the viral particles by the cells. The cells were then
centrifuged at 1,363 rcf for 2 hours at 32 °C before they were incubated at 37 °C.
The cells were transferred to T25 flasks 3 days after the transduction, and cytotoxic
antibiotic G418 (Gemini Bio) was added at 1 mg/mL to enrich the successfully transduced
clones. The cells were frozen after they underwent the selection process for at least two
more passages. Whenever the cells were recovered from freezing, they underwent
another cycle of selection before the experiments started.
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4.9 Verification of successful transduction
Either parental or transduced monocytes were fixed in fixation buffer (Life
Technologies) overnight at 4 °C and washed with permeabilization wash buffer. A total
of 5 x 104 cells of each cell type were resuspended in PBS and plated on microscope
slides using a CytoSpin (Thermo Scientific) at 2,000 rpm for 5 minutes. The cells were
permeabilized with 0.1% Triton X-100 and stained with a mouse anti-histidine tag primary
antibody (HIS.H8, Thermo Fisher), then labeled with donkey anti-mouse IgG-Alexa Fluor
594 (Invitrogen). Prolong-Gold with DAPI mount (Invitrogen) was applied. The cells were
then imaged using a Leica SP8 confocal microscopy at the Advanced Microscopy Core
at UT MD Anderson Cancer Center.

4.10 Determination of proinflammatory cytokine secretion by the engineered
monocytes
Either parental or engineered monocytes were stimulated with o-Tau in a 96-well
plate for 24 hours. The supernatant was collected after the plate was centrifuged. The
supernatant was frozen and stored at -80 °C. Later, the supernatant was thawed on ice,
and the cytokines were detected using the Cytometric Bead Assay and LSRII flow
cytometer (BD Biosciences) or ELISA kit (Thermo Fisher). The standard curve for each
cytokine measured was generated by five-parameter logistic regression using Graphpad
Prism 8.0. The cytokine concentrations were then calculated using the standard curves.

4.11 Determination of oligomeric Tau uptake by the engineered monocytes
Either parental or engineered monocytes were stimulated with o-Tau in a 96-well
plate for 24 hours. The cells were washed with PBS three times before being lysed by
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RIPA Lysis and Extraction buffer with both Proteinase and Phosphatase inhibitors
(Thermo Fisher). After 5 minutes of lysis on ice, the lysate was centrifuged at 14,000 rcf
for 15 min. The supernatant containing the protein extract was transferred to a new 1.5
mL Eppendorf tube and snap-frozen in liquid nitrogen. The frozen extract was stored at
-80 °C for later quantification experiments.
On the day of the quantification experiment, the extract was thawed on ice. The
protein content was determined by using BCA. Without boiling, an equal amount of
protein from each extract was loaded to a precast 4–15% protein gel (Bio-Rad). After
electrophoresis at 100 V for 90 min, the gel was transferred to nitrocellulose paper (BioRad). The blot was blocked with 5% bovine serum album (BSA) in 1% PBST (1% Tween20 in PBS). o-Tau was detected by using anti-o-Tau (T-22) antibody (EMD Millipore)295,
and a secondary goat anti-rabbit Ig antibody conjugated with horseradish peroxidase
(HRP) (Abcam). b-Actin was detected with an anti-b-Actin antibody–HRP (Abcam) in a
subsequent staining of the same blot. After development with Pierce ECL Western
Blotting Substrate (Thermo Fisher), the blot was imaged using the ChemiDoc gel imaging
system (Bio-Rad). Band volume and mean intensity were quantified using the software
included in the imaging system.

4.12 Determination of oligomeric Tau internalization by the engineered monocytes
Either parental or engineered monocytes were stimulated with 125 nM of o-Tau in
a 96-well plate for various lengths of time. After incubation with o-Tau for the specific
duration, half of the FcgRIIb-CSR monocytes were washed with acidic buffer (pH 3) to
remove o-Tau binding from the scFv of CSR on cellular surfaces296. The other half of the
monocytes were washed with PBS to retain both surface-bound and intracellular o-Tau.
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The cells were lysed, and their o-Tau level was quantified using the method described in
4.11.

4.13 Determination of o-Tau clearance by the engineered monocytes
To determine the o-Tau remaining in the supernatant using Western blot, either
parental or engineered monocytes were stimulated with 500 nM of o-Tau in a 96-well
plate for 24 hours in serum-free media. The supernatant was collected and snap-frozen
in liquid nitrogen before stored at -80 °C. On the day of the Western blot experiment, the
supernatant was thawed on ice and loaded to a precast 4–15% protein gel (Bio-Rad)
with an equal amount of protein from each experimental condition. After electrophoresis
and transfer of the gel onto a nitrocellulose membrane, o-Tau was detected using an
anti-o-Tau T-22 primary antibody (EMD Millipore) and a goat anti-rabbit Ig secondary
antibody–HRP. The blot was imaged and quantified using the ChemiDoc gel imaging
system (Bio-Rad) developed with Pierce ECL Western Blotting Substrate (Thermo
Fisher).
Remaining supernatant o-Tau was also analyzed by ELISA: in an independent
experiment, engineered monocytes were stimulated with 500 nM of o-Tau in FBScontaining RPMI media for 24 hours before the supernatant was collected and frozen.
Later, the supernatant was thawed on ice, and o-Tau was determined using the total Tau
ELISA kit (Thermo Fisher) and an absorbance reader (SpectraMax M2, Molecular
Devices).
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4.14 Harvest of primary mouse hippocampal neurons and their culture in vitro
The following procedures were modified from those published by Seibenhener et
al.292. The day before the harvest of primary neurons, the wells of the culture plate were
coated with 150 µL/cm2 of sterile rat-tail Type I collagen (150 µg/mL, Corning) and polyD-Lysine mixture (50 µg/mL, Millipore Sigma). The plate was incubated uncovered under
UV light at room temperature overnight. The plate was then washed with Hank’s
Balanced Salt Solution (HBSS, Cytiva) twice, and each well was filled with HBSS to
prevent drying. The plate was covered and could be used immediately or stored at 4 °C
for later use.
E18–E19 C57BL/6J pups were retrieved and decapitated immediately after the
pregnant mouse was euthanized. The heads of the pups were briefly immersed into 70%
ethanol and rinsed with PBS before being transferred to a plate with sterile PBS on ice.
The skull and the meninge were removed from the pup’s brain under dissection
microscopy. The brain was divided into two hemispheres in which the hippocampi were
revealed and isolated. All the hippocampi were collected into a plate with sterile PBS on
ice. The hippocampi were minced with a sterile scalpel and transferred into a 15 mL
conical tube. The minced tissues were incubated with trypsin (Gibco) at a final
concentration of 0.05% at 37 °C for 15 minutes. Tissues were washed with HBSS three
times. A fire-polished Pasteur pipette was used to triturate the masses. The supernatant
was collected and transferred to a new tube before the cells were spun down. The cells
were resuspended with the Neurobasal plating media. An automatic counter determined
the density of the cells right before plating.
On the first day in vitro (DIV), an equivalent volume of serum-free Neurobasal
feeding media was added to the well. On the third DIV, 50% of the media was replaced
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with Neurobasal feeding media and Cytarabine (Cayman Chemical) at the final
concentration of 5 µM was added to inhibit microglial proliferation. Thereafter, 50% of the
media was replaced with Neurobasal feeding media every 4 days until the 14th DIV.

4.15 Imaging co-cultured neurons with confocal microscopy
A glass microscope coverslip was disinfected with 70% ethanol and air-dried before
being placed into the well of a 6-well plate. The sterile coating described in 4.14 mixture
was added to the well (150 uL/cm2) and incubated under UV overnight at room
temperature. The coated glass slip remained in the well during and after washing away
the excess coating mixture. Primary neurons were harvested, and 2.0 x 105 cells were
plated and cultured using the method detailed in 4.14. On the 14th DIV, 5.0 x 105 cells
of either parental or engineered monocytes were plated in addition to 500 nM o-Tau. The
co-culture plate was incubated at 37 °C. After 72 hours incubation, the plate was washed
with PBS and cells were fixed with 4% formaldehyde. The cells were then permeabilized
with 0.1% Triton X-100 and stained with a primary mouse antibody targeting microtubuleassociated protein 2 (MAP2, Invitrogen), then detected by a donkey anti-mouse
secondary antibody conjugated with Alexa Fluor 555 (Thermo Fisher). The glass
coverslips holding neurons were flipped over to a microscope slide after applying
Prolong-Gold mountant (Invitrogen). The slides were then imaged using SP8 confocal
microscopy at the Advanced Microscopy Core at UT MD Anderson Cancer Center.

4.16 Imaging co-culture neurons with a high-throughput Operetta imager
An Operetta imager compatible, clear-bottom 96-well plate with black walls (Corning)
was coated using the method described in 4.14. Primary hippocampal neurons were
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plated at a density of 1.5 x 104 cells per well and maintained in vitro as described in 4.14.
On the 14th DIV, 3.0 x 104 or 6.0 x 104 cells of specific monocytes, in addition to 500 nM
of o-Tau, were added and incubated at 37 °C. After 72 hours of incubation, the plate was
fixed and stained with a primary antibody specific for MAP2, then detected with a donkey
anti-mouse secondary antibody conjugated with Alexa Fluor 555, as in the co-culture
prepared for confocal imaging (4.15). After the last wash, the wells were filled with PBS,
and the plate was imaged using an Operetta imager at the Neurodegeneration
Consortium and the Institution of Applied Cancer Science (IACS) at UT MD Anderson
Cancer Center. Nine fields around the center of each well were systemically imaged.

4.17 Surgical installation of the intracerebroventricular port
The ICV port is a device that can be connected to a plastic or silicone catheter.
During installation, the ICV port was first linked to a plastic catheter 2.0 cm in length and
was flushed with PBS to remove the gas inside the lumen. After the mouse was
anesthetized using gaseous isoflurane, the hair over the dorsal scalp and anterior back
were shaved before the skin was disinfected with povidone-iodine. A mid-line skin
incision of 8.0 mm was made on the scalp with a scalpel to expose the skull surface. The
periosteum around 1.0 mm right lateral to the Bregma was gently scratched with a needle
to create a bony surface area 6.0 mm in diameter. A burr hole on the skull was made
manually at the point 1.0 mm right lateral and 0.5 mm posterior to the Bregma with a 27G
needle. A subcutaneous pocket in the back was created using a blunt dissection method
with a scissor. The degassed ICV port was attached with a catheter that was placed to
the burr hole and fixed with superglue297. The port was held in place for 1–2 minutes to
allow drying of the glue.
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After the ICV port was secured in place, a Hamilton syringe filled with PBS was
connected to the end of the catheter and 6 uL of PBS was infused over 1 minute to
examine the patency and potential leakage of the ICV port. After the removal of the
syringe, the end of the catheter was sealed using a cauterizer. The catheter was further
stored into the previously-created subcutaneous pocket. The wound was closed with a
matrix suture using 5-O nylon thread, and the mouse was placed under a heat lamp for
recovery. After periodically monitoring the wound for 1 week postoperatively, the stitches
were removed on day 7. The wound was monitored for another week to ensure its healing.

4.18 Surgical procedure for infusion of engineered monocytes via the
intracerebroventricular port
After the wound from the ICV port installation surgery was healed, the mouse was
ready for infusion via the ICV port. The mouse was anesthetized under gaseous
isoflurane. The hair on the back was shaved to create an adequate surgical area to
access the tip of the catheter stored in the subcutaneous pocket. Povidone-iodine was
used to disinfect the surgical field, and a 2.0 mm incision was created using a scissor.
The tip of the catheter was exposed and rested on a povidone-iodine pad. The sealed
end of the catheter was removed with a scissor, and a Hamilton syringe pre-filled with
monocyte suspension (3.33 x 104 cells/μL) was connected to the catheter. The monocyte
suspension (3 μL) was infused slowly over 1 minute before the Hamilton syringe was
disconnected. Another Hamilton syringe pre-filled with PBS was connected to the
catheter, and 3 μL of PBS was infused slowly over 1 minute.
The tip was sealed with a cauterizer after the second Hamilton syringe was removed.
The sealed catheter was stored back into the subcutaneous pocket by retracting the
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catheter into the previously-created 2.0 mm incision. The wound was then closed with a
simple suture using 5-O nylon thread or autoclip, and the mouse was placed under a
heat lamp for recovery. The wound was monitored periodically for a week to ensure
healing without complications.

4.19 Statistical analysis and illustration
The difference in cytokine secretion, cell-associated o-Tau, and cellular viability
across different groups was determined using an unpaired Student’s t-test. The
association between cytokine production with either o-Tau stimulation concentration or
cell-associated o-Tau level was established using the Pearson correlation test and linear
regression. The statistical analysis was performed using GraphPad Prism 8.0. The
figures and illustrations were created with GraphPad Prism 8.0 and BioRender.com.
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Chapter 5: Engineered Monocytes are Neuroprotective through
Enhanced o-Tau Clearance and Reduced Proinflammatory Cytokine
Secretion

5.1 Introduction
More than a disease of proteinopathy, AD is also a disease of chronic
inflammation23. Microglia are the principal innate immune cells in the CNS responsible
for the phagocytosis and degradation of waste products, including pTau assemblies113.
As AD progresses, microglia lose their capacity for pTau clearance but secrete more
proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6100,115. Although peripheral
monocytes recruited into the CNS retain the ability to clear pTau assemblies111,136,171,175,
they also release proinflammatory cytokines in response. The reactive microglia and the
recruited monocytes, along with their secreted proinflammatory cytokines, in return,
accelerate the progression of Tau pathology and cognitive decline (Fig. 1)85,125,147-149,160.
Breaking the vicious cycle between these two pathologies provides a novel approach to
halt

AD

progression

by

stopping

the

accumulation

of

pTau

and

limiting

neuroinflammation.
We apply knowledge gained from tumor immunology and immunotherapy of AD to
propose the concept of engineered peripheral monocytes that preferentially target o-Tau
but limit subsequent proinflammatory polarization. We hypothesize that monocytes
engineered to bind and internalize o-Tau via antibody-redirected CSR will halt the
progression of AD by protecting neurons from o-Tau-mediated neurotoxicity while
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dampening proinflammatory cytokine release. This chapter will demonstrate the proof of
this novel concept in detail and provide supporting evidence for our hypothesis.

5.2 Results
5.2.1 Myeloid cells secrete proinflammatory cytokines upon stimulation by Tau
assemblies.
The presence of activated microglia in AD brain pathologies is well-documented in
the literature1. It has also been demonstrated that resident microglia are activated when
they are stimulated with o-Tau in vitro100. In addition to microglia in the CNS,
accumulating evidence indicates that peripheral monocytes infiltrate the CNS in AD,
partly due to the chemokines and cytokines secreted by the activated microglia112. It has
been shown that peripheral monocytes have a better o-Tau uptake capacity compared
to microglia136. However, it is unclear if peripheral monocytes have a similar
proinflammatory response to o-Tau to microglia, or if they can attenuate the inflammatory
condition in the CNS.
The goal of this experiment was not to determine a specific Tau species that
stimulates myeloid cells but to determine the myeloid responses to Tau assemblies in
general. Therefore, after the Tau assemblies were oligomerized following a published
protocol87, they were not further fractionated using SEC.
After stimulation by Tau assemblies for 72 hours, both bone marrow-derived
peripheral monocytes and a microglia cell line secreted more proinflammatory cytokine
TNF than unstimulated cells (Fig. 2). In contrast, the anti-inflammatory cytokine IL-10
level was below the detection limit of the assay (data not shown). The results support the
concept that peripheral monocytes exhibit a proinflammatory cytokine profile in response
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to Tau, which is similar to their CNS counterpart, microglia. Peripheral monocytes were
shown to be capable of enhanced uptake and degradation of Tau species136, but still at
the cost of exacerbating inflammation100. This experiment suggests that peripheral
monocytes can contribute to neuroinflammation, like microglia.

94

(A)

(B)

PBS

Tau

Primary Monocytes

PBS

PBS

Tau

Tau

Primary Monocytes

BV2

PBS

Tau
BV2

Figure 2: Proinflammatory cytokine production by myeloid cells upon stimulation
by Tau assemblies.
Primary bone marrow-derived monocytes and a microglial cell line (BV2) were stimulated
with either PBS or Tau assemblies (8 µM) for 72 hours before their absolute TNF
secretion level (A) was determined using the Cytometric Bead Assay, and further
expressed as fold change compared to PBS control (B) (N = 1, 4–5 replicates).
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5.2.2 Purification of oligomeric Tau
A range of Tau species of various degrees of aggregation are found in both the
samples collected in vivo and Tau assemblies induced in vitro298. This continuum
represents a dynamic reaction between monomers, oligomers, and higher-order fibrils.
In the spectrum of Tau assemblies, it is o-Tau, rather than Tau fibrils or monomers, that
is most neurotoxic and causes synaptic dysfunction and activation of the apoptosis
pathway in vivo96. Others have also demonstrated that o-Tau impairs the integrity of
primary hippocampal neurons in vitro100. Together with the evidence that Tau pathology
is closely associated with disease progression, it is believed that o-Tau plays a critical
role in the pathogenesis of AD102.
To study the precise effect of this neurotoxic Tau species, it is imperative to isolate
it from the rest of the pTau assemblies. Oligomerization of the Tau repeat domain, as
well as its isolation protocol, have been established by others previously87. Together with
Mr. Nicolas Mendez and Dr. Ines Moreno-Gonzalez, we have further optimized the
protocol in our institution to maximize the yield of full-length o-Tau. Briefly, the full-length
(2N4R) Tau monomer was isolated from E. coli transformed with the Tau40 plasmid and
purified using a cation exchange chromatography column. Oligomerization of Tau
monomer was induced by high molecular weight heparin and incubated at 37 °C for 16
hours in a thermomixer at 500 rpm. The mixed Tau assemblies from the oligomerization
were centrifuged at 10,000 rcf to remove high-order fibrils. o-Tau in the supernatant was
further separated by SEC and eluted with PBS (Fig. 3A).
The fraction of o-Tau was collected and passed through a 0.2 µm filter to remove
potential microbial contaminants. However, possible endotoxin contamination cannot be
eliminated via this physical filtration. To confirm that the collected fraction did not contain
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significant endotoxin levels, which may result in a confounding inflammatory effect, the
endotoxin level from different preparations was determined using an enzyme-based
chromogenic assay. The endotoxin level in the o-Tau fraction was 0.88 ± 0.33 EU/mL in
a µM solution of oligomer (Fig. 3B). From the literature, a o-Tau concentration ranging
from 50 nM to 1 µM was effective in inducing inflammatory responses and neuronal
damage100. Therefore, a concentration of o-Tau ranging from 125 nM to 500 nM was
selected for this study. Accordingly, the final endotoxin level in all the experiments ranged
from 0.11 ± 0.04 to 0.44 ± 0.17 EU/mL, which was well below the threshold of 1.0 EU/mL
to effectively induce the production of proinflammatory cytokines TNF and IL-6 by
peripheral monocytes299.
In summary, we have developed a protocol to generate and isolate o-Tau species
efficiently. Furthermore, the endotoxin level in the o-Tau preparation is below the
threshold for activating monocytes. Therefore, inflammatory responses or neuronal
damages induced by this o-Tau preparation in the following experiments would be
attributable to o-Tau only.
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Figure 3: Generation and isolation of oligomeric Tau.
50 µM of monomeric full-length Tau (2N4R) and 25 µM of high molecular weight heparin
were incubated in thermomixer at 37 °C for 16 hours. (A) Oligomeric Tau (o-Tau) was
then purified using size exclusion chromatography. Fractioned o-Tau was further passed
through a 0.2 µm filter to remove potential microbial contamination. (B) Endotoxin levels
per µM of o-Tau from different preparations (N = 4) were determined using an enzymebased chromogenic assay (averaged duplicates). The graph shows the mean and SEM.
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5.2.3 Design of the chimeric scavenger receptors
The canonical scavenger receptors CD163 and CD204, as well as FcgRIIb, have
been well studied in tumor immunology. They were shown to exhibit anti-inflammatory
properties that promote tumor growth. The structure of scavenger receptors can be
generally categorized into three domains: an extracellular domain that engages their
natural ligands, a transmembrane domain that anchors them on the cell membrane, and
an intracellular domain that triggers internalization and transduces anti-inflammatory
signals. To date, there is no literature reporting o-Tau as a natural ligand for the selected
scavenger receptors. To redirect the signaling initiation through specific activation by oTau, we engineered the murine scavenger receptors and modified the extracellular
domain with an scFv derived from a monoclonal antibody that prevents o-Tau-induced
cytopathology in neurons100.
In the CD163- and CD204-CSR constructs, we replaced the extracellular natural
ligand-binding domains with the scFv derived from the antibody (Fig. 4A, B). To avoid
disruptions in their tertiary structures, we replaced the essential ligand-binding regions
of the extracellular domains with scFv. In the FcgRIIb-CSR construct, we modified the
ligand-binding domain by inserting the scFv into the area responsible for its original
binding capability to IgG Fc and Ab, to disrupt the native binding capacity (Fig. 4C).
Furthermore, in the DNA constructs, we also designed restriction enzyme sites, without
altering amino acid translation, at the junctions between different functional domains to
enable future modification to the areas.
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Figure 4: Design of the chimeric scavenger receptors.
The natural ligand-binding domains of the scavenger receptors (A) CD163, (B) CD204,
and (C) FcgRIIb were modified and replaced with an scFv of a monoclonal antibody that
protects neurons from oligomeric Tau.
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5.2.4 Demonstration of modular modification of domains in the construct
Our designed construct encoding an anti-o-Tau scFv supported by an FcgRIIb,
CD163, or CD204 scaffold was synthesized into plasmids by a commercial service. I
cloned the constructs into a retroviral vector, pMG-Neo, that has a cytotoxic antibiotic
selection gene. The successfully cloned vectors were validated using various restriction
enzyme digestions as well as Sanger sequencing to verify that the genetic material had
been correctly cloned.
Cloning of the designed CD163-CSR into the retroviral vector was not successful
initially, and I repeatedly found various sizes of restriction products. This phenomenon
was observed in both ligation-dependent and ligation-independent cloning methods, in
using different viral vector backbones, and in multiple strains of competent cells. These
trials suggested an inherent factor in the construct that was independent of the
experimental procedures. Upon re-examination of the designed construct, I hypothesized
that the repeated regions in the cassette domain of the CD163 backbone might cause
recombination in competent cells, resulting in unsuccessful CD163-CSR cloning.
By removing the cassette domain using the previously-designed restriction enzyme
sites, I generated a shorter version of the CD163-CSR plasmid that is free of the cassette
domain (Fig. 5A). Without the cassette domain, the cloning was successful, which was
verified by both restriction enzyme digests and Sanger sequencing (Fig. 5B). Reintroduction of the cassette back into the cassette-free CD163-CSR vector again resulted
in various sizes of products. This result suggests the repeated sequence in CD163-CSR
contributed to unsuccessful cloning in competent cells, which might result from
recombination.
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This example illustrates the usefulness of the designed restriction enzyme sites
encasing distinct domains. This design not only helps facilitate cloning when needed, but
it also makes it possible to swap the original domains with other functional domains in
future engineering.
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Figure 5: Modular modification of domains in the construct via predesigned
restriction enzyme sites.
(A) CD163-CSR has four major domains that are separated by three predesigned
restriction enzyme (RE) sites, which enable modular removal of domains like the cassette
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domain and while keeping the rest intact. (B) Successful modification of CD163-CSR
plasmid into the cassette-free CD163-CSR plasmid was verified using a different set of
RE digestions. U: Undigested plasmid; C1: single RE digested plasmid; C2: double RE
digested plasmid.
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5.2.5 Generation of engineered monocytes
As a proof-of-concept, the verified vectors packaged as viruses were transduced
into a murine peripheral monocyte/macrophage cell line PMJ2-PC, and stable CSRexpressing cell lines were obtained by drug (G418) selection. To further verify the
successful transduction, the cells were examined using confocal microscopy. The
cassette-free CD163-CSR and the FcgRIIb-CSR constructs were both linked to a
histidine tag, and thus they could be detected using a fluorescein-labeled anti-histidine
tag antibody. Compared to both parental untransduced and empty vector-transduced
monocytes, the cassette-free CD163-CSR and FcgRIIb-CSR transduced cells stably
expressed the histidine tag, indicating their successful transductions (Fig. 6A).
During the construction of the CSR, modifications of extracellular domains have
inevitably removed essential sites that can be detected by commercially available
monoclonal antibodies. An antibody (SinoBiological) that was generated against amino
acids 83-354 of CD204, which correspond to the remaining coiled-coil and collagen
domains, showed suboptimal staining (Fig. 6B). This result could be due in part to the
stereotactic hindrance of scFv preventing effective recognition, which has also been
observed in ligand–antibody competition studies in other scavenger receptors228.
We expected to detect CD204 on untransduced parental monocytes because
monocytes were shown to express CD204 constitutively. CD204 expression found on
untransduced monocytes might suggest that some of the CD204 staining signal in the
CD204-CSR transduced cells was from the natural cellular CD204 expression. Because
the CD204-CSR transduced cells survived repeated rounds of cytotoxic antibiotic
selection pressure and showed an increased CD204 staining signal, these findings
suggest that transduction was successful.
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In summary, we concluded our research Aim 1 by 1) designing CSR constructs
composed of an scFv that limits o-Tau propagation and M2-skewing scavenger receptor
cytoplasmic domains, and 2) engineering peripheral monocyte/macrophage cell lines
that stably express the designed CSRs.
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Figure 6: Validation of the successful retroviral transduction of the chimeric
scavenger receptor constructs in a peripheral monocyte/macrophage cell line.
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(A) After plating by CytoSpin, the transduced cells (PMJ2-PC) were fixed and stained
with DAPI and fluorescein-labeled anti-Histidine tag antibody (His-Tag). The cells were
then imaged using confocal microscopy. (B) Both untransduced parental and CD204CSR transduced monocytes were stained with an anti-CD204 monoclonal antibody and
analyzed using a flow cytometer. The plots show only live cells, determined by Live/Dead
staining.
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5.2.6 Engineered monocytes inhibited proinflammatory cytokine secretions
In our research Aim 1, we successfully generated monocytes stably expressing the
FcgRIIb-CSR, CD204-CSR, or the cassette-free CD163-CSR. Because the chosen
intracellular domains were reported to possess immune regulatory properties, we
hypothesized that the CSR monocytes would limit their proinflammatory cytokine
secretion upon o-Tau stimulation. To examine the hypothesis, both the untransduced
parental monocytes and the engineered monocytes were incubated with o-Tau for 24
hours before cytokine levels were determined (Fig. 7A). The concentration of 500 nM of
o-Tau was selected to determine the functions of our engineered monocytes because
the concentration of soluble Tau in the brain ranges approximately from 150 nM to 900
nM103,300.
Compared to the untransduced parental monocytes, FcgRIIb-CSR monocytes had
lower production of the proinflammatory cytokines TNF (p = 0.0033) and IL-6 (p = 0.0411).
In this experiment, the CD204-CSR monocytes appeared to have a modest reduction in
IL-6 secretion compared to the parental line, but the difference was not statistically
significant. The cassette-free CD163-CSR monocytes appeared to have a lower
secretion of both TNF and IL-6 in one single experiment with three technical replicates.
Among the three engineered monocytes, the FcgRIIb-CSR monocytes secreted the
lowest level of proinflammatory cytokines upon o-Tau stimulation (Fig. 7B-D).
It is important to note that the decreased cytokine production in the engineered
monocytes was not due to a specific batch of o-Tau preparation. A similar trend of
reduced cytokine secretion by the engineered monocytes was reproduced in five
independent experiments using different batches of o-Tau preparation. These
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experiments verified that the CSR, especially FcgRIIb-CSR, enables peripheral
monocytes to limit their proinflammatory cytokine secretion upon binding o-Tau.
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Figure 7: Proinflammatory cytokine secretion and oligomeric Tau uptake capacity
by the engineered monocytes.
(A) Either parental or engineered monocytes were incubated with 500 nM of oligomeric
Tau (o-Tau) for 24 hours (B, C) before their proinflammatory cytokine (TNF and IL-6)
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secretion was determined by the Cytometric Bead Array (N = 5, in triplicate; except for
CD163 where N = 1, in triplicate). (D) The cytokine profile of the FcgRIIb-CSR monocytes
is detailed in comparison with parental monocytes and PBS controls. The graphs show
the mean and SEM of independent experiments. Unpaired Student’s t-test, ns = not
significant, * p < 0.05, ** p < 0.01.
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5.2.7 The inhibited proinflammatory cytokine secretion in CSR monocytes is not
due to impaired cellular viability
Independent experiments demonstrated that the engineered monocytes inhibited
proinflammatory cytokine secretion upon o-Tau stimulation. To further determine that the
low proinflammatory cytokine output was not due to cytotoxicity or a lower proliferative
potential of the engineered monocytes, I examined the number of viable cells and
normalized the cytokine output per 1,000 viable cells for FcgRIIb-CSR and CD204-CSR
monocytes. After 24 hours of incubation with 500 nM of o-Tau, cellular viability and cell
numbers as well as proinflammatory cytokine levels were analyzed. When cell number
was used to normalize cytokine production, I found that FcgRIIb-CSR monocytes
secreted the lowest amount of TNF (p = 0.0031) and IL-6 (p = 0.0004) per 1,000 cells.
However, there was no significant difference in cytokine secretion level between CD204CSR monocytes and the parental monocyte control (Fig. 8A, B). Additionally, there was
no statistically significant decrease in viability in either FcgRIIb- and CD204-CSR
monocytes upon o-Tau stimulation (Fig. 8C). Overall, the normalized cytokine secretion
level followed the same trend as the non-normalized cytokine secretion level results,
which indicates that the reduced proinflammatory cytokine production by FcgRIIb-CSR
monocytes is not due to impaired cell viability, or reduced cell number or proliferation.
To further evaluate the potential toxicity of o-Tau to the engineered monocytes, I
incubated FcgRIIb-CSR and CD204-CSR monocytes with a gradient of o-Tau
concentration for 24 hours and evaluated their cellular viability. The result indicated that
there was no significant impairment in the cellular viability of FcgRIIb-CSR and CD204CSR monocytes or parental monocytes with the o-Tau levels tested, up to 500 nM (Fig.
8D). Together, these data support our hypothesis that engineered monocytes, especially
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FcgRIIb-CSR monocytes, remain viable in the presence of o-Tau and secrete less
proinflammatory cytokines upon o-Tau stimulation than the parental controls.
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Figure 8: Normalization of proinflammatory cytokine secretion level.
Either parental or engineered monocytes were incubated with 500 nM of oligomeric Tau
(o-Tau) for 24 hours before proinflammatory cytokine (TNF and IL-6) secretion levels
were determined using Cytometric Bead Array. An automatic cell counter also
determined viable cell numbers. Cytokines were normalized to 1,000 cells (A, B), and
cell viability was calculated (C). In an independent experiment, monocytes were
incubated with various concentrations of o-Tau for 24 hours before their viability was
determined (D). The graphs show the mean and SEM (N = 1, in triplicate). Unpaired
Student’s t-test, ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.001.
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5.2.8 Engineered monocytes have enhanced oligomeric Tau clearance
We have shown that CSR monocytes are capable of limiting their proinflammatory
cytokine secretion upon o-Tau stimulation. Because the scFv of the CSR was derived
from a monoclonal antibody that inhibits o-Tau propagation effectively, we hypothesized
that CSR monocytes are capable of clearing o-Tau by efficient o-Tau uptake. To examine
the o-Tau uptake capability of CSR monocytes, their cell-associated o-Tau after
incubation with 500 nM of o-Tau for 24 hours was determined by using Western blot (Fig.
9A). Quantification of the blots revealed that FcgRIIb-CSR monocytes had significantly
higher cell-associated o-Tau compared to the parental line (p = 0.0166). The cellassociated o-Tau of both CD204-CSR and CD163-CSR monocytes appeared to be
slightly increased compared to the parental line, but this difference was not statistically
significant (Fig. 9B).
To further investigate the o-Tau clearing capacity of the FcgRIIb-CSR monocytes,
a complementary approach was used to assess the remaining o-Tau in the culture
system. The level of o-Tau remaining in the supernatant after a 24-hour culture with
FcgRIIb-CSR monocytes was determined by using either Western blot (N = 1) or ELISA
(N = 1, in triplicate) in independent experiments. In both experiments, o-Tau removal
from the supernatant of the FcgRIIb-CSR monocyte culture appeared to be modestly
enhanced compared to the culture of the parental line (Fig. 9C, D). This increased
elimination of o-Tau from the system complemented the previous finding that FcgRIIbCSR monocytes have a greater capacity to bind o-Tau. Together, these data suggest
that FcgRIIb-CSR monocytes clear o-Tau from the system by an efficient uptake.
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Figure 9: Oligomeric Tau clearance capacity of the Fc𝛾RIIb-CSR engineered
monocytes.
Either parental or FcgRIIb-CSR monocyte cell lines were incubated with 500 nM
oligomeric Tau (o-Tau) before lysis for evaluation of the cell-associated o-Tau and
leftover o-Tau in the system. Representative Western blot of cell-associated o-Tau in the
cell lysate (A) and quantification from independent experiments (N = 1 or 4) (B). Leftover
o-Tau in the system after incubation with monocytes was determined by Western blot (N
= 1) (C), and total Tau was determined by ELISA (N = 1, in triplicate) (D). The graphs
show the mean and SEM. Unpaired Student’s t-test, * p < 0.05.
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5.2.9 Chimeric scavenger receptors enable decoupling of proinflammatory
cytokine secretion from o-Tau uptake
We and others have demonstrated that both monocytes and microglia have innate
proinflammatory responses to o-Tau stimulation100. The idea of the CSR is not only to
remove extracellular o-Tau more efficiently but also to decouple the linked inflammatory
process after the engagement. To evaluate the dose-dependent association between oTau uptake capacity and proinflammatory cytokine secretion, parental and engineered
monocytes were incubated with either 0, 125, or 500 nM of o-Tau for 24 hours before
analysis of the cell-associated o-Tau as well as TNF and IL-6 levels in the supernatant.
Using Western blot for cell-associated o-Tau quantification, I observed increased
cell-associated o-Tau with increasing o-Tau incubation concentration. Despite the
concentration of o-Tau being limited to 500 nM in this experiment, the saturating point
for o-Tau uptake by monocytes may be more than 500 nM (Fig. 10A). Additionally,
increasing levels of the proinflammatory cytokines TNF and IL-6 as determined by CBA
was also observed in both parental and engineered monocytes when stimulated with
increasing concentrations of o-Tau, suggesting a dose-dependent cytokine production
(Fig. 10B). Similar to the previous proinflammatory cytokine evaluation studies, this
experiment also found that FcgRIIb-CSR monocytes have the lowest proinflammatory
cytokine secretion at both 125 nM and 500 nM of o-Tau stimulation. Unlike the high TNF
level, IL-6 level was lower in both parental and engineered monocytes.
Moreover, a threshold was observed for o-Tau to stimulate IL-6 secretion effectively.
In either parental or engineered monocytes, o-Tau concentration below 125 nM was not
able to stimulate a sufficient IL-6 to be detected by CBA (≥ 2.8 pg/mL). The more

118

sensitive and dramatic response in TNF secretion suggests that TNF might play a more
critical role in initiating inflammation in response to o-Tau.
The association between cellular uptake and cytokine output was further
investigated by using the Pearson correlation test. I found that there is a significant
positive correlation between o-Tau stimulation concentration and TNF secretion in both
parental and CD204-CSR monocytes (Fig. 10C). A statistically significant positive
correlation between cell-associated o-Tau and cytokine levels was only found in TNF
secretion by the parental monocytes (Fig. 10D). No significant association was found for
IL-6 across different monocytes, which might be due to a higher threshold for IL-6
secretion and a lower range of o-Tau concentration tested in this study. Because the IL6 levels were mostly below the detection limit recommended by the assay, the correlation
between IL-6 and o-Tau uptake should be treated with caution.
While there was a dose-dependent trend of increased TNF secretion by CD204CSR monocytes in response to increasing concentrations of o-Tau, the correlation
between TNF cytokine level and cell-associated o-Tau was not statistically significant.
Strikingly, the TNF profile of FcgRIIb-CSR monocytes was not positively associated with
either o-Tau stimulation concentration or o-Tau uptake level. More importantly, the linear
regression line demonstrating the association between o-Tau uptake and cytokine
response had a less steep slope in both engineered monocytes compared to the parental
monocytes. Collectively, these analyses suggest that the CSRs are capable of
decoupling the cytokine production from o-Tau engagement in peripheral monocytes.
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Figure 10: Association of oligomeric Tau uptake and proinflammatory cytokine
secretion by the engineered monocytes.
Parental and CSR monocyte cell lines were incubated with 0, 125, or 500 nM of
oligomeric Tau (o-Tau) for 24 hours before evaluation of their cell-associated o-Tau by
using Western blot (A), and proinflammatory cytokine secretion by using Cytometric
Bead Assays (B). The Pearson correlation analyses determined the correlation between
cytokine secretion with o-Tau stimulation (C) or with o-Tau uptake (D). The association
was demonstrated by linear regression analyses (C, D) (N = 1, in triplicate). Unpaired
Student’s t-test in (B), ns = not significant, * p < 0.05, ** p < 0.01, **** p < 0.0001.
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5.2.10 The phenotype of the chimeric scavenger receptor cells is reproducible in
a new transduction
Several independent experiments had shown inhibited proinflammatory cytokine
production in our FcgRIIb-CSR monocytes. To further confirm that the enhanced o-Tau
uptake and reduced proinflammatory cytokine secretion in the FcgRIIb-CSR monocytes
was not limited to one specific transduction experiment or transduced clone, I transduced
another batch of parental monocyte cell line PMJ2-PC with the FcgRIIb-CSR retroviral
vector in a new trial. Following the same protocol in the earlier transduction experiment,
the transduced cells were also enriched by cytotoxic antibiotic selection before any
functional assays.
The experimental procedures were similar to the previous assays. The enriched
clone was stimulated with 500 nM of o-Tau for 24 hours before analysis of the o-Tau
uptake and proinflammatory cytokine production. Similar to the previous experiments,
the newly-transduced FcgRIIb-CSR monocytes secreted lower levels of the
proinflammatory cytokines TNF and IL-6 compared to the parental line (Fig. 11A). There
appeared to be a small increase in the level of cell-associated o-Tau in the newlytransduced FcgRIIb-CSR monocytes compared to the parental line in this experiment.
(Fig. 11B, C).
The significantly reduced proinflammatory cytokine output and observation of a
slightly higher o-Tau uptake capacity, similar to the previously generated clone, not only
demonstrated that the phenotype of FcgRIIb-CSR is reproducible in different transduction
experiments, but also confirmed the potential of FcgRIIb-CSR to decouple the o-Tauinduced inflammatory machinery in peripheral monocytes.
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Figure 11: Proinflammatory cytokine secretion and oligomeric Tau uptake capacity
in newly-transduced Fc𝛾RIIb-CSR engineered monocytes.
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monocyte/macrophage cell line PMJ2-PC. These newly-transduced monocytes
(FcgRIIb-CSR’) were further selected and enriched by cytotoxic antibiotics. (A) The
enriched FcgRIIb-CSR’ monocytes were stimulated with 500 nM of oligomeric Tau (oTau) for 24 hours before the cytokines were examined by Cytometric Bead Assay. (B, C)
Cell-associated o-Tau in the cell lysates was determined by Western blot and quantified.
Unpaired Student’s t-test, *** p < 0.001, **** p < 0.0001.
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5.2.11 Engineered monocytes may use the lysosomal system for oligomeric Tau
degradation
The FcgRIIb-CSR monocytes had the most significant potential for o-Tau uptake
among the engineered monocytes. To further verify that the CSR monocytes internalize
the increased cell-associated o-Tau, the ratio of internalized o-Tau versus total cellassociated o-Tau was determined. After incubation with o-Tau for specific lengths of time,
FcgRIIb-CSR monocytes were collected and divided into two groups. One group was
washed with acid buffer (pH 3) to remove surface-bound o-Tau, while the other group
was washed with PBS to preserve total o-Tau bound to the cells296. The o-Tau level in
both groups was determined using Western blot. The ratio between the o-Tau level in
the two groups indicated the proportion of o-Tau being internalized intracellularly. Over
the various stimulation times tested, I found that FcgRIIb-CSR monocytes internalized
most of the cell-associated o-Tau (87.7 ± 2.8%). Increased incubation time resulted in
elevated o-Tau binding as well as internalization by FcgRIIb-CSR monocytes. The
internalization efficiency was not significantly impaired up to the 2 hours tested in this
experiment (Fig. 12A, B).
It was shown that the engineered monocytes actively internalize o-Tau. However,
the fate of the internalized o-Tau facilitated by FcgRIIb-CSR remains unclear. Based on
the evidence indicating that ligand-bound FcgRIIb is transported to the lysosomal
compartment for degradation271,301, I hypothesize that the o-Tau internalized via FcgRIIbCSR is degraded via lysosomes in the engineered monocytes. While a decrease in
lysosome-associated membrane protein-1 (LAMP-1) staining signal has been used to
indicate the active consumption of the lysosome302,303, LAMP-1 signal can be used as an
indicator of lysosomal activity. Within 2 hours of o-Tau stimulation of FcgRIIb-CSR
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monocytes, there was a time-dependent decrease of LAMP-1 signal associated with an
elevated o-Tau internalization (Fig. 12C). Moreover, internalized o-Tau was also shown
to co-localize with lysosome using Amnis flow cytometry (Fig. 13). Together with the
increasing time-dependent o-Tau internalization, these data suggest that o-Tau
internalized via FcgRIIb is processed via the lysosomal system.
To further validate this observation, a more extended period of o-Tau stimulation of
FcgRIIb-CSR monocytes was conducted to confirm consistent lysosomal consumption.
The decrease of the LAMP-1 signal was more evident when FcgRIIb-CSR monocytes
were stimulated with o-Tau for more than 8 hours. Moreover, compared to parental
monocytes, FcgRIIb-CSR monocytes had a higher lysosomal consumption activity (Fig.
14). These results suggest an increased degradation activity of the internalized o-Tau in
FcgRIIb-CSR monocytes, which might be associated with their higher o-Tau uptake
capacity.
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Figure 12: Internalization efficiency of oligomeric Tau by the Fc𝛾RIIb-CSR
engineered monocytes.
(A) FcgRIIb-CSR monocytes were incubated with 125 nM of o-Tau for 30, 60, and 120
minutes before analysis. Cells were washed by acid buffer or PBS, and their oligomeric
Tau (o-Tau) level was determined by using Western blot. (B) Quantification of the
Western blot result is plotted against time. (C) Cells were stained with a fluorescentlylabeled antibody specific for lysosome-associated membrane protein-1 (LAMP-1) and
analyzed using flow cytometry. LAMP-1 fold change relative to the mean fluorescence
intensity (MFI) at 0 minutes is plotted against time.
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Figure 13: Co-localization of the internalized oligomeric Tau with lysosomes in the
FcgRIIb-CSR engineered monocytes.
After a 6-hour incubation with fluorescently-labeled oligomeric Tau (o-Tau, green),
FcgRIIb-CSR monocytes were imaged using Amnis flow cytometry. The lysosomes were
stained with a fluorescently-labeled antibody specific for lysosome-associated
membrane protein-1 (LAMP-1, red). Representative images are presented.
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Figure 14: FcgRIIb-CSR monocytes have a higher lysosomal consumption activity
after oligomeric Tau stimulation.
Parental and FcgRIIb-CSR monocytes were incubated with oligomeric Tau (o-Tau) for
various durations. Lysosome-associated membrane protein-1 (LAMP-1) staining
indicates lysosomal consumption activity at different time points post-o-Tau stimulation
using flow cytometry. LAMP-1 mean fluorescence intensity (MFI) fold change is relative
to the MFI at 0 hours in the respective groups.
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5.2.12 FcgRIIb-CSR monocytes have limited proinflammatory cytokine secretion
and protect neurons from oligomeric Tau toxicity
The engineered CSR monocytes secrete less neurotoxic cytokines upon o-Tau
stimulation and show a higher capacity for removal of o-Tau. However, it is unknown if
monocytes will induce contact-dependent damage to the neurons. A previous study had
demonstrated that one mechanism of microglial damage to neurons was via microglial
phagocytosis147. To evaluate the neuroprotectivity of CSR monocytes against o-Tau
instead of contact-dependent impairment, the E18-19 primary hippocampal neurons
were co-cultured with engineered monocytes and o-Tau (Fig. 15A). By staining for
microtubule-associated protein 2 (MAP2), which targets neuronal dendrites, the fitness
of neurons can be determined by examining the integrity of dendritic staining using
confocal microscopy and other imaging modalities100.
Using immunofluorescence confocal microscopy, I found that the neurons cocultured with FcgRIIb-CSR monocytes had greater neuronal integrity compared to the
neurons co-cultured with parental monocytes (Fig. 15B). One caveat of this experiment
was that parental monocytes, but not the empty vector-transduced monocytes, were
used as the positive control, although both of the cell lines have a significantly higher
TNF secretion compared to FcgRIIb-CSR monocytes. This issue was addressed in the
next co-culture experiment.
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Figure 15: FcgRIIb-CSR monocytes limit neuronal damage in vitro.
(A) Primary E18 hippocampal neurons were cultured on a collagen-coated cover slide
for 2 weeks before incubation with 500 nM oligomeric Tau (o-Tau), and either parental
or FcgRIIb-CSR monocytes for 72 hours. (B) Neurons on the slide were stained with
antibody specific for microtubule-associated protein-2 (MAP2) and imaged using
confocal microscopy (arrowheads indicate fragmentation on neuronal dendrites).
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5.2.13 Engineered monocytes have the potential to protect neurons from o-Tau
toxicity
To further validate that FcgRIIb-CSR monocytes protect neurons from oligomeric
Tau toxicity observed by confocal imaging, another imaging modality capable of
efficiently evaluating multiple neurons in various conditions was used. In collaboration
with Dr. Jim Ray at the Neurodegeneration Consortium, the co-cultured neurons were
imaged using Operetta, a high-content imaging system. Without the presence of
monocytes or o-Tau stimulation, primary hippocampal neurons presented intact MAP2
staining integrity, which suggests their fitness in the in vitro culture system (Fig. 16A).
Upon stimulation by o-Tau, MAP2 staining showed more fragmentation compared to the
unstimulated neurons, suggesting neurotoxicity due to o-Tau (Fig. 16B). In AD brains,
neurons are exposed to both o-Tau as well as myeloid cells such as microglia and
peripheral monocytes. To simulate the harsh condition neurons face in AD, primary
neurons were co-cultured with empty-vector monocytes along with o-Tau stimulation in
vitro. I found that the fragmentation of MAP2 staining of the primary neurons became
more evident, suggesting an exacerbated damage to the neurons (Fig. 16C). This result
also supports the hypothesis that both o-Tau and inflammation contribute to the
neurodegeneration in AD.
Compared to the neurons co-cultured with parental monocytes, MAP2 staining of
neurons was substantially preserved when primary neurons were co-cultured with
FcgRIIb-CSR monocytes, which suggest neuronal fitness in this condition (Fig. 16D).
These findings validate the neurotoxic effect of o-Tau as well as parental monocytes and
the neuroprotectivity of FcgRIIb-CSR monocytes observed by using confocal imaging.
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Furthermore, the neuronal protectivity of CD204-CSR and CD163-CSR monocytes
was also evaluated using the same method. The primary neurons co-cultured with
CD204-CSR monocytes had moderate MAP2 staining integrity (Fig. 16E). However, the
primary neurons co-cultured with CD163-CSR monocytes do not show abundant intact
MAP2 staining, in comparison to the neurons co-cultured with the FcgRIIb-CSR
monocytes (Fig. 16F). Albeit not as dramatic as observed in FcgRIIb-CSR monocyte coculture, the neurons in CD204-CSR monocyte co-culture still appeared more intact than
the neurons co-cultured with the parental line.
Collectively, these data suggest that the engineered CSR monocytes are capable
of protecting neurons from o-Tau in vitro to varying degrees. In line with the previous
findings that FcgRIIb-CSR monocytes have a higher o-Tau uptake capability and a limited
proinflammatory profile, this experiment not only demonstrates the significant
neuroprotectivity of FcgRIIb-CSR monocytes in vitro, but also demonstrates again the
essential roles of o-Tau and myeloid cell-induced inflammation in neurodegeneration.
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Figure 16: Co-culture of primary neurons with the engineered monocytes.
E18 primary neurons (15 x103 cells) were cultured in vitro for 14 days before co-culture
with 30 x103 parental monocytes or CSR monocytes in addition to 500 nM of oligomeric
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Tau (o-Tau). After 72 hours of incubation, the neurons were fixed and stained with a
microtubule-associated protein-2 (MAP2)-specific antibody, then imaged using the
Operetta high-content imager. Representative images show primary neurons in various
co-culture conditions: (A) without stimulation by o-Tau, (B) with stimulation by o-Tau, (C)
with stimulation by o-Tau and co-culture with empty-vector monocytes, (D) with
stimulation by o-Tau and co-culture with FcgRIIb-CSR monocytes, (E) with stimulation
by o-Tau and co-culture with CD204-CSR monocytes, and (F) with stimulation by o-Tau
and co-culture with CD163-CSR monocytes.
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5.2.14 FcgRIIb-CSR monocytes appear to protect neurons against oligomeric Tau
in a dose-dependent fashion
FcgRIIb-CSR monocytes had demonstrated the highest neuroprotective capability
among the CSR monocytes, which might be due to their minimal proinflammatory
cytokine secretion. It is logical to postulate that a higher number of FcgRIIb-CSR
monocytes may provide a better neuroprotectivity. However, because FcgRIIb-CSR
monocytes still produce proinflammatory cytokines, albeit at a deficient level, it is not
known if an increasing number of FcgRIIb-CSR monocytes will eventually build up
enough proinflammatory cytokine secretion to harm the primary neurons instead of
protecting them from o-Tau. Therefore, I conducted a dose exploration study in which I
incubated FcgRIIb-CSR monocytes at a 4:1 ratio to primary neurons along with 500 nM
of o-Tau. This dose-dependent analysis of FcgRIIb-CSR monocytes showed that the
level of the proinflammatory cytokine TNF increased when more FcgRIIb-CSR
monocytes were present. However, the TNF level was still significantly lower in
comparison to the group co-cultured with control monocytes (Fig. 17A).
Examination of the MAP2 staining of primary neurons found that primary neurons
co-cultured with FcgRIIb-CSR monocyte at a ratio of 4:1 (Fig. 17F) had better dendritic
integrity compared to the neurons co-cultured with FcgRIIb-CSR monocyte at a ratio of
2:1 (Fig. 17E), closer to the integrity observed in the unstimulated group (Fig. 17B). Both
co-culture conditions with FcgRIIb-CSR monocytes showed better MAP2 staining
integrity compared to the culture condition with o-Tau only (Fig. 17C) or along with
control monocytes (Fig. 17D).
In summary, this experiment showed that FcgRIIb-CSR monocytes at a higher ratio
to neurons (4:1 in this case) helped to preserve the neuronal integrity despite an increase
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in the TNF level. This effect might result from the capability of FcgRIIb-CSR monocytes
to decouple o-Tau uptake and proinflammatory cytokine production effectively. A future
experiment including higher ratios of FcgRIIb-CSR monocytes to primary neurons is
needed to determine a balance point between a maximal o-Tau clearance and a tolerable
proinflammatory cytokine level to achieve optimal neuroprotectivity in vitro. Furthermore,
an assay to investigate the competition between FcgRIIb-CSR monocytes and other
untransduced myeloid cells, including microglia and monocytes, will also help to shed
light on the dynamics of FcgRIIb-CSR monocytes in vivo.
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Figure 17: Co-culture of primary neurons with various ratios of the FcgRIIb-CSR
monocytes.

137

E18 primary neurons (15 x103) were cultured in vitro for 14 days before co-culture with
30 x103 parental monocytes, or 30 x103 or 60 x103 FcgRIIb-CSR monocytes, in addition
to 500 nM of oligomeric Tau (o-Tau). After 72 hours of incubation, the neurons were fixed
and stained with a MAP2-specific antibody, then imaged using the Operetta high-content
imager. (A) The TNF level of the supernatant from different conditions was determined
using ELISA. The graph shows mean and SEM, (N = 1, in five replicates).
Representative images show primary neurons in various co-culture conditions: (B)
without stimulation by o-Tau, (C) with stimulation by o-Tau, (D) with stimulation by o-Tau
and co-culture with empty-vector monocytes at a ratio of 2:1, (E) with stimulation by oTau and co-culture with FcgRIIb-CSR monocytes at a ratio of 2:1, and (F) with stimulation
by o-Tau and co-culture with FcgRIIb-CSR monocytes at a ratio of 4:1. Unpaired
Student’s t-test in (A), ** p < 0.01, *** p < 0.001.
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5.2.15 Improvement of FcgRIIb-CSR design based on an FcgRIIb isoform
The demonstrated inhibited proinflammatory cytokine profile, enhanced o-Tau
clearance capacity, and a better neuroprotective capability of FcgRIIb-CSR monocytes
encouraged us to investigate the biology of FcgRIIb further. Studies have indicated that
two isoforms exist for FcgRIIb, FcgRIIb1 and FcgRIIb2, due to alternative splicing (Fig.
18A). Mouse FcgRIIb1 is 47 amino acid longer in length than FcgRIIb2, and this sequence
functions to tether FcgRIIb on the cell membrane and disrupts the accumulation in
clathrin-coated pits. Without this sequence in FcgRIIb2, the internalization in myeloid
cells occurs at a faster rate compared to the B cell-specific FcgRIIb1193,271.
A more rapid internalization rate after engagement with ligand enhances ligand
clearance from the environment, which could be advantageous for a more efficient o-Tau
uptake by engineered monocytes. Therefore, I constructed an FcgRIIb2-CSR by
removing the differential sequence found in FcgRIIb1. This new vector was cloned into a
yellow fluorescent protein (YFP) retroviral vector (Fig. 18B). Peripheral monocyte cell
line PMJ2-PC was successfully transduced with the vector and enriched by FACS sorting.
The proinflammatory cytokine profile, o-Tau clearance capability, and neuroprotectivity
will be examined in the future using the methods for the FcgRIIb1-CSR monocytes used
in the present study.
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Figure 18: Modified design of FcgRIIb-CSR based on FcgRIIb isoform.
(A) A diagram showing FcgRIIb-CSR indicates the sequence difference between
isoforms with an arrow. (B) Successful cloning of FcgRIIb2-CSR construct into retroviral
vector pMG-YFP was confirmed by two restriction enzyme digestions.
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5.2.16 Optimization of the intracerebroventricular delivery method in vivo
Engineered CSR monocytes, especially FcgRIIb-CSR monocytes, were shown to
have a higher capacity for o-Tau clearance by enhanced uptake. More importantly, the
FcgRIIb-CSR monocytes secreted minimal proinflammatory cytokines and protected
neurons in vitro. We hypothesized that treatment with CSR monocytes would reduce Tau
burden and limit proinflammatory cytokine production in the brain, which would improve
cognitive function in an AD mouse model. To address this hypothesis, I proposed to
deliver the CSR monocytes into the brain via an ICV port to avoid entrapment of the cells
in the peripheral organs171.
Because this delivery route for cellular therapy has not been proposed before, it is
essential to first validate and optimize the route of delivery before investigating the
neuroprotectivity of FcgRIIb-CSR monocytes in vivo. The depth of the infusion is a crucial
parameter as it determines the efficiency of the delivery and prevents the reflux of the
infused cells. With the stereotactic frame for brain injection, I found that a depth of 2.5–
3.0 mm below the skull is the optimal depth in C57BL/6 background mice, where delivery
of trypan blue dye via the ICV port stained the lateral ventricles well. Using a previouslydeveloped ICV port297, I implanted the port on the skull with a needle penetrating at a
depth of 2.5 mm (Fig. 19A). The successful access to the ventricles was also
demonstrated by staining the lateral ventricles with trypan blue (Fig. 19B).
Both the equipment necessary for the experiment and the critical parameter were
now validated. Next, I established the surgical protocol for our in vivo experiment. Briefly,
an 8 mm-long longitudinal wound is created over the scalp of a mouse under general
anesthesia. A bur hole on the skull is established at 1.0 mm right lateral to the Bregma
(Fig. 20A). A pre-flushed and degassed ICV port connected to a catheter is then
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implanted and fixed. The end of the catheter is sealed with a cauterizer to prevent
communication between the periphery and the lateral ventricles. The sealed catheter is
then buried in the subcutaneous pocket created on the back of the mouse (Fig. 20B).
The skin is closed with a nylon suture, and the mouse is allowed to heal for 2 weeks
before infusion (Fig. 20C). After the wound is healed, a 2 mm incision is made to access
the sealed end of the catheter. A Hamilton syringe filled with monocytes is connected to
the catheter after the seal has been removed (Fig. 21A, B) and 3 µL of cell suspension
is infused slowly over 1 minute. The catheter is next flushed with 3 µL of PBS to expel
the cells inside the tube toward the ICV. The end of the catheter is sealed again after the
removal of the Hamilton syringe and stored back into the subcutaneous pocket. The 2mm wound is then closed by one stitch with nylon suture or autoclip (Fig. 21C, D).
In a preliminary experiment, I delivered repeated weekly infusions of either PBS,
parental, or FcgRIIb-CSR monocytes into P301S mice for a total of eight doses. The mice
tolerated the surgeries well, and there was no mortality related to the procedures. This
trial has validated the feasibility of this novel adoptive transfer protocol and has laid the
foundation for our future in vivo studies.
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(A)

(B)

Figure 19: Determination of the optimal depth of the intracerebroventricular
infusion port.
(A) The intracerebroventricular infusion port (ICV port) is a minimally-invasive device that
can be subcutaneously installed on the dorsal surface of the skull for long-term
placement. The needle of the ICV port can penetrate through the skull to the desired
depth, reaching the lateral ventricle. A catheter attached to the port enables infusion via
a Hamilton syringe. (B) In the C57BL/6 and P301S mouse model, a depth of 2.5 mm
below the skull surface was determined as the optimal depth to access lateral ventricles.
Neither reflux nor resistance was noted during the infusion of trypan blue through the
catheter into the right lateral ventricle. Successful implantation was demonstrated by
staining of trypan blue over the ventricles that are shown in different brain sections.
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(A)

(B)

(C)

Figure 20: Demonstration of the intracerebroventricular infusion port installation
protocol.
(A) After the mouse is anesthetized, a mid-line skin incision of 8.0 mm is made on the
scalp with a scalpel to expose the skull surface. A burr hole on the skull is made manually
at the location 1.0 mm right lateral to the Bregma with a 27G needle. (B) The
intracerebroventricular infusion port (ICV port) attached with a catheter is degassed with
PBS before it is placed to the burr hole and fixed. (C) After the ICV port is secured in
place, the wound is closed with nylon sutures.
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(A)

(B)

(C)

(D)

Figure 21: Surgical procedure of the adoptive transfer of engineered monocytes
via the intracerebroventricular infusion port.
The port is ready for infusion after a 2-week recovery to allow wound healing postintracerebroventricular infusion (ICV) port installation. The end of the catheter is localized
by palpation over the skin after the mouse is under general anesthesia. A 2.0 mm incision
is created to expose the infusion catheter after disinfecting the surgical field (A). The
cauterized seal at the end of the catheter is removed, and 1x105 monocytes in 3 µL are
infused through the catheter over 1 minute using a Hamilton syringe. The catheter is
flushed with another 3 µL of PBS over 1 minute to expel the remaining cells into the ICV
(B). After the Hamilton syringe is removed, the catheter opening is sealed with a
cauterizer (C), and the incision is closed with a 5-O nylon suture (D).
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5.2.17 FcgRIIb-CSR monocytes may improve motor functions in a preclinical
Alzheimer’s disease model
P301S Tau-overexpressing transgenic mice are frequently used when studying
frontotemporal dementia and AD. Because the literature has demonstrated that o-Tau is
a more clinically-relevant pathogenic factor in driving AD progression, our engineered
monocytes were designed to target o-Tau. Moreover, our engineered PMJ2-PC cell line
is of a C57BL/6 background that will be less likely to be rejected in P301S mice, which
have a C57BL/6 x C3H/HeJ background. Based on the considerations of its relevance in
studying AD, the target protein of our engineered monocytes, and the likelihood of fewer
rejections, we selected the P301S mouse model to study the in vivo efficacy of our
engineered monocytes.
Previous research on P301S mice showed abundant pTau tangles in the brain, limb
paralysis, and cognitive impairment starting at 6-7 months old108,304. Because the coexistent motor deficit in this model may interfere with the interpretation of cognitive tests,
it is crucial first to determine the motor functions of these transgenic mice.
In my preliminary study, I delivered eight doses of weekly 1x105 FcgRIIb-CSR
monocyte infusions via the ICV port when the P301S mice were 4 months old. Motor
functions, including wire hang and footprint tests, were examined at the end of treatments
when they were 6 months old. In the wire hang test, the mice which received the control
monocytes were observed to have a shorter mean hanging time compared to the mice
receiving PBS, although the difference was not statistically significant (p = 0.0789),
suggesting poor motor function that could be due to exacerbated inflammation. The mice
receiving FcgRIIb-CSR monocytes had a similar hanging time compared to the PBS
control (p = 0.4849), indicating no detected improvement in this specific test (Fig. 22A).
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In the footprint test, the mice that received the FcgRIIb-CSR monocytes were
observed to have a narrower forepaw base width compared to the PBS control, but the
difference was not statistically significant (p = 0.0864). This may suggest an
improvement in motor function in the FcgRIIb-CSR monocyte group. However, there was
no difference between the mice receiving control monocytes and the mice receiving PBS
(p = 1.000) (Fig. 22B). Assessment of other parameters, including stride length and
forepaw/ hind paw overlap, did not reveal any significant difference between the FcgRIIbCSR monocyte treated group and the control monocyte treated group or the PBS control
(Fig. 22C, D).
When compared to the control monocyte treated group, there was an indication that
the FcgRIIb-CSR monocyte treated group in this preliminary study may have better motor
function, although the differences were not statistically significant. This result suggests
that anti-inflammatory modulation by FcgRIIb-CSR may have the potential to halt AD
progression in vivo.
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Figure 22: Motor tests of the P301S mice treated with engineered monocytes.
Male P301S mice received eight doses of weekly infusion of either PBS vehicle, control
monocytes, or FcgRIIb-CSR monocytes from 4 months of age. Motor tests, including wire
hang test (A) and footprint test (B-D), were performed at the end of eight treatments
when the mice were 6 months old. The graphs show the mean and SEM. p-values were
calculated using unpaired Student’s t-tests.
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5.3 Summary
To address both of the key pathogenic factors of o-Tau accumulation and
inflammation in AD progression, we have invented CSR that harbor the potential to target
o-Tau and to transduce an intracellular inhibitory signal. Using the peripheral
monocyte/macrophage cell line PMJ2-PC as a model for the proof-of-concept
experiments, I generated engineered monocytes stably expressing our designed CSR
constructs, verified using cytotoxic antibiotic selection and confocal immunofluorescence
microscopy. I demonstrated that compared to parental monocytes, the engineered
monocytes have a better o-Tau clearance capability though a more efficient uptake, and
at the same time, secrete limited proinflammatory cytokines. The lower proinflammatory
cytokine secretion was not due to an impaired proliferation or an enhanced cell death.
Among the engineered monocytes generated, FcgRIIb-CSR monocytes, in particular,
had a superior capability to decouple o-Tau uptake from the linked inflammatory
responses, which could be reproduced in a newly-transduced PMJ2-PC cell line.
Furthermore, my data show that the o-Tau associated with the FcgRIIb-CSR
monocytes was mostly internalized and triggers intracellular lysosomal consumption
which may contribute to its degradation. More importantly, the engineered monocytes,
especially the FcgRIIb-CSR monocytes, were found to protect primary hippocampal
neurons from o-Tau toxicity in vitro that could result from an enhanced clearance of oTau, and an inhibited subsequent inflammatory cytokine secretion.
To further translate this novel cellular therapy into the clinic, the adoptive transfer is
better performed via an ICV route to prevent off-site entrapment and the related side
effects.

I have developed a minimally-invasive surgical protocol that enables the

repeated treatments of engineered monocytes into a preclinical AD mouse model.
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Moreover, after eight weekly treatments, 6-month old male P301S Tau-overexpressing
transgenic mice that received the engineered FcgRIIb-CSR monocytes were observed to
have modestly better motor function as evaluated by the footprint test. On the contrary,
the mice receiving control monocyte infusions had a worse motor function as assessed
by the wire hang test. Neither of these preliminary results reached statistical significance.
Albeit preliminary, these in vivo data suggest that FcgRIIb-CSR monocytes may have
immune-modulatory functions that could potentially halt AD progression in vivo.
Collectively, these results support our hypothesis that monocytes engineered to
bind and internalize o-Tau via antibody-redirected CSR will protect neurons from o-Taumediated neurotoxicity while dampening proinflammatory cytokine release.
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Chapter 6: Discussion
We proposed the novel concept of CSR and designed three CSRs by replacing the
natural ligand-binding domains of FcgRIIb, CD163, and CD204 with an scFv from an antio-Tau

antibody.

We

also

materialized

this

concept

using

a

peripheral

monocyte/macrophage cell line PMJ2-PC as our model. Engineered monocytes,
especially FcgRIIb-CSR monocytes, were shown to be neuroprotective in vitro via an
enhanced o-Tau clearance and an inhibited linked proinflammatory cytokine secretion.
Adoptive transfer of FcgRIIb-CSR monocytes via ICV delivery in P301S Tauoverexpressing transgenic mice also suggested that FcgRIIb-CSR monocytes may
produce a better motor response, indicating its potential in halting AD progression in vivo.
In the present study, I demonstrated the capability of FcgRIIb-CSR monocytes in
protecting neurons both in vitro and in vivo. In the preliminary in vivo study, I evaluated
the motor functions of the P301S mice. Other assessments, including inflammatory
status in the CNS and cognitive tests, will also be investigated in future work. Despite
FcgRIIb-CSR monocytes showing neuroprotective efficacy, the mechanism of FcgRIIbCSR internalization and how o-Tau is degraded after its facilitated internalization by
FcgRIIb-CSR remain unclear. Ascertaining the underlying biology of the FcgRIIb-CSR will
not only illuminate how the CSR catalyzes o-Tau degradation but will also enhance our
understanding of how o-Tau clearance can be improved. Therefore, it is also crucial to
investigate the mechanisms of both internalization and degradation of o-Tau in the
FcgRIIb-CSR monocytes, as our immediate future directions.
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6.1 Preclinical studies evaluating the therapeutic efficacy of engineered
monocytes
6.1.1 Concurrent ex vivo analysis
In addition to the motor tests performed in the preliminary in vivo study, brain
pathology was also obtained to determine pTau burden and neuronal damages in the
CNS, which will provide additional evidence for the neuroprotective capacity of FcgRIIbCSR monocytes in vivo. Furthermore, brain homogenate was also acquired for the
analysis of cytokine mRNA levels, which will indicate an overall assessment of the
inflammatory status in the CNS. RT-PCR of a selected panel of cytokines and
chemokines based on the literature will enable us to evaluate the immunomodulatory
effects of FcgRIIb-CSR monocytes. Further RNA sequencing will provide not only
complementary evidence for RT-PCR but also a broader scope in identifying potential
players. The data will further inform on how to improve the design of our engineered CSR
monocytes or provide a treatment rationale in combination with other immune modulators.

6.1.2 Optimization of the in vivo study design
In my preliminary in vivo study, I observed a modest therapeutic effect determined
by motor tests, which was not statistically significant. In addition to increasing the sample
size, there are other factors to be considered. Because motor impairment reportedly
occurs in 6- to 9-month-old P301S mice on average108,304, my results could be due in
part to the inability of 6-month-old mice to reflect disease severity adequately. Therefore,
an improved experimental design using older animals (9 months old) is ongoing.
Because motor deficits might interfere with the interpretation of cognitive tests,
motor tests, including wire hang and footprint tests, were performed first in my preliminary
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experiment. In the future study, a battery of cognitive evaluations, including novel object
recognition, Y-maze, and Morris water maze tests, will also be assessed in addition to
the motor test. Moreover, the survival benefit from the engineered monocyte adoptive
transfer therapy will also be examined. Upon the completion of the proposed exams in
the optimized aged transgenic mice, we will be able to determine the preclinical
therapeutic impact on cognitive decline.

6.2 Determination of the mechanism of o-Tau degradation in CSR monocytes
Evidence indicates that ligand-bound FcgRIIb is transported to the lysosomal
compartment for degradation271,301. My data also demonstrate co-localization of
internalized o-Tau and lysosomes, and an enhanced lysosomal activity measured by
LAMP-1 staining302,303 in FcgRIIb-CSR monocytes upon stimulation with o-Tau. Based
on the collective evidence, I hypothesize that the o-Tau internalized via FcgRIIb-CSR is
degraded via lysosomes in the engineered monocytes.
To evaluate the necessity of lysosome in the degradation of the endocytosed o-Tau,
the CSR monocytes could be pre-treated with a lysosome inhibitor (e.g., chloroquine or
bafilomycin A305,306), before pulse stimulation with fluorophore-labeled o-Tau. The
intensity of the intracellular fluorescence from o-Tau will be determined using Amnis
imaging flow cytometry and by confocal microscopy. The intracellular signal difference
between the inhibitor-treated group and the non-treated group will indicate the
degradation of o-Tau via lysosome.
My previous data showing the co-localization of o-Tau and increased lysosomal
consumption in CSR monocytes suggest the involvement of the lysosomal pathway in oTau degradation. However, if the treatment of lysosome inhibitor does not result in
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different intracellular signals, it would indicate that lysosomes are not necessary for the
degradation of the internalized o-Tau and that an alternative pathway degrades o-Tau.
Previous literature shows that the proteasomal pathway is also involved in the
degradation of ligand-bound FcgR307. To assess the alternative hypothesis that the
proteasomal system is necessary for the internalized o-Tau degradation, inhibition of the
proteasomal activities in the CSR monocytes can be achieved using a proteasome
inhibitor like lactacystin or MG132308,309. An intracellular signal difference in the inhibitortreated and non-treated groups would suggest the involvement of the proteasome in
degrading o-Tau.

6.3 Determination of the mechanism of o-Tau internalization in CSR monocytes
FcgRIIb-CSR expressed on peripheral monocytes were shown to promote o-Tau
binding and internalization in vitro. However, the mechanism by which FcgRIIb-CSR
facilitates o-Tau internalization in monocytes is unknown. Previous literature indicates
that the internalization pathway of unmodified FcgRIIb is dependent on the size of the
ligand bound to the receptor. FcgRIIb is internalized via clathrin-mediated endocytosis if
its ligand is < 1 μm in diameter or via phagocytosis if the ligand is > 3 μm in diameter271,301.
Even though o-Tau is estimated at ~20 nm in diameter93, it is unclear if the modified
structure of FcgRIIb-CSR will result in a differential internalization pathway in monocytes
than its unmodified counterpart.
Based on the evidence, I hypothesize that the FcgRIIb-CSR-transduced monocytes
use clathrin-mediated endocytosis to facilitate the internalization of o-Tau. This
hypothesis can be addressed by stimulation of FcgRIIb-CSR monocytes with
fluorophore-labeled o-Tau after pre-incubation with a clathrin inhibitor (e.g., Pitstop2 or
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monodansylcadaverine310,311). By tracking the location and movement of the fluorescent
signals indicating the cellular internalization activity, it could be determined if the clathrinmediated pathway is necessary for o-Tau internalization via FcgRIIb-CSR.
Although clathrin-dependent endocytosis is the predominant pathway for receptormediated endocytosis, it is also possible that CSR internalizes through clathrinindependent pathways. The caveolar pathway is a clathrin-independent pathway for
receptor-mediated endocytosis312. The necessity of the caveolar pathway in CSR
internalization can be examined by pre-treatment of the CSR monocytes with the siRNA
of caveolin, which is the critical component of the pathway313. Another alternative
mechanism could be receptor-mediated phagocytosis, which is a pathway used by
monocytes/macrophages and can be determined by the pre-incubation of CSR
monocytes with a phagocytosis inhibitor like cytochalasin D or latrunculin314.
Furthermore, the literature indicates that the intracellular di-leucine motif of the FcgRIIb
is responsible for its internalization273. Therefore, mutating the di-leucine motif should
prevent the internalization of FcgRIIb-CSR after binding to o-Tau. This FcgRIIb-CSR
variant will serve as an ideal negative control for o-Tau internalization. In addition to
knowing how o-Tau is internalized intracellularly, it will also be important to understand
if FcgRIIb-CSR is being degraded or recycled to the surface. The intracellular location of
FcgRIIb-CSR can be detected using a fluorescein-labeled anti-histidine tag antibody in a
pulse-chase experiment.
In summary, upon the completion of the experiments outlined above, we will learn
the mechanisms of both internalization and degradation of the FcgRIIb-CSR–bound oTau. Moreover, the gained knowledge will enable us to improve our FcgRIIb-CSR
monocytes further.
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6.4 Future generation of CSR monocytes
6.4.1 FcgRIIb2-CSR monocytes
The literature indicates that there exist two isoforms of FcgRIIb. Both FcgRIIb1 and
FcgRIIb2 are expressed on myeloid cells at a lower level than on B cells and basophils,
respectively193. FcgRIIb2 has a more rapid internalization compared to FcgRIIb1. It will
be interesting to see if the faster internalization observed in the unmodified receptor can
also be found in the modified scavenger receptor. To address this question, I have made
an FcgRIIb-CSR based on the FcgRIIb2 and successfully transduced into the peripheral
monocyte cell line PMJ2-PC.
Although FcgRIIb2 has a faster internalization rate that might enhance ligand uptake,
this also indicates that its signaling capability may be lower than FcgRIIb1. Therefore, in
addition to investigating the o-Tau uptake efficiency by FcgRIIb2-CSR monocytes, it is
also crucial to determine its capacity to decouple o-Tau clearance and proinflammatory
signaling as this parameter will better reflect the neuroprotectivity of the engineered
monocytes.

6.4.2 Fine-tuning the expression level of FcgRIIb-CSR on monocytes
By cloning the construct into vectors with fluorescent protein genes such as YFP in
this study, I have separated the high CSR-expressing cells from the low expressing cells
after transduction. The differential expression will enable us to examine the dose
association between CSR expression with o-Tau uptake and the subsequent
proinflammatory cytokine secretion in vitro. Compared to the cytotoxic antibiotic selection
gene used earlier in this study, using fluorescent protein allows purification of cells with
very high expression. However, due to the risk of immunogenicity of YFP when
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introduced in vivo, a less immunogenic selection method was used to prevent limitations
on its use in vivo. Nonetheless, the dose relationship between expression and functional
output of CSR from in vitro assays will further guide us to the optimal dose of viral
particles to transduce cells when we use a non- or less-immunogenic vector.

6.4.3 FcgRIIb-CSR with a fortified intracellular signaling domain
No significant anti-inflammatory cytokines such as IL-10 and IL-4 were found to be
secreted by FcgRIIb-CSR monocytes in response to o-Tau stimulation. While the
neuroprotectivity by FcgRIIb-CSR monocytes were established, it would be beneficial for
the CSR monocytes to further express anti-inflammatory cytokines that could further
counter-balance the proinflammatory environment in the AD brain. Therefore, in addition
to modifying the intracellular domain for a more efficient internalization, we can also add
on an anti-inflammatory signaling domain while avoiding impairment of the o-Tau
degradation activity in the CSR monocytes.

6.4.4 Chimeric scavenger receptors beyond targeting oligomeric Tau
We have designed the CSR constructs in a modular fashion by strategically placing
restriction enzyme sites that encase essential functional domains. This feature enables
us to edit the CSR by swapping the existing domains with other desired functional
domains. As this dissertation demonstrates the proof-of-concept of our innovative idea
of engineered CSR monocytes against o-Tau, our concept, and the designs of the CSR,
can also be applied to other prion-like diseases like a-synuclein in Parkinson’s disease
which also has an inflammatory component in the pathogenesis315. For example, by
swapping the extracellular o-Tau-specific scFv domain with the scFv that targets a157

synuclein, it will enable the monocytes to remove a-synuclein efficiently while preventing
proinflammatory responses.

6.5 Conclusion
AD is not only a medical problem but is also becoming a pressing social issue as
the world ages rapidly. The holy grail of an AD therapy is to halt or even reverse its
disease course. Searching for a disease-modifying agent to tackle this ever-growing
disease has been a century of effort after the first discovery of the AD pathology.
However, we are still searching today, while many giant pharmaceutical firms have
withdrawn from the pursuit. As we are learning more about AD, our view of the disease
is no longer limited to one single etiology, and so must be our strategy to treat the
pathogenesis.
o-Tau and inflammation were both found to be vital pathogenic factors driving the
progression of AD. Studies further identified o-Tau as the dominant neurotoxic species
among Tau assemblies and o-Tau is closely associated with clinical progression. Myeloid
cells in the CNS are essential in clearing abnormal aggregates of protein, including Tau,
although at the cost of concomitant proinflammatory responses. Previous efforts to halt
the propagation of o-Tau using monoclonal antibodies have induced exacerbated
myeloid cell inflammation due to the activation from engagement of the Fc domain of the
antibody. Modification of the Fc region helps reduce the inflammation. However, it risks
the clearance of o-Tau from the CNS because of an impaired engagement of the oTau:antibody complex to Fc receptors. Therefore, a novel therapy that can
simultaneously target these two etiologies is urgently needed.
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This study has demonstrated the novel concept that the engineered peripheral
monocytes stably expressing CSRs can protect neurons from o-Tau and inflammation.
CSRs on the engineered monocytes, especially FcgRIIb-CSR, not only can efficiently
internalize o-Tau but also can effectively decouple o-Tau uptake from proinflammatory
cytokine secretion. Furthermore, FcgRIIb-CSR monocytes were shown to protect
neurons in vitro from toxicities caused by o-Tau and inflammation. Delivery of cellular
immunotherapy into the brain has been made possible in this study by developing a
minimally-invasive surgical protocol that enables repeated ICV infusion of engineered
monocytes. This protocol for preclinical studies establishes a novel route for the adoptive
transfer of cellular therapy in AD and other fields such as cancer. Moreover, P301S Tauoverexpressing transgenic mice that received engineered monocytes through this route
were observed to have a modest improvement in motor functions, although the difference
was not significant. Overall, the data suggest that efficient o-Tau uptake and antiinflammatory modulation by FcgRIIb-CSR monocytes has the potential to halt AD
progression in vivo.
Investigation of the mechanisms of the engineered monocytes and improving the
CSR designs for second-generation engineered monocytes are ongoing. We hope that
further understanding the biology of CSR and the engineered monocytes will pave the
way for the first effective therapy for AD in decades (arguably ever), and also help
frontotemporal dementia patients who completely lack therapeutic options. We also hope
that this concept can be applied in other neurodegenerative diseases to help more
patients in the future.

159

Appendix:

Novel Murine Glioblastoma Models that Reflect the Immunotherapy
Resistance Profile of Human Disease

Chao-Hsien Chen1,2, Renee L. Chin1,2, Genevieve P. Hartley2, Cheng-En Hsieh1,2,
Rishika Prasad2, Takashi Shingu3, Amy B Heimberger4, Jian Hu3, David S. Hong5,
Michael A. Curran1,2*

1

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of

Biomedical Sciences, Houston, TX 77030.
2

Department of Immunology,

3

5

Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer

Cancer Biology,

4

Department of Neurosurgery,

Center, Houston, TX 77030. *Corresponding author. email: mcurran@mdanderson.org

Key words: glioblastoma, anti-CTLA-4, anti-PD-1, immunotherapy

160

Abstract
The lack of murine glioblastoma models that mimic the immunobiology of human disease
has impeded both basic and translational immunology research.

We therefore

developed immunocompetent glioblastoma stem cell (QPP) lines derived from NestinCreERT2 QkL/L; Trp53L/L; PtenL/L mice driven by clinically relevant genetic mutations
common in human glioblastoma. QPP lines are syngeneic to C57BL/6J mice and
demonstrate varied sensitivities to T cell immune checkpoint blockade ranging from
curative responses to complete resistance. Infiltrating tumor immune analysis of QPP8
reveals improved T cell fitness and augmented effector to suppressor ratios when
implanted subcutaneously (sensitive), which are absent upon implantation in the brain
(resistant). Upregulation of PD-L1 across the myeloid stroma acts to establish this state
of immune privilege in the brain. In contrast, QPP7 responds to checkpoint
immunotherapy even in the brain likely resulting from its elevated mutational burden.
Together, these findings indicate that dominant glioma-mediated immune suppressive
mechanisms dictate immunotherapeutic sensitivity.
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Introduction
Glioblastoma is the most aggressive primary brain tumor with a median survival of
15 months316. Despite the success of T cell checkpoint blockade therapy in cancers such
as melanoma and lung adenocarcinoma, recent clinical trials have established that
antibody blockade of Programmed Death 1 (PD-1) fails to improve survival in
glioblastoma317. In the broadest sense, immunotherapy resistance in glioblastoma may
originate at the level of the glioma stem cells (GSCs) and can be associated with the
inherent intratumoral heterogeneity of this cancer318,319. Further, glioblastoma recruits a
microenvironment highly enriched for myeloid-derived suppressor cells (MDSCs), tumor
associated macrophages (TAMs) and microglia, which contribute directly to the exclusion
and functional suppression of tumor-specific T cells320. Beyond the myeloid stroma,
inhibitory checkpoint molecules such as programmed cell death ligand 1 (PD-L1) are
often highly enriched across the glioblastoma microenvironment and act in a cooperative
fashion to negatively impact both local immune activation and overall prognosis in
patients321.
Despite the failure of checkpoint blockade as a therapy for glioblastoma in the clinic,
the widely utilized murine model, GL261, is highly immune sensitive and readily cured
by blockade of PD-1322 (Supplementary Fig. S1). This incongruity between encouraging
preclinical findings in GL261 and the lack of immunotherapy responses in patients
indicates that new and more robust models are needed which more accurately reflect
the immune composition and therapeutic sensitivity, or lack thereof, of human disease.
On the other hand, mice engineered to spontaneously develop glioblastoma in situ using
the RCAS/Ntv-a system require little or no genetic “second hits” beyond the driver
oncogenes (e.g. PDGF-b, BCL-2) and therefore likely lack immune targetable mutations
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which are present, albeit at a low to moderate frequency, in human disease323. CD8 T
cell infiltration in these models tends to be sparse (< 3% of CD45+ cells) and are of
uncertain specificity and low affinity324.
Quaking (QKI) is a tumor suppressor gene which is deleted, mutated or
suppressed in GSCs in more than half of human glioblastomas, with low or absent
expression correlating with poor patient survival325,326. The QKI protein posttranscriptionally regulates, among other processes, cell membrane-endolysosome
trafficking through selective binding and stabilization of messenger RNAs of
endolysosomal components. Deletion of QKI also results in dysregulated mitophagy and
induces reactive oxygen species as well as DNA damage, all of which act together to
foster genomic instability and potential secondary genetic mutations. With the
concomitant genetic loss in the commonly mutated or deleted tumor suppressor genes
PTEN and TP53, we have previously described GSCs derived from Nestin-CreERT2 QkL/L;
Trp53L/L; PtenL/L (QPP) mice. These QPP tumors demonstrate histopathological
heterogeneity as well as a transcriptomic profile that can resemble that of all four
subtypes of human glioblastoma327, features that indicate that they are relevant models
for preclinical glioblastoma research.
In the current study, we establish four murine syngeneic QPP tumors and
determine their distinct immune sensitivities to T cell checkpoint blockade therapy in both
the brain and subcutaneous niches. Emblematic of the potential utility of these novel
glioblastoma preclinical models, we utilize comparative analysis of the immune
microenvironments and mutational profiles of T cell checkpoint blockade sensitive versus
resistant clones to understand the factors which establish glioma immune privilege in the
central nervous system (CNS). For the first time, these novel glioblastoma mouse models
which replicate both the histopathological and transcriptomic features and immune
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checkpoint insensitivity of human disease may provide critical tools for both
understanding the immunobiology of glioblastoma, as well as for vetting potential
immunotherapeutic approaches to select the most promising for clinical advancement.

Results
Four C57BL/6 syngeneic QPP tumor lines grow with varied kinetics across
immunocompetent versus immune deficient hosts
To identify glioma cell lines derived from Nestin-CreERT2 QkL/L; Trp53L/L; PtenL/L
(QPP) mice with the broadest possible utility for preclinical tumor modeling, we tested
multiple lines for the capacity to grow progressively in syngeneic C57BL/6 hosts. Eight
of these QPP glioma-stem cell (GSC) lines were inoculated subcutaneously on the flanks
of immunocompetent C57BL/6J mice and immune deficient B6 Rag1-/- (RagKO) mice.
Four QPP cell lines, namely QPP4, QPP5, QPP7 and QPP8, demonstrated the potential
to grow progressively in both the immune competent and deficient mice (Fig. 1A, 1B). In
terms of kinetics, QPP7 grows significantly more rapidly than the other lines, while QPP8
was the slowest in vivo. Further, the growth of QPP7 was significantly attenuated in wild
type versus RagKO mice suggesting that the adaptive immune response can both
recognize and impede the progression of this tumor line (Fig. 1B).

QPP tumor lines express a subset of recognized GSC markers but little to no
immune checkpoint ligands at baseline
All of these QPP lines can form neurospheres in serum-free media, which has
been described as a key characteristic of glioma stem cells328. To further define the GSC
features preserved by these lines, we examined their expression of common stem cell
surface markers by flow cytometry. In fact, all four QPP lines express classical GSC
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markers such as CD171 and a2b5, which are critical in tumor initiation, maintenance and
invasion (Table 1, Supplementary Fig. S2)329-331. While expression of immune inhibitory
checkpoint ligands such as PD-L1 by glioblastoma has been described332, the range of
inhibitory ligands expressed by the tumor-initiating GSCs, as well as the conditions
governing such expression, remain unknown. We observe little to no expression of T cell
checkpoint molecules, such as PD-L1 or PD-L2, on the syngeneic QPP cell lines in vitro
without stimulation. Upon stimulation with interferon (IFN)-g, however, a cytokine
commonly expressed by tumor infiltrating T cells, all of the QPP lines upregulate
moderate to high levels of PD-L1. QPP7, in particular, is the only line to show measurable
baseline expression of PD-L1 in vivo and shows the highest levels of inducible
expression predicting the potential for sensitivity to blockade of the PD-1/PD-L1
interactions (Table 1, Supplementary Fig. S2).

QPP gliomas are differentially sensitive to blockade of the T cell checkpoints
CTLA-4 and PD-1
Although glioma is clearly a disease of the CNS, the capacity for a murine cancer
model to grow both in the brain and on the flank can be an important advantage for both
investigating comparative biology and for some therapeutic screening applications. To
assess the immunotherapeutic sensitivity of the four QPP lines, we implanted these lines
in the flank and treated them with systemic injection of antibodies which block either PD1 (29F.1A12 or RMP1-14) or cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4)
(9H10) on days 7, 10 and 13. As predicted from its PD-L1 expression and slower growth
in wild-type versus RagKO mice, the QPP7 tumor line proved to be highly sensitive to
PD-1 blockade (Fig. 2 and Supplementary Fig. S3). In contrast to QPP7 and the
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prevalent glioma model GL261, however, the QPP4 and QPP5 lines were resistant to
anti-PD-1 therapy. All four lines did retain significant sensitivity to CTLA-4 blockade.
QPP8 shows a clinically relevant profile of response to anti-CTLA-4, and in some mice
to anti-PD-1, in which tumor immunity drives nearly complete tumor regression but lacks
durability and gives way to subsequent progression. While this pattern of response and
relapse is common in the clinic, few mouse models exist which replicate it.
An essential property for any murine model of glioma is the capacity to grow
progressively in the brain. To evaluate orthotopic growth of these QPP gliomas, we
implanted each line via stereotactic injection in the brain and treated them with systemic
administration of anti-PD-1 or anti-CTLA-4 on days 7, 10, and 13. All four lines grew
progressively in the brain without treatment and, again, manifested varied levels of
sensitivity to immune checkpoint blockade (Fig. 3). QPP7 demonstrates the most
aggressive growth (median survival 37.5 days) while QPP8 has the slowest growth
among the four QPP lines (median survival 63.0 days). As with clinical glioblastoma,
QPP4 and QPP8 tumors are resistant to both CTLA-4 and PD-1 blockade. QPP5 and
QPP7 are both sensitive to CTLA-4 blockades (p < 0.01 and p < 0.05, respectively);
however, QPP7, unlike QPP5, also shows a trend toward anti-PD-1 sensitivity as well (p
= 0.0692) (Fig. 3). In this model, the unique combination of Pten, p53 and Qk loss
appears capable of imprinting varied patterns of immune sensitivities likely reflecting
underlying genomic heterogeneity.

Elevated ratios of CD8 T cells relative to suppressive T and myeloid cells drive
CD8 response in the flank versus resistance in the brain
We investigated changes in the QPP8 immune infiltrate when treated in the flank
(sensitive) versus in the brain (resistant). Surprisingly, there is no significant change in
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cellular density of CD45+ immune cells in response to either CTLA-4 or PD-1 blockade
regardless of implantation site suggesting primary mechanisms of immune suppression
that are conserved (Fig. 4A). Although brain QPP8 fails to respond therapeutically to
checkpoint blockade, CD8 T cell frequencies in the tumor are more significantly
increased in comparison to when QPP8 is implanted subcutaneously. This CTLA-4
antibody can deplete Tregs in peripheral tumors, which we observed as a trend (p =
0.084) in this setting, an effect that may be contributing to the response in the flank (Fig.
4B). Consistent with this effect, we observed significantly enhanced ratios of CD8 T cells
relative to Treg in QPP8 in the flank with both anti-CTLA-4 and anti-PD-1 therapy (Fig.
4C and Supplementary Fig. S4). Further, ratios of CD8 T cells relative to suppressive
myeloid stroma are all elevated following checkpoint blockade in flank QPP8 indicative
of pro-inflammatory conditioning of the tumor microenvironment. In contrast, the
enhanced ratio of CD8 to suppressive T or myeloid populations were not observed in
brain-resident QPP8 with the exception of an improved ratio of CD8 T cells to
granulocytic MDSC (Gr-MDSC). Of note, Gr-MDSC are the least abundant myeloid
population in QPP8 regardless of site of implantation. The capacity of checkpoint
blockade to reshape the cellular composition of the flank, but not brain, QPP8 tumors to
favor anti-tumor immunity partially explains QPP8 immunotherapy resistance in the brain.
Next, we explored whether changes in the functional phenotypes of these populations
might also play a role in dictating sensitivity to immunotherapy.
In flank QPP8, CD8 T cells increase expression of Granzyme B and Ki67 and
decrease their expression of PD-1 in response to PD-1 blockade (p < 0.05) (Fig. 4d).
Effector CD4 T cells also show elevated expansion (i.e. Ki67) following both anti-PD-1
and anti-CTLA-4 therapy, which together suggest better cytotoxicity and fitness post
checkpoint blockade. A subset of these improvements to T cell fitness are also found in
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brain QPP8, where PD-1 blockade results in enhanced Granzyme B expression coupled
with reduced PD-1 fold change – a marker of T cell fitness that is also observed with
CTLA-4 blockade. A critical difference between the flank and brain, however, occurs at
the level of T cell proliferation. Whereas T cells expand in response to checkpoint
blockade in subcutaneous QPP8, in the brain their proliferation remains static or even
declines. This suggests either the presence of additional mechanisms of dominant T cell
proliferative suppression operating the brain tumor site, and/or that checkpoint antibodies
no longer protect the T cells once they reach the QPP8 brain tumor microenvironment
(TME). Consistent with these findings, the highly immune checkpoint sensitive GL261
glioma model shows an immune infiltrate pattern more similar to flank QPP8 than
resistant brain-implanted QPP8 (Supplementary Fig. S5). In brain GL261, like flank
QPP8, we find, as others have reported, that Granzyme B and Ki67 significantly increase
following PD-1 blockade in the CD8 and CD4 effector compartments, while PD-1
expression in the CD4 effector compartment decreases322.
Across the myeloid stroma of both flank and brain QPP8, checkpoint blockade
triggers upregulation of PD-L1 (Fig. 4D). The most significant induction occurs in brain
QPP8 for both CTLA-4 and PD-1 blockade perhaps contributing to the additional
immunotherapy resistance observed in this site. As our T cell analysis revealed signs of
increased T cell effector function (i.e. elevated Granzyme B) with checkpoint blockade,
it is likely that adaptive PD-L1 upregulation is triggered, at least in part, by increased T
cell effector cytokine production (e.g. IFN-g). Changes in TGF-b (LAP, latency associated
peptide) and arginase between flank and brain QPP8 were either inconsistent between
CTLA-4 and PD-1 blockade (LAP) or did not reach statistical significance (arginase). We
cannot rule out that the enhanced immune resistance of brain QPP8 results, at least in
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part, from the expression of arginase by microglia which are among the most prevalent
myeloid cells in brain QPP8 while absent in the flank (Fig. 4d). Despite the significant
induction of PD-L1 in flank QPP8, ratios of CD8 T cells to nearly all suppressive myeloid
stromal populations increase in the presence of PD-1 blockade and, to a lesser extent,
CTLA-4 blockade (Fig. 4C). In contrast, brain QPP8 CD8 to suppressor ratios are
unaffected by checkpoint blockade excepting those relative to Gr-MDSC density. These
findings suggest that PD-1 blockade can successfully counteract the PD-L1 upregulation
observed in flank QPP8, but that the antibody may not effectively block PD-L1 induced
by brain QPP8, perhaps due to a limited capacity to access the brain TME.

QPP7 remains checkpoint sensitive in the CNS despite adaptive upregulation of
arginase
Comparative analysis of the tumor microenvironments of resistant brain QPP8
versus sensitive flank QPP8 indicated the importance of lack of checkpoint-induced
upregulation of T cell proliferation and adaptive upregulation of PD-L1 on the myeloid
stroma (including microglia in the brain) as potentially key factors driving immunotherapy
responsiveness versus resistance in glioblastoma. While the QPP lines share a common
set of driver mutations, the loss of Qki drives histopathological heterogeneity that yielded
lines with substantially divergent immune sensitivity suggesting underlying genomic
heterogeneity. To understand the influence of these alterations on the immune
microenvironment of glioblastoma, we performed comparative analysis of checkpointsensitive brain QPP7 and checkpoint resistant brain QPP8. Although sensitive to PD-1
blockade, brain QPP7 ratios of CD8 versus suppressive T and myeloid cells improved
less in response to PD-1 blockade than those in resistant QPP8 (Fig. 5A). Similarly,
CTLA-4 blockade generated a more pro-inflammatory profile in brain QPP8 than in
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sensitive QPP7 where ratios of CD8 T cells versus Gr-MDSC and microglia actually
declined relative to untreated controls. As immune sensitivity of QPP7 could not be
explained by these observations of cellular changes to the stroma, we examined
phenotypic changes to key T cell and myeloid populations in response to therapy.
Compared to resistant QPP8, sensitive QPP7 showed less PD-L1 induction in the
myeloid stroma, particularly following CTLA-4 blockade, but also more consistent
upregulation of arginase and TGF-b (LAP) (Fig. 5B). CD8 T cells elevated Granzyme B
expression in response to both checkpoint antibodies in both tumors, with the only
immunologic advantage for QPP7-infiltrating T cells being a trend toward higher
proliferation in the CD4 effector compartment in response to CTLA-4 blockade. This
finding is counterbalanced, however, by the higher expression of both the proliferation
marker Ki67 and TGF-b (LAP) in Treg from QPP7 versus QPP8. Among these lines, only
QPP7 expresses GFP that interfered with PD-1 measurement using our standard flow
cytometry panel. In a separate study, we found that PD-1 is downregulated with
treatment as in QPP8 (Supplementary Fig. S6). This comparative analysis reinforces
the importance of the broad-based upregulation of PD-L1 as an adaptive resistance
mechanism for QPP8, but raises questions as to why the arginase upregulation by QPP7
in the brain fails to shield these tumors from checkpoint-blockade mobilized T cell
responses.
The role of arginase in suppressing T cell anti-tumor immunity has been well
established333,334; however, there are also reports in the literature that glioblastoma cells
are sensitive to arginine depletion especially in the context of the loss of p53, a shared
feature of QPP tumors and the majority of patients335,336. Administration of arginase as a
therapeutic intervention to deplete arginine has been shown to limit glioblastoma growth
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and enhance the efficacy of the standard of care chemotherapeutic agent temozolomide
as well as radiotherapy335,337. Consistent with prior findings in glioblastoma335, we found
that QPP7 and QPP8 undergo proliferative arrest in the absence of arginine in vitro (Fig.
5C, 5D). These data indicate that while upregulation of arginase by QPP7 in response to
checkpoint blockade may cause some inhibition of T cell responses, that deleterious
impact on anti-tumor immunity may be outweighed by the more substantial negative
impact on the proliferation and survival of the QPP tumor cells themselves.
Even in the context of less pronounced PD-L1 upregulation and a potentially tumor
damaging impact of arginase induction, the extreme immune sensitivity of QPP7 relative
to QPP8 in the brain seemed incompletely explained. Across immunotherapy, tumors
with higher mutational burden generally respond better to checkpoint blockade338, and
pediatric glioma patients with biallelic mismatch repair deficiency are highly responsive
to PD-1 blockade339. As QPP7 was the most checkpoint blockade sensitive glioblastoma
line in both the flank and brain and showed the most evidence for immune editing moving
from Rag1-/- mice to wild-type mice, we hypothesized that QPP7 might have a higher
mutational burden compared to QPP4, 5, and 8. We performed whole exome sequencing
of each QPP line and sequence analysis relative to the C57BL6 reference genome
revealed that QPP7 has the highest density of mutations including non-synonymous
single nucleotide variants (SNV) (Fig. 6A), as well as insertions and deletions (indels) in
coding regions (Fig. 6B). The other QPP lines show lesser and relatively homogenous
mutational frequencies of ~7.5 mutations/MB that fall within the upper normal range for
human glioblastoma, but below QPP7 (~ 12 mutations/MB) and well below the frequency
for nearly all transplantable mouse models that average 37 mutations/MB340. QPP7 and
GL261 have a similar frequency of SNV in coding regions, perhaps explaining their
shared sensitivity to anti-PD-1; however, GL261 still has more than 8 times the frequency
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of highly immunogenic frameshift mutations almost certainly as a result of its generation
by chemical mutagenesis341. This finding suggests an important role for neoantigen load
in predicting checkpoint sensitivity in glioblastoma, even in the context of a significantly
suppressive microenvironment such as that of brain QPP7.

Discussion
More than 8 years after Food and Drug Administration (FDA) approval of the first
T cell checkpoint blocking antibody, ipilimumab, development of immunotherapy for
glioblastoma remains hampered by the lack of preclinical tumor models which reflect the
immunogenicity of clinical disease. The most commonly used preclinical model, GL261,
predicts exceptional sensitivity to PD-1 blockade, an approach that in general does not
benefit glioblastoma patients317,322. Genetically engineered mouse models (GEMM)
capture key tumor driver genes and can be useful models for preclinical evaluation of
targeted or chemotherapy approaches; however, the strength of these mutations often
obviates the need for acquisition of secondary and/or passenger mutations leaving an
absence of immune-targetable tumor neoantigens. Xenograft tumor models allow study
of human cancer, but the lack of a functional immune system in the host mice renders
these models mostly useless for evaluation of immune-based therapies that rely on
adaptive immunity342. In this manuscript, we describe QPP cell lines driven by mutations
common in human glioblastoma that can be implanted either subcutaneously or
intracranially in immune competent C57BL/6J mice. The presence of the Qk mutation
confers histopathological heterogeneity to these tumor lines327, which is reflected in their
differential sensitivity to T cell checkpoint blockade therapy. Like human glioblastoma,
two of these lines (QPP4, QPP8) are completely resistant to anti-CTLA-4 and anti-PD-1
therapy when growing in the brain. Not only will these new lines be valuable tools to
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study the origins of immune resistance in glioblastoma as we have done here, but they
will also provide critical tools for preclinical evaluation of prospective immunotherapies
so that, in the future, only the most promising approaches advance to patients.
Previously, the PD-1/PD-L1 axis has been identified as a valuable prognostic tool
in glioblastoma patients, where higher PD-L1 expression correlates with a poor
prognosis321. PD-L1 is often implicated in “acquired resistance” to immunotherapy in
which the IFN-g produced by infiltrating T cells elicits compensatory upregulation of PDligands that dampen the response343,344. We established the capacity of IFN-g to potently
induce PD-L1 on the QPP tumor lines. In addition, our comparative analysis also
revealed significantly enhanced PD-L1 expression on the QPP myeloid stroma after antiCTLA-4 and anti-PD-1 antibody treatment, particularly in the resistant brain QPP8 tumor.
The findings illustrate that the potential prognostic value of PD-L1 expression both by the
tumor cells themselves and by the surrounding myeloid stroma. Analysis of the distinct
tumor microenvironments of QPP8 in the subcutaneous versus orthotopic niches reveals
multiple factors associated with treatment resistance. Even in resistant brain QPP8, we
do observe an increased CD8 T cell frequency in the tumor following checkpoint
blockade. As such, modest increases in their frequency should not be interpreted as an
absolute indication of therapeutic response. In response to the IFN-g and other
inflammatory cytokines produced by these cells, PD-L1 is upregulated across the QPP8
myeloid stroma including on the microglia. In addition to TGF-b and arginase, these cells
can also act through PD-L1 to suppress anti-glioblastoma T cells345-347. Whereas PD-1
blockade likely prevents induced myeloid PD-L1 from adversely impacting the T cell
response in flank QPP8, the PD-1 antibodies fail to rescue T cell function in brain QPP8.
This failure could result from inadequate quantities of the antibody reaching the brain
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TME in sufficient therapeutic concentrations to protect or rescue tumor-infiltrating T cells,
or from other suppressive mechanisms exerting dominant suppression over the release
of T cells from PD-1 inhibition348,349. These findings are consistent with the key role
recently attributed to myeloid cells in human glioblastoma in mediating immune
resistance to immune checkpoint inhibitors350.
QPP7 is the most aggressive of the tumor cell lines we generated; however, it is
also the most immune and immunotherapy sensitive. Among the four lines tested, QPP7
is the only one to respond therapeutically to both CTLA-4 and PD-1 blockade in both the
subcutaneous and orthotopic sites. In the brain, QPP7 showed signatures of a
suppressive microenvironment with sub-optimal ratios of CD8 T cells versus suppressive
stroma, high expression of arginase in the myeloid stroma, and modest induction of PDL1 in response to checkpoint blockade. While these adaptations would often be sufficient
to grant tumor immune privilege, in this case they may fail due to a combination of both
the adverse impact of arginase on the tumor stem cells and the more diverse anti-tumor
T cell repertoire likely resulting from the higher mutation frequency of QPP7. Although
potentially a driver of accelerated tumorigenesis and, potentially the aggressive
phenotype of this tumor, this elevated rate of mutation also elicits more diverse and
higher affinity anti-tumor T cell responses which may underlie the checkpoint sensitivity
observed in the current study351. Although mutation frequencies are generally low in
spontaneous glioblastoma and mismatch repair defects are uncommon352,353, studies
across many cancers including pediatric gliomas have validated that higher sensitivity to
immune checkpoint blockade therapy is linked with higher mutational burden339,354-361.
Despite its relatively low antigen density, systemically administered tumor neoantigen
vaccines have proven capable of mobilizing T cells that traffic to glioblastoma growing in
the brain362.
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In conclusion, we have created and characterized four murine syngeneic GSC
lines driven by clinically relevant genetic mutations which reflect the heterogeneity of
human glioblastoma including differential patterns of sensitivity and resistance to
immune checkpoint blockade. Through comparative analysis of the same line (QPP8) in
a resistant (brain) versus sensitive (flank) TME, and cross-comparison of a sensitive
(QPP7) versus a resistant (QPP8) line growing in the brain, we identified key factors
influencing resistance to immune checkpoint inhibitors. Enhanced PD-L1 expression
across the myeloid stroma of QPP8 in the brain appears to be one of these key factors
in checkpoint resistance and mirrors the established negative prognostic association with
PD-L1 expression in patients. We believe that these QPP models provide the most
accurate reflection of the immunobiology of human glioblastoma and will contribute to
advancing effective immunotherapeutic interventions into clinical practice.
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Methods
Animals. Male and female C57BL/6J mice and male RagKO (B6.129S7-Rag1tm1Mom/J)
mice were obtained from The Jackson Laboratory (Bar Harbor, ME). The mice were
housed according to the Association for Assessment and Accreditation of Laboratory
Animal Care and NIH standards. All experiments were conducted in accordance with the
protocols approved by the University of Texas MD Anderson Cancer Center Institutional
Animal Care and Use Committee.

Cell lines and reagents. The QPP stem cells were derived from QPP mice327 and
cultured in DMEM/F12 media with B-27 supplement (Gibco), epidermal growth factor
(EGF) and fibroblast growth factor (FGF) (STEMCELL technologies)327. Argininedeficient media was used for the QPP arginine auxotrophy experiment. Interferon-g
(PeproTech) (200 ng/mL) was used to induce PD-L1 expression in QPP in vitro. GL261
was obtained from Dr. Amy Heimberger (MDACC) and cultured in Dulbecco’s Modified
Eagle Media (DMEM) with 15% fetal bovine serum (FBS) and non-essential amino acids.

Subcutaneous tumor growth studies. 1x106 cells of each QPP cell line were mixed
with 30% collagen matrix (Matrigel, Corning) and subcutaneously implanted into the
flanks of male C57BL/6J or male RagKO mice. The tumor dimensions were measured
with calipers.

Phenotypic characterization of QPP cell lines. In vitro QPP cell lines were prepared
as a single cell suspension and stained for surface markers CD171 (Miltenyi Biotec),
a2β5, CD44, CD133 (Biolegend), Sca-1 (Thermo), PD-L1 and PD-L2 (BD Biosciences).
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Tumors extracted from tumor challenged mice were digested with Collagenase H (Sigma)
and DNase (Roche) into a single cell suspension as described363. Cells were stained for
the above surface markers in addition to CD45.2 (Biolegend) to exclude immune cells.
Expressions of the indicated markers on cells were measured by using a BD LSRII flow
cytometer.

Immune sensitivity studies. For subcutaneous study, 1x106 cells of QPP4, 5 ,7 and 8
were mixed with 30% Matrigel and subcutaneously implanted at the left flank of male
C57BL/6J mice. For intracranial study, 1x105 cells (QPP7 and GL261), 2x105 cells
(QPP4 and 5), and 3x105 cells (QPP8) for optimal engraftment and growth kinetics were
mixed with 50% of methyl cellulose (Acros Organics) to a total volume of 5 μL. The cells
were injected into right striatum of C57BL/6J mice, at approximately 2 mm anterior and
2 mm right lateral to the Bregma at a depth of 4 mm, using a stereotactic device.
Therapeutic antibodies modulating T cell co-inhibitory molecules CTLA-4 (9H10 [Syrian
Hamster Ig], 100 µg/dose) and PD-1 (29F.1A12 [Rat IgG2a], 200 µg/dose or RMP1-14
[Rat IgG2a], 250 µg/dose) were purchased from Bio X cell and Leinco technologies. All
doses indicate quantity administered per injection. In all in vivo treatment studies, 3
doses of antibody treatment or phosphate buffer saline (PBS) were given i.p. on day 7,
10 and 13. Subcutaneous tumor volume was measured with calipers until tumors reach
1,000 mm3 and the survival of brain tumor bearing mice was recorded.

Flow cytometry analysis of tumor immune infiltrate. For subcutaneous analysis,
1x106 of QPP8 cells were mixed with 30% Matrigel and implanted into the left flank of
male C57BL/6J mice. 3 doses of antibody treatment as described in the immune
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sensitivity study or PBS were given i.p. every 3 days when tumor volume grew to > 250
mm3. For orthotopic analysis, 1x105 cells of QPP7 and GL261; and 5x105 cells of QPP8
were mixed with 30% Matrigel to a total volume of 5 μL and inoculated into right striatum
of C57BL/6J mice. Three doses of antibody treatment or PBS were given i.p. every 3
days starting on day 5 for GL261, on day 33 for QPP7 and on day 48 for QPP8. All mice
were sacrificed 2 days after the last dose of treatment. Tumors were harvested and
digested with Collagenase H and DNase for 30 minutes and the cell numbers are
counted using automatic cell counter. After removal of myelin via Percoll gradient
separation (Sigma) for brain tumors364, the live infiltrating immune cells were enriched by
Ficoll gradient centrifugation (Sigma; 1119 density). The enriched immune cells were
stained for surface markers LAP (Thermo) and TMEM119 (Abcam), then fixed,
permeabilized (eBioscience FoxP3 Fix/Perm kit), and stained in Brilliant Stain Buffer (BD
Biosciences) for markers CD45.2, NK1.1, CD4, CD11c, CD11b, Ly6G, Ly6C, Ki67, PDL1 (BD Biosciences), CD3, CD8a, FoxP3, F4/80, PD-1 (Thermo), Granzyme B
(Biolegend), and Arginase 1 (R&D Systems). Expressions of the indicated markers on
cells were measured by using 18-color flow cytometry on a BD LSRII flow cytometer365.
FlowJo Version 10 was utilized to analyze the data. Analysis of immune subsets are
defined in Supplementary Fig. S7.

Analysis of genomic alterations in QPP cell lines. Genomic DNA was extracted from
the fresh cultured QPP lines using GeneJET Genomic DNA Purification Kit (Thermo
Fisher). The integrity of purified DNA was validated on 1% agarose gels and the
concentration was determined by using Qubit® DNA Assay Kit in Qubit® 2.0 Fluorimeter
(Life Technologies). A total of 1.0 µg genomic DNA per sample was used as input
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material for the DNA sample preparation. Sequencing libraries were generated using
Agilent SureSelectXT Mouse All Exon kit (Agilent Technologies). Briefly, fragmentation
was carried out by the hydrodynamic shearing system (Covaris) and the fragments were
enriched by polymerase chain reaction (PCR). Exons were captured and enriched using
PCR, and index tags added to prepare for hybridization. Products were purified using
AMPure XP system (Beckman Coulter) and quantified using the Agilent high sensitivity
DNA assay on the Agilent Bioanalyzer 2100 system. The qualified libraries were then
sequenced by utilizing Illumina sequencing platform using the paired end 150 method
with the depth of 50-100X and coverage of > 99%.

Construction of heat maps. All heat maps are showing the log of fold changes of the
indicated ratio or specific parameter MFI compared to the QPP line and tissue site
matched PBS control group. Each ratio or MFI fold change in the treatment groups was
normalized to the mean of the same parameter of the PBS group in each tumor immune
infiltrate experiment. The normalized results in each independent experiment were then
combined. For each parameter, Student’s t-test was used to compare the combined
normalized fold changes in the treatment groups with the combined fold changes in the
PBS group (mean = 1). “*” indicate differences with a p-value < 0.05.

Statistical analysis. All statistics were calculated using Graphpad Prism Version 8 for
Macintosh. Two-sided Student’s t-test applying Welch’s correction for unequal variance
was used to determine statistical significance. p-values < 0.05 were considered
significant.
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Figures

Fig. 1. Four QPP lines grow in both immune-deficient and immunocompetent
C57BL/6J mice. 1x106 cells of each QPP cell line were subcutaneously implanted
in both (A) C57BL/6J (n=4) and (B) B6 Rag1 knockout (RagKO) mice (n=2) and their
growth measured with calipers. Each curve and error bar represents mean (a and b)
and SEM (a) of each QPP line.

Fig. 2. T cell checkpoint blockade sensitivity of flank-implanted QPP cell lines.
1x106 cells were implanted on the left flank of male C57BL/6J mice on day 0 and mice
were treated via i.p. injection of anti-PD1 (29F.1A12 or RMP1-14) or anti-CTLA-4
(9H10) monoclonal antibodies or control (phosphate buffer saline, PBS) on day 7, 10
and 13. Tumors were measured with calipers until reaching 1,000 mm3. Each curve
and error bar represent cumulative mean over time and SEM from two independent
experiments of 5 mice per group.
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Fig. 3. QPP lines engraft in the brains of C57BL/6J mice and are differentially
sensitive to checkpoint blockade. 1x105 (QPP7), 2x105 (QPP4 and 5) and 3x105
(QPP8) cells were implanted via stereotactic injection to the right striatum of male
C57BL/6J mice. On days 7, 10 and 13, mice were treated via i.p. injection of anti-PD1
(29F.1A12 or RMP1-14) or anti-CTLA-4 (9H10) or control (PBS). Survival was
monitored and significance is shown based on the Log-Rank (Mantel-Cox) test. 2
(QPP4 and 5) to 3 (QPP7 and 8) independent experiments were performed with 4-5
mice per group.
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Fig. 4. Comparative infiltrate analysis of flank versus brain implanted QPP8.
1x106 cells and 5x105 cells of QPP8 were implanted at the flank and in the brain of
C57BL6/J male mice respectively. QPP8 tumor bearing mice were treated with 3
doses of i.p. anti-CTLA-4 (9H10) or anti-PD-1 (RMP1-14) antibody or PBS every 3
days starting when average flank tumor volume was > 250 mm3 or on day 48 for brain
tumor bearing mice. The mice were sacrificed 2 days after the last dose of treatment
and the extracted tumors were digested with Collagenase H and DNAse. Tumorinfiltrating immune cells were enriched by Ficoll gradient centrifugation after removal
of myelin via Percoll gradient separation (brain tumors only). The enriched immune
cells were stained with phenotypic and functional markers and analyzed by flow
cytometry. Immune infiltrate density fold changes compared to the control group (A)
and T cell subset frequencies (B) in response to T cell checkpoint blockade in both
flank and brain tumors are shown as mean ± SEM. Fold changes of CD8 T cells over
suppressive subset ratios (C) and functional marker MFI fold changes compared to
the matched control group for each immune subset in the indicated site (D) were
calculated and are presented on a log scale. Data are cumulative of 3 independent
experiments with 3-8 mice per group. Statistical significance was determined by using
Student’s t-test. *p < 0.05. (Gzmb: Granzyme B; LAP: latency associated peptide;
PD-1: programmed cell death 1; PD-L1: programmed cell death ligand 1; CD4
Teff/Treg: CD4 effector/regulatory T cells; Gr-/Mo-MDSC: granulocytic-/ monocyticmyeloid derived suppressor cells; TAMs: tumor associated macrophages; DC:
dendritic cells)
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Fig. 5. QPP7 remains checkpoint sensitive in the CNS despite adaptive
upregulation of Arginase. 1x105 cells of QPP7 or 5x105 cells of QPP8 were
implanted in the right striatum of male C57BL/6J mice. The mice were treated with 3
doses of i.p. anti-CTLA-4 (9H10), anti-PD-1 (RMP1-14) or PBS every 3 days starting
on day 33 for QPP7 and on day 48 for QPP8. Tumors were digested with Collagenase
H and DNAase for 30 minutes. Next, the tumor infiltrating immune cells were enriched
by Ficoll gradient centrifugation after removal of myelin via Percoll gradient
separation. The enriched immune cells were stained for phenotypic and functional
markers and analyzed by flow cytometry. Fold changes of CD8 T cells over
suppressive subset ratios (A) and functional marker MFI fold changes compared to
the matched control group for each immune subset in the indicated site (B) were
calculated and are presented on a log scale. Data are cumulative of 3 independent
experiments with 3-8 mice per group. Statistical significance was determined by using
Student’s t-test (*p < 0.05). QPP7 and QPP8 cells were cultured in F12/DMEM media
supplemented with B27, FGF and EGF for 5 days before they were collected and
washed twice using PBS. 6x105 cells (dash line) were then seeded in 10 mL of the
above culture media either with or without arginine. After in vitro incubation for 6 days,
the cells were imaged using fluorescence or light microscope (C) and viable cell
number was counted using automatic cell counter (D). Graph shows mean and SEM
from 2 independent experiments. (†Separate evaluation of PD-1 expression in
Supplementary Fig. S6. Gzmb: Granzyme B; LAP: latency associated peptide; PD1: programmed cell death 1; PD-L1: programmed cell death ligand 1; CD4 Teff/Treg:
CD4 effector/regulatory T cells; Gr-/Mo-MDSC: granulocytic-/monocytic-myeloid
derived suppressor cells; TAMs: tumor associated macrophages; DC: dendritic cells)
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Fig. 6. Genomic profile of QPP cell lines. DNA was extracted from the cultured
QPP lines and sent for whole exome sequencing using the paired end 150 method
with a depth of 50-100X and coverage of > 99%. Tumor mutational burden in each
QPP line is presented as number of single nucleotide variants (SNV) in coding
regions and non-synonymous SNV (A); as well as number of small insertion and
deletion (Indels) and frameshifts by Indels (B).
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Table 1. Expression of glioma stem cell (GSC) markers and checkpoint molecules
on QPPs. Cells were cultured in vitro in F12/DMEM supplemented with B27, epidermal
growth factor (EGF) and fibroblast growth factor (FGF) for 4-5 days with or without IFNg for 48 hours. In vivo cells were harvested from subcutaneous or intracranial (QPP4)
tumors digested with collagenase H and DNAse for 30 minutes. Cells were then stained
for the indicated markers and analyzed by flow cytometry. (% of indicated marker positive
QPP cells/total QPP cells is presented. -, < 2%; +, 2-20%; ++, 20-40%; +++, 40-60%;
++++, > 60%. (Sca-1: stem cell antigen-1; PD-L1 and 2: programmed cell death ligand 1
and 2)
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GL261 survival in C57BL/6J mice

Supplementary Fig. S1. The glioblastoma line GL261 is acutely sensitive to PD1 blockade. 1x105 GL261 cells were implanted orthotopically into the brain of female
C57BL/6J mice by stereotactic injection and then treated with 3 doses of anti-PD-1
(n=5), anti-CTLA-4 monoclonal antibodies (n=4) or phosphate buffer saline (PBS) as
control (n=4) every 3 days starting on day 7.

Supplementary Fig. S2. Programmed cell death ligand 1 (PD-L1) expression on
QPP cell lines in response to Interferon (IFN)-g. Cells were cultured in vitro in
F12/DMEM supplemented with B27, FGF and EGF for 4-5 days with or without IFNg (200 ng/mL) for 48 hours. Cells were then collected, stained with fluorescently
labeled PD-L1 antibody and analyzed by flow cytometry. Percent of PDL1+ QPP
cells/total QPP cells after IFN-g stimulation is presented as fold change compared to
the unstimulated controls (A). PD-L1 expression level with or without IFN-g stimulation
in each QPP line is presented in mean fluorescence intensity (MFI) (B).
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Control

aCTLA-4

aPD-1

QPP4

QPP5

QPP7

QPP8

Supplementary Fig. S3. T cell checkpoint blockade sensitivity of flankimplanted QPP cell lines. 1x106 cells were implanted on the left flank of male
C57BL/6J mice on day 0 and mice were treated via i.p. injection of anti-PD1
(29F.1A12 or RMP1-14) or anti-CTLA-4 (9H10) monoclonal antibodies or control
(PBS) on day 7, 10 and 13. Tumors were measured with calipers until reaching 1,000
mm3. Each curve represents individual tumor volume over time. Two independent
experiments of 5 mice per group were performed.
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Control
αCTLA-4
αPD-1

Supplementary Fig. S4. CD8 T cells over immune suppressive subset ratios in
flank QPP8 tumors. 1x106 cells of QPP8 were implanted on the left flank of male
C57BL/6J mice and treated with 3 doses of anti-CTLA-4 (9H10), anti-PD-1 (RMP114) or PBS starting when tumor volume reached > 250 mm3. Mice were sacrificed
and tumors were harvested 2 days after the last treatment. The tumors were digested
with Collagenase H and DNAse and tumor immune infiltrates were enriched by Ficoll
gradient centrifugation. The enriched immune cells were stained with the indicated
antibodies and analyzed by flow cytometry. Ratios were calculated by dividing CD8
T cell frequencies by indicated suppressive subset frequencies. Data are cumulative
of 3 independent experiments with 3-5 mice per group. Statistical significance was
determined using Student’s t-test. *, p < 0.05; **, p < 0.01. (Treg: CD4 regulatory T
cells; Gr-/Mo-MDSC: granulocytic-/monocytic- myeloid derived suppressor cells;
TAMs: tumor associated macrophages)

189

(A)

(B)
Control
αCTLA-4
αPD-1

Ki67

LAP

PD1

Gzmb

CD4 effector T cells

Ki67

LAP

PD1

CD8 T cells

Supplementary Fig. S5. T cell effector function improves following checkpoint
blockade in orthotopic GL261 glioblastoma. 1x105 cells of GL261 were
stereotactically inoculated into the right striatum of female C57BL/6J mice. Mice were
treated with i.p. anti-CTLA-4 (9H10), anti-PD-1 (RMP1-14) or PBS on day 5, 8, 10
and were sacrificed on day 12. Tumors were digested with Collagenase H and
DNAase for 30 minutes. Next, the tumor infiltrating immune cells were enriched by
Ficoll gradient centrifugation after removal of myelin via Percoll gradient separation.
The enriched immune cells were stained with phenotypic and functional markers and
analyzed by flow cytometry. Graphs show mean ± SEM for the indicated markers in
CD4 effector T cells (A) and CD8 T cells (B). Data are from 1 experiment with 11 or
12 mice per group. Statistical significance was determined by using Student’s t-test.
*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. (Gzmb: Granzyme B; LAP:
latency associated peptide; PD-1: programmed cell death 1)
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Supplementary Fig. S6. Decreased PD-1 expression on T cells in the anti-CTLA4 treated QPP7. 1x105 cells of QPP7 were implanted in the right striatum of male
C57BL/6J mice. The mice were treated with 3 doses of i.p. anti-CTLA-4 (9H10), antiPD-1 (RMP1-14) or PBS every 3 days starting on day 33. Tumors were digested with
Collagenase H and DNAase for 30 minutes. Next, the tumor infiltrating immune cells
were enriched by Ficoll gradient centrifugation after removal of myelin via Percoll
gradient separation. The enriched immune cells were stained for phenotypic and
functional markers and analyzed by BD X-30 flow cytometry. Graph shows mean ±
SEM for PD-1 MFI on the indicated T cell subsets. Data are from 1 experiment with
5 mice per group. Statistical significance was determined by using Student’s t-test (*p
< 0.05; **, p < 0.01).
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FSC and SSC gate

Singlet gate

CD45.2+ Immune cells

Microglia

Mo-MDSCs

CD11b
Myeloid cells

NK cells

NKT cells

Gr-MDSCs

T cells
DC

CD8
T cells
Treg
cells
TAMs
CD4
T cells

Teff
cells

Supplementary Fig. S7. Definition of the immune subset by flow cytometry
analysis. Tumor infiltrating immune cells were stained with antibodies for the
indicated markers and data were acquired using 18-color flow cytometry on a BD
LSRII flow cytometer. FlowJo Version 10 was used to analyze the acquired data. After
FSC/SSC and singlet gating, CD45.2+ cells were selected for analysis. Microglia was
first separated from the rest of the population which was then divided into natural killer
(NK), natural killer T (NKT), T cells and myeloid population. T cells were separated
as CD8 T, CD4 regulatory T (Treg) and effector T (Teff) cells. The myeloid population
was further identified as dendritic cells (DC), monocytic-/granulocytic- myeloid
derived suppressor cells (Mo-/Gr-MDSCs) and tumor associated macrophages
(TAMs).
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